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Many plants in biodiversity hotspots have not yet been screened for biological activity 
in humans. Plants synthesise secondary metabolites that may be unique to each 
species or induced in response to specific conditions. Assam in North East India forms 
part of the Indo-Burma biodiversity hotspot for conservation and is a rich source of 
medicinal plants for traditional Indian medicine. This study concerns the potential 
cytotoxic effects of three Assamese medicinal plant extracts, from Clitoria ternatea root, 
Mucuna pruriens seed and Cheilocostus speciosus rhizome. The aim of the study was 
to characterise the cytotoxic activity, to elucidate the biological mechanism and to 
isolate the bioactive agents for further investigation. Clitoria was prioritised for study, as 
its crude extract was found to have a dose related, cytotoxic effect that was 2-3 fold 
more effective on breast cancer cells than non-cancer cells. Two bioactive fractions of 
Clitoria were isolated in bioassay-led fractionation with high performance liquid 
chromatography. The fractions demonstrated a selective dose related cytotoxic effect 
over a range of 100 to 700 ng/µL. In live cell observation, crude extract and a bioactive 
fraction were cytostatic at non-lethal treatment doses, and crude extract reduced cells’ 
motility by 50%. Both crude extract and fractions caused structural changes in the actin 
cytoskeleton which could be contributing to the cytotoxic and cytostatic effects and 
reduced motility. Liquid Chromatography-Mass Spectrometry analysis indicates that the 
two isolated bioactive agents are novel homoisoflavones, polyphenolic secondary 
metabolites, which were also detected in extracts made from Indonesian sourced 
Clitoria root and are likely to be in extract made from UK sourced Clitoria root. Results 
suggest that bioactive components of Clitoria extract are worthy of further study and 
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MTT: 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide 
MW: molecular weight 
m/z: mass-to-charge ratio 
N: number of replicates 
N. A.: not assayed 
NCE: new chemical entity 
NMR: nuclear magnetic resonance 
N.S.: not significant 
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p: probability of rejecting the null hypothesis 
PARP: poly ADP ribose polymerase inhibitor 
PBS: phosphate buffered saline 
PDA: photodiode array 
PFA: paraformaldehyde 
PI3K: phosphatidylinositide 3-kinase  
PR: progesterone receptor 
PS: phosphatidylserine 
R: regression coefficient 
RE: rotary evaporator 
Rf: Retention factor 
RNA: ribonucleic acid 
ROCK: Rho kinase 
RP-HPLC: reversed phase HPLC 
rRNA: ribosomal RNA 
R.T.: retention time 
S: synthesis 
SAC: spindle assembly checkpoint 
SD: standard deviation 
SD: subdomain 
SPARC: secreted protein acid rich in cysteine  
STS: staurosporine 
TCM: traditional Chinese medicine 
TFA: trifluoroacetic acid 
TLC: thin layer chromatography 
TM: traditional medicine 
TMR: tetramethylrhodamine 
TNF: tumour necrosis factor  
TNFR: TNF receptor 
UV: ultraviolet 
VEGF: vascular endothelial growth factor  
v/v: volume/volume 
WASP: Wiskott-Aldrich syndrome protein 
λmax: wavelength of peak 
λmax1: wavelength of peak 1 
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Chapter 1 Introduction 
1.1 Breast cancer 
Breast cancer is the most common cancer in the UK, with around 50,000 new cases in 
women and 350 in men per year, representing 15% of all cancers diagnosed (CRUK, 
2014c). Globally it is the second most common cancer, with 12% of all cancer 
incidence and 25% of all cancers in women (GLOBOCAN, 2015). Although the five-
year survival rate for women in the UK is 87% (CRUK, 2014b), breast cancer is the 
second most common cause of UK cancer death in women (15%), after lung cancer 
(21%) (CRUK, 2014d). It is the most common cause of female cancer death worldwide, 
with 14.3% of all cancer deaths in women (GLOBOCAN, 2015). 
Human breasts contain around 20 milk-producing regions called lobes, separated by 
fibrous septa and embedded in fat (Ellis, 2002). Each lobe, made up of many smaller 
units called lobules, drains via a duct to a nipple which contains a cluster of secretory 
alveoli (Figure 1-1) (Ellis, 2002). Both lobules and ducts are lined with an epithelium 
consisting of luminal cells surrounding the lumen and basal myoepithelial cells adjacent 
to the basal membrane (Visvader and Stingl, 2014). Alveoli are surrounded by 
myoepithelial cells which can contract to force milk out of the breast (Seeley et al., 
2007). 85% of breast cancers occur in the ductal epithelium, primarily in luminal cells, 
and the majority of the rest occur in the lobule (Seeley et al., 2007; Visvader and Stingl, 
2014). 
Spontaneous mutations in the DNA of a breast cell take place continuously as a result 
of exposure to environmental chemicals, biochemical reactions, or errors during cell 
division (Alberts et al., 2002). Many DNA errors, such as single erroneous bases, are 
repaired (Pearl et al., 2015), and of those that are not, most are harmless, or cause a 
cell to die (Lane, 1992), but if a series of errors occurs that gives a cell a growth 
advantage over its neighbours, the dividing cells form a cluster which becomes a 
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tumour (Alberts et al., 2002). The cluster of cells may invade the surrounding fatty 
tissue, at which point the cancer is invasive, and if cells detach and travel to other sites 
in the body in the bloodstream or lymphatic system the cancer has become metastatic 
(CRUK, 2014f). Women with one of the most common inherited mutations of BRCA1 or 
BRCA2 genes have a 45-90% lifetime risk of cancer (The Royal Marsden NHS Trust, 
2013), but only 10% of breast cancers are linked to familially inherited alleles 
(McPherson et al., 2000). The other major risk factors are age and living in a developed 
country (McPherson et al., 2000). 
  
Figure 1-1: Diagram of lactating human breast showing ducts, lobes, lobules and alveoli. Image  
from MedicineNet (2013) used with permission. Lobes are absent in the non-lactating breast.  
 
 
Survival rates are greatly improved if the cancer is diagnosed and treated early. The 5-
year survival rate for breast cancer diagnosed at early stage in the USA is 98.6% but if 
metastatic (Table 1-1) at diagnosis the 5-year survival rate is 6% (SEER, 2015); 
therefore early diagnosis is a priority. The UK National Health Service Breast 
Screening Programme has since 1988 screened women aged 50-70 for 
mammographic abnormalities which may be tumours or pre-cancerous cells appearing 
as ductal carcinoma in situ (DCIS) (Blanks et al., 2000). Around 75% of women are 
screened and 1% of screened women require treatment for breast cancer (HSCIC, 










benign lesions, which contributes to a proportion of screened women undergoing 
unnecessary treatment (Gøtzsche and Nielsen, 2011). 




Early breast cancer Cancer is confined to breast tissue and lymph nodes in the armpit on the 
same side of the body. 
Local recurrence Cancer has been treated and has recurred in the same breast. 
Locally advanced breast cancer Cancer is confined to the breast but is either >5 cm across, or growing into 
the skin or chest wall, or present in the lymph nodes in the armpit and the 
affected lymph nodes are stuck to each other or to other structures. 
Secondary / advanced / metastatic 
breast cancer 
Cancer has spread to other parts of the body, usually the bone, liver or 
lung. 
1 
Compiled from information from CRUK (2014f). 
 
 
1.2 Breast cancer therapies 
1.2.1 Introduction 
Breast tumours were described in 1600 BC in an early Egyptian medical text, which 
described treatment by cauterization (Verrill, 2009). It was noted by Galen, writing in 
the 2nd century, that cancer in the breast could be treated by surgery if discovered early 
(Papavramidou et al., 2010). Surgery has been performed on breast and lymph nodes 
since the seventeenth century, and in the nineteenth century William Halsted adopted 
the procedure of radical mastectomy of breast, lymph nodes, muscle tissue and the 
contralateral breast (Verrill, 2009). Chemotherapy agents were discovered in the 
second world war and in 1976 the combination therapy of cyclophosphamide, 
methotrexate and fluorouracil was being used for early breast cancer with less radical 
surgery (Verrill, 2009). Radiotherapy became common in the 1960s, and since then, 
surgery, chemotherapy and radiotherapy have been the main options for cancer 
treatments. 
When cancer is first discovered, the treatment is usually a combination of surgery to 
remove the tumour, radiotherapy and adjuvant chemotherapy. For larger tumours, 
neoadjuvant chemotherapy or hormone therapy may be given before surgery to reduce 
the size of the tumour. If cancer recurs after treatment, new growth may be surgically 
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removed, if possible, and a combination of hormone therapy, biological therapy or 
chemotherapy may be offered (CRUK, 2014j). 
1.2.2 Surgery  
For early stage breast cancer the aim of the combination of surgery with other 
therapies is to remove the cancer, to kill all remaining cancer cells from the breast and 
to prevent cancer recurrence. As 87% of UK women survive for 5 years after breast 
cancer, and 79% for 10 years (2010-2011 figures) this is an effective strategy (CRUK, 
2014b). In the 5% of women who already have metastatic breast cancer (MBC) when 
they present for treatment, surgery may be performed to remove the primary tumour 
and secondary tumours, and those who undergo surgery have improved survival 
(Ruiterkamp and Ernst, 2011).  
Surgical options include removal of a breast (mastectomy) or radical mastectomy, 
where the breast and additional tissues such as the axillary lymph node, the lymph 
node into which most breast fluid drains, are removed, or less aggressive breast 
conservation surgery (BCS) to remove either the lump alone (lumpectomy) or part of 
the breast (partial mastectomy) (Chagpar et al., 2006). In advanced breast cancer, 
surgery can be performed to remove secondary metastases, or radiofrequency ablation 
can remove liver metastases (Ruiterkamp and Ernst, 2011). 
1.2.3 Radiotherapy 
Conventional external beam radiotherapy may be administered before surgery to 
reduce the tumour or after surgery to kill any remaining cancerous cells. BCS is 
normally offered with a 6-week programme of daily radiation therapy (Chagpar et al., 
2006). Although lumpectomy with radiotherapy led to a lower risk of recurrent disease 
(14% recurrence) than lumpectomy without radiation (39% recurrence), in one study, 
there was only a marginally significant difference in overall survival after 20 years 
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(Fisher et al., 2002). Side-effects of radiotherapy include skin reddening and 
permanent changes to skin, fatigue and sometimes radiation damage to heart muscle 
(CRUK, 2014e).  
1.2.1 Chemotherapy 
Chemotherapy targets dividing cells, killing a greater proportion of cancer cells 
because they cycle faster than non-cancer cells. After surgery for early and localised 
breast cancer, the aim of adjuvant chemotherapy is to kill remaining cancer cells in the 
breast or that have migrated to other parts of the body and thereby to prevent the 
cancer recurring. Adjuvant therapy is normally combination chemotherapy, both in 
order to kill cells by more than one mechanism and to reduce the risk of tumours 
becoming drug resistant. There are many breast cancer chemotherapy regimens, but 
each involves a combination of drugs with different cytotoxic modes of action. Two of 
the most commonly used regimens for adjuvant chemotherapy are cyclophosphamide, 
methotrexate and fluorouracil (CMF) and fluorouracil, epirubicin and cyclophosphamide 
(FEC) or FEC with docetaxel (FEC-T) (Table 1-2). CMF is 4-6 4-weekly cycles which 
each consist of 1 tablet per day for 14 days of cyclophosphamide, and injections on 
day 1 and day 7 of methotrexate and fluorouracil (CRUK, 2012). FEC is 6-8 3-weekly 
cycles of one injection of fluorouracil, epirubicin and cyclophosphamide, and in FEC-T 
the FEC regimen is followed by 3-4 3-weekly cycles of a 1-hour infusion of docetaxel 
(CRUK, 2012). Dosing is calculated based on patients’ body weight and other factors to 
avoid both over- and under-dosing, but is imperfect because patients vary in their drug 




Table 1-2: Primary modes of action of chemotherapy drugs commonly used in adjuvant treatment 
for non-advanced breast cancer. 
Chemotherapy agent (brand 
name) 
Main mode of action 
Cyclophosphamide (Cytoxan) Nitrogen mustard alkylating agent (attaches CH2 group to DNA). 
Alkylated DNA forms a cross-link between the two DNA strands. If DNA repair proteins fail to 




Fluorouracil (Adrucil) Antimetabolite (mimics a biological metabolite), thymidylate synthase inhibitor.  
Main mode of action is as thymidylate synthase inhibitor, prevents the synthesis of 
deoxyribonucleotide thymidine monophosphate (dTMP), a component of DNA, and the cell 
initiates thymineless cell death, a type of apoptosis that occurs rapidly as a consequence of 
DNA strand breaks that arise at missing thymidines during DNA synthesis
2
. Also acts as 
antimetabolite incorporated into RNA during transcription in place of uracil, interfering with 
cell metabolism and viability 
3,4
. 
Methotrexate Antimetabolite, antifolate.  
Antifolates compete with folic acid in binding to folate enzymes, which prevents synthesis of 
dTMP. Thymineless cell death is initiated 
2
. 
Epirubicin (Pharmorubicin) Anthracycline. 
Probable main mode of action as topoisomerase II inhibitor interfering with untwisting of DNA 
during synthesis; other possible modes include DNA cross-linking and generation of free 
radicals. All cause DNA damage leading to apoptotic cell death or growth arrest 
4, 5
. 





 Jordan et al. (1993); Foley et al. (1961). 
2
 Foley et al. (1961). 
3
 Ahmad et al. (1998). 
4 





Minotti et al. (2004). 
6 
Microtubule inhibitors prevent proper segregation of chromosomes in mitosis. Microtubule inhibitors are discussed 
further in section 1.4.3. 
 
 
Around 20% of breast cancer patients develop incurable MBC (Eckhardt et al., 2012). 
The median breast cancer specific survival in one study of MBC patients was 25 
months after diagnosis, although there is great variability and in another study 3% of 
MBC patients were disease-free 5 years after chemotherapy (Telli and Carlson, 2009). 
Therefore the aims of chemotherapy for MBC are different from those for early stage 
breast cancer and consist of improving quality of life for as long as possible and of 
extending survival time by reducing growth in primary and secondary tumours. There is 
no drug approved for use that specifically targets metastasis (Weber, 2013). 
Chemotherapy for MBC is usually given as sequential single-agent therapy (Table 1-3) 
to reduce the side-effects from toxicity of combination therapy (Telli and Carlson, 2009) 
although combinations of two drugs with different modes of action are also used, for 
instance gemcitabine and paclitaxel, known as GemTaxol, or capecitabine and 
docetaxel (CRUK, 2014h). Metastatic breast cancers develop resistance to every 
treatment at which point the cancer stops responding and another chemotherapy agent 
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with a different mode of action may be chosen. It is not certain that combination 
therapy for MBC improves overall survival time or quality of life, but the time to 
treatment failure may increase slightly with combination therapy, from around 6 to 8 
months in one study (Conlin and Seidman, 2008; Dear et al., 2013). The number of 
cycles for each agent ranges from 3 to 8 or until toxicity becomes unbearable (Gennari 
et al., 2011).  
Table 1-3: Modes of action of chemotherapy drugs commonly used for advanced breast cancer 
1
. 
Chemotherapy agent (Brand 
name) 
Main mode of action
 
Paclitaxel (Taxol, Abraxane) Taxane, microtubule inhibitor
 2
. 
Docetaxel (Taxotere) Taxane, microtubule inhibitor 
2
. 
Vinorelbine (Navelbine) Vinca alkaloid, microtubule inhibitor 
2
. 
Capecitabine (Xeloda) Antimetabolite. 
Prodrug converted in vivo to fluorouracil 
3, 4
.  
Gemcitabine (Gemsar) Antimetabolite. 
Prodrug phosphorylated in the cell to a nucleoside analogue that is 
incorporated into DNA during synthesis but prevents extension of the 
molecule beyond one further nucleotide; also inhibits DNA polymerase 
and ribonucleoside reductase enzyme, reducing the pool of available 
nucleotides. DNA repair enzymes do not recognise the error and 
apoptosis follows failed cell division 
5
. 
Epirubicin (Pharmorubicin) Anthracyline 
3, 4
. 
Eribulin (Halaven) Microtubule inhibitor 
2
. 








Carboplatin (Paraplatin) Platinum-based cross-linker. 







 Microtubule inhibitors prevent proper segregation of chromosomes in mitosis. Microtubule inhibitors are discussed 
further in section 1.4.3. 
3 
Blum et al. (1999). 
4
 See Table 1-2. 
5 
Mini et al. (2006). 
6 
Ntukidem et al. (2009). 
7 
Florea and Büsselberg (2011). 
 
 
Chemotherapy agents are toxic to all cells, and populations of non-cancer cells that are 
actively dividing such as in hair, skin, intestinal tract, blood and the immune system, 
are also killed, leading to side-effects. Side-effects are specific to each drug and are 
experienced differently by patients and severe toxicity may require discontinuation of 
therapy. Hair loss, ulcers, nausea, diarrhoea, constipation and tiredness are frequently 
experienced with chemotherapy agents. Neutropenia (low neutrophils in blood), low 
platelets and low erythrocytes can lead to poor infection resistance, bleeding and 
bruising and anaemia. Anthracylines are toxic to heart muscle and doxorubicin is 
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associated with sensitivity to sunlight. Docetaxel and eribulin can cause peripheral 
neuropathy (CRUK, 2012; FDA, 2010). Side-effects are carefully monitored and 
patients are given a range of other drugs to treat side-effects. 
To reduce toxicity of treatments, improvements are being made in the delivery of 
chemotherapeutic agents. Dosages can be increased if more of the drug reaches the 
tumour cells, or if the drug is better tolerated. Doxil is a formulation of doxorubicin 
contained in liposomes that allow it to be transported in blood without eliciting an 
immune response, which improves its circulation lifetime (Oja et al., 2000). 
Capecitabine is converted to its active form in tumour cells and the toxic effect is better 
targeted to the tumour. Epirubicin is a second-generation anthracycline with better 
bioavailabilty and therefore lower dosage than doxorubicin (Minotti et al., 2004). 
However, chemotherapy is systemic, toxic and still largely non-specific.  
1.2.2 Targeted treatments 
Newer treatments target breast cancer according to its biology. Hormone therapy 
disrupts the growth signals of the estrogen pathway, while biological therapy targets 
specific pro-growth cell mechanisms. In order to guide treatment and assess prognosis, 
breast biopsies are tested immunohistochemically for expression of the estrogen 
receptor (ER), progesterone receptor (PR) and HER2 receptor. Estrogen is a steroid 
hormone that has many effects in the body, including control of the menstrual cycle, 
development of the ductal system in the growing breast, and growth of ductal breast 
tissue in the follicular phase of the cycle (Strauss III and Barbieri, 2013). The estrogen 
receptors ERα and ERβ are transcription factors activated when bound to estrogen, 
with distinct functions and distribution in the body (Pettersson and Gustafsson, 2001). 
In the ER classical mode of action the estrogen-ERα complex binds to specific DNA 
estrogen response elements (EREs) that promote the transcription of genes involved in 
cell proliferation and cell cycle progression (Figure 1-2) (Ring and Dowsett, 2004). ERα 
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expression in normal breast tissue rises and falls with the menstrual cycle, but its 
elevated expression is one of the earliest pre-cancerous changes in breast epithelial 
cells and it is present in 75% of breast tumours, called ER positive (Hoskins et al., 
2009). High levels of ER may allow the tissue to respond to even low levels of estrogen 
with increased growth (Allred et al., 2001). Absence of ER expression (ER negative) is 
an indicator of disease progression and poorer prognosis (McGuire and Clark, 1986). 
ERβ, on the other hand, when bound to estrogen inhibits transcription, reduces 
angiogenesis and can reduce tumour growth in a mouse model (Hartman et al., 2006). 
Many ERα binding sites on DNA also bind ERβ, suggesting that the resulting effect is 
driven by the relative concentrations of both ERs in the cell (Grober et al., 2011). In 
non-classical modes of action, ERα can also upregulate proliferation genes by binding 
to transcription factors Jun and Fos (Figure 1-2), and it may have additional non-
nuclear activity through interacting with c-Src and activating the mitogen-activated 
protein kinase (MAPK) pathway and the mechanistic target of rapamycin (mTOR) 
pathway which induce transcription of pro-growth and anti-apoptotic genes (Ring and 
Dowsett, 2004). 
Around 50% of patients are PR positive, 6-10% of these testing negative for ER 
(Hoskins et al., 2009). Progesterone is a steroid hormone secreted during the 
menstrual cycle that stimulates growth of the terminal ducts and lobes (Strauss III and 
Barbieri, 2013). In pre-cancerous stages PR expression increases, and its absence is 
also a marker of progression and poor prognosis (McGuire and Clark, 1986). In MBC 
patients, the worst prognosis is in patients whose ER and PR status are negative 
(McGuire and Clark, 1986). There is a complex interaction between PR and ER, as PR 
can act as a co-repressor for ER transcription, but can also activate the pro-




                
  
Figure 1-2: Estrogen-ER complex initiates transcription of pro-growth genes in classical (A) and 
non-classical (B, C) modes of action. ER: estrogen receptor α. ERE: estrogen receptor elements. 
coact: coactivator. MAPK: mitogen-activated protein kinase. mTOR: mechanistic target of 
rapamycin. Adapted and redrawn from Ring and Dowsett (2004). 
 
 
The receptor tyrosine kinase receptor HER2, also called ErbB2 or Neu, is 
overexpressed in 20–30% of breast cancers known as HER2-positive, and poor 
prognosis correlates with the degree of amplification (Slamon et al., 1987). It is one of 
four transmembrane proteins in the epidermal growth factor receptor (EGFR) or ErbB 
family which also includes ErbB1, ErbB3 and ErbB4 (Badache and Gonçalves, 2006). 
EGFR family members have an extracellular peptide-binding region and various 
ligands bind ErbB1, ErbB3 and ErbB4, although none has been found that binds HER2 
(Badache and Gonçalves, 2006). On binding, ErbB1, ErbB3 and ErbB4 change 
conformation, dimerise as homo- or heterodimers and transduce an intracellular signal 
(Figure 1-3) (Badache and Gonçalves, 2006). HER2 dimerises with one of the other 
family members, frequently ErbB3, which binds a number of ligands (Badache and 
Gonçalves, 2006). Overexpression of HER2 leads to signalling in the absence of ligand 
(Badache and Gonçalves, 2006). The EGFR family proteins are signalling proteins in 
the MAPK pathway and the mTOR pathway, which induce expression of genes 
involved in survival, proliferation and cell migration (Tinoco et al., 2013). 
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Figure 1-3: HER2 signalling in breast cancer. A: Unliganded ErbB3 does not transduce signal. On 
binding, ErbB3 can dimerise with HER2 and transduce signal via the MAPK cascade (B) or the 
mTOR pathway (C). D: Overexpression of HER2 leads to signalling in the absence of ligand. E: 
Trastuzumab interferes with signalling from overexpressed HER2, while pertuzumab targets both 
overexpressed and ligand-induced signalling. MAPK: mitogen-activated protein kinase. mTOR: 




1.2.2.1 Hormone therapy 
Upregulation of the ER pathway is a major contributor to the cause and the growth of 
breast cancer, and can to a large extent be controlled with hormone-based therapy. 
During the menstrual cycle binding of estrogen to ERα stimulates proliferation of cells 
in normal tissue, and continuous or enhanced transcription from the ER-estrogen 
complex results in cell overgrowth. In addition, this repeated cell division provides more 
opportunity for DNA replication errors or mutations, some of which are themselves 
tumourigenic as they disrupt normal cell functions such as proliferation, apoptosis, DNA 
repair or cell migration. ER positive breast cancer normally benefits from hormone 
therapy drugs which reduce the activity of the ER pathway, either by blocking binding 
of estrogen to the ER or by reducing estrogen synthesis. Hormone therapy may be 
prescribed before surgery, to reduce the size of the tumour, or after surgery and 
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chemotherapy with the aim of preventing recurrence or secondary growth. If surgery is 
not possible, hormone therapy is typically given for 18 months to two years (CRUK, 
2014i). After recurrence, hormone therapy is still effective in many ER positive cases, 
and other treatment options include surgical removal or chemical ablation of the 
ovaries to stop their estrogen production (CRUK, 2014i; Telli and Carlson, 2009). The 
two main hormone based therapies in use are tamoxifen and the aromatase inhibitors 
(AIs). 
Tamoxifen, patented in 1985, was the first estrogen-based treatment for breast cancer 
and has been a highly successful orally administered treatment. Tamoxifen is initially 
effective in 70% of ER positive breast cancers (Hoskins et al., 2009). With five years of 
adjuvant tamoxifen after chemotherapy there is a 50% decrease in recurrences and a 
one third decrease in mortality in ER positive patients 15 years after diagnosis 
compared with chemotherapy alone (Jordan and Brodie, 2007; Davies et al., 2013). 
Tamoxifen is a selective ER modulator that binds ERα with similar affinity to estrogen 
but does not bind ERβ (Figure 1-4) (Katzenellenbogen et al., 2000; Matthews et al., 
2000). PR status is considered when prescribing. Adding tamoxifen to the regimen for 
early breast cancer patients under 50 years old who are PR negative had a worse 
outcome than the chemotherapy alone; however, in PR negative patients over 50 its 
addition improved overall disease free survival (McGuire and Clark, 1986). Tamoxifen 
carries an increased risk of endometrial cancer and thromboembolism and some risk of 
osteoporosis in post-menopausal women due to its agonist estrogenic activity in the 
uterus, vascular system and bone, but overall these risks are far outweighed by its 
prevention of recurrence (Fisher et al., 1994; Chumsri et al., 2011; Jordan and Brodie, 
2007). It is also effective in metastatic breast cancer (Gale et al., 1994). 




Figure 1-4: Drugs targeting the estrogen receptor. ER: estrogen receptor α. AI: aromatase inhibitor. 
ERE: estrogen response elements. coact: coactivator. Adapted and redrawn from Jordan and 
Brodie (2007); Ring and Dowsett (2004). 
 
 
Around 8% of breast cancer patients have resistance to tamoxifen because they do not 
express Cyp2D6, the enzyme that is responsible for converting tamoxifen from a 
prodrug to its active form (Hoskins et al., 2009). Some women develop resistance to 
tamoxifen when they lose ER positive status. In others, mutations in the ESR1 gene 
that encodes the ER enable the ER to induce ligand-independent transcription (Polyak, 
2014), or changes in the co-factors involved in ER binding to EREs may prevent 
tamoxifen from blocking transcription (Ring and Dowsett, 2004). ER positive MBC 
patients all eventually develop resistance (Ring and Dowsett, 2004). 
Aromatase inhibitors (AIs) were introduced in the 1990s, initially for post-menopausal 
MBC patients where they showed a better response than tamoxifen (Jordan and 
Brodie, 2007). The aromatase enzyme, which is primarily expressed in the ovaries 
before menopause and body fat after menopause, catalyses the conversion of 
androstenedione to estradiol, the main estrogen in breast cancer (Reed et al., 2005). 
Aromatase activity is found in 40-60% of breast cancers at higher levels than in 
surrounding tissue (Reed et al., 2005). This pathway reaction provides enough 
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estrogen to stimulate growth of breast tumours in post-menopausal women. AIs inhibit 
the aromatase enzyme, thus limiting the supply of estrogen as ligand for the ER (Figure 
1-4). The newest, third-generation aromatase inhibitors bind to the heme group on 
aromatase, saturating the binding site so that it is not available for substrate binding 
(Chumsri et al., 2011). The AIs anastrozole, exemestane and letrozole are the 
preferred hormone treatment for post-menopausal women with ER positive cancer both 
as adjuvant treatment for early stage breast cancer to shrink a tumour pre-operatively, 
to prevent recurrence after surgery, and to control growth of metastatic cancer 
(Chumsri et al., 2011; Baum et al., 2002). Treatment duration with AIs after surgery is 
normally four years (CRUK, 2014i).  
AIs are well tolerated and do not increase the risk of endometrial cancer (Kaufmann et 
al., 2007) or thromboembolism, but may cause loss of bone density with a risk of 
osteoporosis and fractures (Gaillard and Stearns, 2011). If bone density drops 
considerably, bisphosphonate drugs may be administered to prevent further fall 
(Bundred, 2009). Many tamoxifen-resistant patients respond to AIs but AI resistance 
develops in all patients with MBC and in some being treated with adjuvant AIs 
(Chumsri et al., 2011).  
1.2.2.2 Biological therapy 
Biological therapy interferes with specific cell processes to reduce the growth of cancer 
or the vasculature that supports a tumour and is normally administered alongside 
chemotherapy to target two pro-proliferation mechanisms simultaneously (Tinoco et al., 
2013). Trastuzumab (Herceptin) is a monoclonal antibody that binds antagonistically to 
the extracellular portion of the HER2 receptor (Figure 1-3) (Tinoco et al., 2013). It is 
effective in the 20-25% of breast cancer patients who are HER2 positive and given to 
both early stage and MBC patients (Bartsch et al., 2007). Early stage patients undergo 
one cycle every three weeks for a year and MBC patients weekly or three-weekly 
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cycles until the cancer stops responding (CRUK, 2014g). A clinical trial in ER positive 
MBC patients showed a 50% increase in progression free survival between patients 
given anastrozole alone and those given anastrozole and trastuzumab, from 3.8 
months to 5.6 months, but with no increase in overall survival between the groups 
(Kaufman et al., 2009). However, many patients become resistant to trastuzumab. The 
side-effects of trastuzumab consist of nausea, fatigue and occasionally cardiotoxicity 
(Nielsen et al., 2013).  
Other biological therapies are offered to patients with advanced breast cancer. 
Pertuzumab (Perjeta) is a monoclonal antibody that binds to HER2 and obstructs its 
dimerisation with other EGFR receptors (Figure 1-3) (Baselga and Swain, 2010). 
Pertuzumab as monotherapy has shown a response rate of 3% and 10% in two studies 
but when given with trastuzumab the response rate was 18% and progression free 
survival improved from 7 weeks with pertuzumab to 17 weeks with pertuzumab and 
trastuzumab together (Nielsen et al., 2013). It is approved for use with trastuzumab in 
the USA. 
Tumours cannot normally grow beyond a few millimetres in size without an improved 
blood supply, and angiogenesis, the process that develops new vasculature, is 
signalled through hypoxia in the tumour and a change in the balance of pro- and anti-
angiogenic factors, including vascular endothelial growth factor (VEGF)-A. 
Bevacizumab (Avastin) is an angiogenesis inhibitor monoclonal antibody that targets 
VEGF-A. It is used in the UK for MBC, administered intravenously every two or three 
weeks (CRUK, 2014a). The ARTemis trial is looking at the effects of giving 
bevacizumab with chemotherapy as neoadjuvant therapy for HER2 negative early 
stage breast cancer (CRUK, 2015a). Patients on bevacizumab experience many of the 
side effects common to chemotherapy, with nausea and digestive disturbance, but can 
also suffer from increased bleeding, such as from gums, poor wound healing, high 
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blood pressure and peripheral neuropathy (CRUK, 2014a). Rarer side effects include 
haemorrhaging from a tear in the bowel and heart failure (Couzin-Frankel and Ogale, 
2011).  
Triple negative breast cancer is a group with generally poor prognosis which tests 
negative for ER, HER2 and PR. These cancers are unresponsive to hormone treatment 
and HER2 targeted biological therapy and there are no other targeted treatments 
specifically for this group, therefore chemotherapy is the favoured treatment, as single 
agent or in combination. Bevacizumab is one of the few non-chemotherapy options for 
triple negative breast cancer (Conlin and Seidman, 2008). A majority of triple negative 
patients have low expression of the DNA repair protein BRCA1 and platinum agent 
chemotherapy agents such as carboplatin that target the DNA repair pathway (Table 
1-3) have shown good response (Conlin and Seidman, 2008). 
Everolimus (Afinitor) is an mTOR inhibitor. Deregulation of the mTOR pathway (Figure 
1-3) which is involved in glucose metabolism, protein synthesis, the cell cycle and cell 
survival, is found in many breast cancers and is thought to play a major part in drug 
resistance (Downward, 1998; Ghayad and Cohen, 2010). Everolimus is prescribed with 
exemestane for post-menopausal women with advanced breast cancer (CRUK, 
2014h). Side-effects that occur in women treated with this combination therapy include 
stomatitis (inflammation of the mouth lining), anaemia, dyspnea (shortness of breath), 
hyperglycemia, fatigue, and pneumonitis (inflammation of lung tissue) (Baselga et al., 
2012). 
1.2.2.3 New developments in targeted treatments 
Research into the mechanisms of cancer has identified a number of new biological 
targets for cancer drugs, many of which have entered clinical trials. Among these, poly 
ADP ribose polymerase (PARP) inhibitors aim to prevent DNA damage repair in 
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BRCA1/BRCA2 cancer by targeting the DNA repair pathway for single-strand DNA 
breaks (Farmer et al., 2005). The PARP inhibitor olaparib (Lynparza) was approved by 
the EU in 2014 for advanced ovarian cancer patients with familial BRCA1/BRCA2 
(AstraZeneca, 2014) and is undergoing Phase III trials as a treatment for advanced 
familial BRCA1/BRCA2 breast cancer (CRUK, 2015b). An inhibitor of cell cycle 
regulators cyclin dependent kinase (CDK)4 and CDK6, Palbociclib (Ibrance), is in trials 
with letrozole for ER positive, HER2 negative advanced stage post-menopausal 
patients, having received accelerated approval from the FDA while in Phase II trials 
(FDA, 2015; Cadoo et al., 2014). Trastuzumab emtansine (Kadcyla), a form of 
trastuzumab conjugated to derivative of maytansine, a microtubule poison, binds 
specifically to HER2 positive breast cancer cells with the dual action of biological 
therapy and chemotherapy (LoRusso et al., 2011).  
Breast cancers demonstrate considerable inter- and intra-tumoural heterogeneity 
(Polyak, 2014). Even expression of the discriminating biomarkers ER, PR and HER2 
can vary between clonal populations in the same tumour, and between primary tumour 
and metastasis (Zardavas et al., 2015). It has been suggested that the tumour 
microenvironment, including the immune system and the stroma, might be a more 
stable target and less variable between patients (Zardavas et al., 2015).  
Immunotherapy drugs stimulate the immune system to respond to tumour cells or make 
tumour cells more visible to immune system cells. The immune system checkpoint 
inhibitors Nivolumab (Opdivo), which targets programmed death receptor-1 (Johnson, 
2015), and Ipilimumab (Yervoy), which targets cytotoxic T-lymphocyte antigen-4 
(Tarhini et al., 2010), are in Phase III trials for melanoma (Crow, 2015). In breast 
cancer, the immunotherapy focus is on cancer vaccines. The cancer vaccine 
nelipepimut-S (NeuVax) is in Phase III trials to prevent recurrence in HER2 positive 
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patients after surgery (NIH, 2015) and in Phase II had low toxicity (Peoples et al., 
2008).  
Processes and pathways that are common to many cancers, such as metastasis which 
shares common features across cancer types, could offer more general targets 
(Eckhardt et al., 2012). Cancer cells manipulate their environment. Breast cancer cells 
secrete fibroblast-activating growth factors which generate a response in local cancer 
associated fibroblasts (CAFs) of secreting growth factors for epithelial cells (Eckhardt 
et al., 2012). Several drugs that target CAFs are in pre-clinical or Phase I-III trials (Mao 
et al., 2013). The extracellular structural protein osteopontin is common to over 30 
types of metastatic cancer including breast cancer (Weber, 2013) and may provide a 
target. Vimentin is a protein component of intermediate filaments that is upregulated in 
many cancers including breast cancer and important in metastasis and is considered a 
druggable target (Satelli and Li, 2011). However, to assess toxicity, drugs have to be 
tested on a representative model, and there is a shortage of animal models that can 
reflect the metastatic process on a range of organs and tissues (Eckhardt et al., 2012).  
 
1.3 Cell death and chemotherapy 
Cell death is necessary to balance normal cell division and maintain homeostasis 
(Galluzzi et al., 2007). There is controversy over precise definitions of the forms of cell 
death (Table 1-4) and considerable crosstalk between the apoptosis, necrosis and 
autophagy pathways with many signalling molecules having a role in one or more 
routes (Nikoletopoulou et al., 2013). Uncontrolled cell proliferation is a hallmark of 
cancer and the aim of cytotoxic cancer treatments is to induce cell death in the 
excessive growth and the proliferating cancer cells. Chemotherapy drugs and 
radiotherapy make use of one or more cell death pathways with different morphological 
characteristics (Table 1-4). 
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Table 1-4: Cell death pathways initiated by chemotherapy
1
.  
Type of cell death Initiated by: Morphology Reversible 
Apoptosis (intrinsic) Intracellular stress, e. g. DNA 
damage 
Blebbing, shrinking, chromatin 
condensation, DNA laddering, nuclear 
fragmentation. 
No 
Apotosis (extrinsic) Extracellular signal, e.g. from 
immune system cells 
Apoptosis (anoikis) Loss of attachment 
Autophagy Starvation / stress Blebbing, autophagic vesicles in 
cytoplasm, partial chromatin condensation, 






Loss of intracellular ions, 
especially potassium 
Cytoplasmic vacuoles, swelling, loss of 
membrane integrity, rupture, release of 
inflammatory contents 
No 
Necrosis Tissue injury, ATP depletion Loss of membrane integrity, swelling, 
rupture, release of inflammatory contents 
No 
1 
Based on data from Bortner and Cidlowski ( 2014); Notte et al.( 2011); Weerasinghe and Buja (2012). 
2
 Morphological characteristics of autophagy are not well defined (Gozuacik and Kimchi, 2004). 
 
 
The most organised form of programmed cell death is apoptosis which is identified 
morphologically (Table 1-4) (Kroemer et al., 2009). Both intrinsic and extrinsic 
apoptosis pathways converge on a series of proteases called caspases which cleave 
intracellular contents, and there is cross-talk between the apoptotic pathways (Danial 
and Korsmeyer, 2004). Intrinsic apoptosis is mediated by the mitochondria in response 
to intracellular stress signals arising from DNA damage or reactive oxygen species 
(Haupt et al., 2003). Pro-apoptotic members of the Bcl-2 protein family, primarily Bax 
and Bak, activate mitochondrial outer membrane permeabilisation (MOMP) which 
allows the release of cytochrome c into the cytosol (Green, 2005). Anti-apoptotic Bcl-2 
family members block the action of pro-apoptotic members to prevent MOMP. 
Cytochrome c binds the apoptotic protease activating factor Apaf-1 which recruits the 
protease procaspase-9 to form the sevenfold-symmetrical apoptosome complex and 
causes self-activation of procaspase-9 (Green, 2005). Caspase-9, the active form, 
initiates an apoptotic cascade via proteases caspase-3 and caspase-7 resulting in 
cleavage of intracellular components and the loss of ionic strength, after which the cell 
shrinks and breaks into apoptotic bodies (Bortner and Cidlowski, 2014; Shalini et al., 
2015). These are consumed by other cells by phagocytosis without an immune 
response (Bortner and Cidlowski, 2014).  
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Figure 1-5: Simplified model of the intrinsic and extrinsic apoptotic pathways. ROS: reactive 
oxygen species. FADD: Fas associated death domain. FASR: Fas receptor. MOMP: mitochondrial 
outer membrane permeabilisation. DISC: death inducing signalling complex. Apaf-1: Apoptotic 
protease activating factor 1. The apoptosome consists of seven copies of cytochrome c, Apaf-1 




The extrinsic pathway is a response to extracellular signalling activated by members of 
the tumour necrosis factor (TNF) family, including FasL, ligands for the TNF receptor 
(TNFR) family of transmembrane proteins, which includes Fas receptor (FASR) (Figure 
1-5). For example, after FasL binds extracellularly to Fas receptor (FASR), the 
intracellular domain of FASR recruits Fas associating death domain containing protein 
and procaspase-8 to form a death inducing signalling complex (DISC). The DISC 
activates procaspase-8 whose active form, caspase-8, initiates an apoptotic cascade 
via caspase-3 and caspase-7 (Danial and Korsmeyer, 2004). Anoikis, a form of 
apoptosis initiated by inappropriate signalling between the cell and the extracellular 
matrix, normally ensures that cells that are detached from their environment do not 
survive and has features of both intrinsic and extrinsic apoptosis in a cell type specific 
manner (Gilmore, 2005). 
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Autophagy is selective degradation of organelles as a starvation response to make 
cellular materials available for re-use and can lead to autophagic cell death or precede 
apoptosis (Liang et al., 2006). In autophagy, Beclin 1 promotes the formation of 
autophagosomes, structures enclosed by a double membrane in the cytoplasm, which 
encapsulate organelles, including mitochondria (Notte et al., 2011). Autophagosomes 
then fuse with lysosomes where the contents are degraded by lysosomal enzymes and 
recycled within the cell (Ricci and Zong, 2006). There is crosstalk with other pathways. 
For instance, in addition to its anti-apoptotic role in apoptosis, Bcl-2 is able to inhibit 
Beclin-1 and prevent autophagy (Notte et al., 2011). Necrosis occurs as a result of 
damage causing loss of ATP generation and has been thought of as accidental, but 
there is now evidence for necrosis being induced by intracellular and extracellular 
signals (Krysko et al., 2008). Swelling and membrane rupture release intracellular 
contents that can cause local inflammation and an immune response (Kroemer et al., 
2009). 
The means of cell death in cells treated by chemotherapy and radiotherapy is primarily 
through apoptosis. DNA-damaging agents and ionizing radiation activate the DNA 
damage response, leading to the stabilization of tumour suppressor protein p53 which 
would otherwise be degraded by mouse double minute 2 homolog (Lane, 1992). p53 
arrests the cell cycle temporarily to allow time for DNA damage repair, or initiates 
intrinsic apoptosis by transcription of pro-apoptotic genes (Ricci and Zong, 2006). In 
the cancer context, autophagy may have either a tumour suppressor function and 
promote necrosis, or, later in the disease’s progress, a pro-survival function (Notte et 
al., 2011). Pro-apoptotic Bid provides a route for convergence of the intrinsic and 
extrinsic pathways (Figure 1-5) and autophagy may be an important means of cell 
death in cancer cells with part of the apoptotic pathways disrupted (Notte et al., 2011; 
Haupt et al., 2003).  
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1.4 The cytoskeleton in cancer 
1.4.1 Introduction 
The hallmarks of cancer include sustained cell division and cell invasion and 
metastasis, both mediated by actions of the cytoskeleton (Hanahan and Weinberg, 
2011). The cytoskeleton is the intracellular network of structural proteins composed of 
actin filaments, microtubules and intermediate filaments. Both microtubules and actin 
filaments are involved in cell division, while the actin network is also active in cell 
motility (Hall, 2009). Microtubules are composite filaments of around 13 protofilaments 
(Tilney et al., 1973) which are themselves polymers of tubulin protein subunits: 
heterodimers of α-tubulin and β-tubulin each bound to guanosine triphosphate (GTP) 
(Jordan and Wilson, 1998). Actin filaments or microfilaments are polymers formed of a 
helix of two strands of filamentous actin (F-actin) which is polymerised from a pool of 
free actin subunit monomers (G-actin) in solution in the cytoplasm and bound to 
adenosine triphosphate (ATP) (Allingham et al., 2006). 
There are similarities in the polymerisation mechanisms of microtubules and actin 
filaments. Net polymerisation occurs when the concentration of subunits in the 
cytoplasm is higher than the critical concentration for growth, and net depolymerisation 
when it is lower (Raxworthy, 1988; Remedios et al., 2003). The filaments have a 
polarised structure with a plus end where conditions are more favourable for growth 
and a minus end where they are less favourable, although both growth and shrinkage 
can occur at either end (Raxworthy, 1988; Remedios et al., 2003). Soon after the unit 
binds to the filament, tubulin or actin catalyses hydrolysis of the triphosphate to 
guanosine diphosphate (GDP) or adenosine diphosphate (ADP) (Figure 1-6), which 
causes a conformational change in the subunit that introduces torsions in the filament 
structure (Amos and Löwe, 1999; Oda et al., 2009). The torsional stress is overcome 
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by intrafilament lateral binding, but makes shrinkage favourable at the minus end 
(Figure 1-6) (Chen et al., 2000; Tilney et al., 1973). 
               
 
Figure 1-6: Growth and shrinkage of a microtubule. Soon after the dimer joins the plus end, GTP 
hydrolyses to GDP and intrafilament bonding is weakened. Dimers at the minus end are lost. If 
rates of growth and shrinkage are equal, treadmilling occurs. Adapted and redrawn from Jordan 
and Wilson (2004). 
 
 
In treadmilling, common to both microtubules and microfilaments, the concentration of 
monomers in the cytoplasm is such that the polymerisation reaction is in equilibrium, 
the growth rate at the plus end is matched by shrinkage at the minus end and there is a 
cap of unhydrolysed GTP or ATP (Jordan and Wilson, 2004). Microtubules also display 
dynamic instability behaviour, in which filaments are stable until growth stops and the 
cap of GTP-tubulin is lost, whereupon instability in the protofilaments causes a fast 
shrinkage at the plus end called catastrophe (Jordan and Wilson, 2004). 
1.4.2 Microtubules in cell division 
In interphase, microtubules are distributed throughout the cell where they operate as 
tracks for intracellular transport, but during mitosis they undergo reorganisation to form 
the mitotic spindle (Lancaster and Baum, 2014). Microtubules are nucleated at the 
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centromeres at opposite positions in the cell, then extend towards the centre and 
retract with dynamic instability repeatedly until they are connected to kinetochores in 
the centres of all chromosomes to make the spindle (Lancaster and Baum, 2014). At 
anaphase in mitosis the spindle pulls the chromosomes to the two poles by a 
combination of motor transport and treadmilling (Sharp et al., 2000; Jordan and Wilson, 
2004).  
1.4.3 Drugs that target microtubules 
Cancer cells cycle more frequently than normal cells leading to excessive growth. 
Drugs that interfere with spindle processes in mitosis can block cell division and initiate 
cell death. The taxane paclitaxel, the first microtubule inhibitor to be introduced as a 
chemotherapeutic agent, stabilises microtubules (Jordan et al., 1993). Paclitaxel binds 
to the polymerised β-tubulin subunit and inhibits the conformational changes that occur 
on hydrolysation so that the torsion is reduced, making the microtubule more stable 
and preventing dynamic instability (Manfredi et al., 1982; Verweij et al., 1994).  
The precise mechanism of cell death in tumours in vivo following paclitaxel treatment is 
unclear, but observations from cell lines suggest a combination of mitotic block and 
p53-dependent apoptosis. In many cancers p53 is inactive or elements of its pathway 
are deficient, therefore paclitaxel cytotoxicity must partly be mediated by means of cell 
death independent of p53 (Woods et al., 1995). The spindle assembly checkpoint 
(SAC) prevents anaphase until all chromosomes are attached (Figure 1-7) (Jordan and 
Wilson, 2004). If anaphase is delayed, mitotic block causes a p53 independent 
apoptosis or an exit from mitosis without dividing and with tetraploid chromosomes in a 
process called mitotic slippage (Woods et al., 1995). Woods et al., (1995) saw mitotic 
slippage in a minority of paclitaxel-treated normal fibroblasts. The G1 checkpoint 
checks for errors in DNA including tetrapoloidy and if damage cannot be repaired 
initiates p53-dependent apoptosis, which was seen in the tetraploid fibroblasts (Woods 
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et al., 1995). In breast cancer cell lines, paclitaxel treated cells developed increasingly 
abnormal spindle morphology as dose increased, resulting in star-shaped bundles or  
   
 
              
 
Figure 1-7: The cell cycle. A: Phases of the cell cycle and checkpoints. G1, G2: growth phases. S: 
synthesis. M: mitosis. Interphase: G1, S, G2. B: Stages of mitosis. SAC: Spindle assembly 
checkpoint. Adapted and redrawn from Weaver and Cleveland (2005); Kunda and Baum (2009). 
 
 
asters of microtubules, entered mitotic block and subsequently apoptosis after 24 hours 
(Yeung et al., 1999). However, 50% of cells are blocked in mitosis at paclitaxel doses 
too low to cause additional microtubule polymerisation, which suggests that a low level 





and Wilson, 2004). The explanation for mitotic block causing apoptosis is unclear, but 
may be through prolonged mitotic inhibition of protein transcription leading to a 
reduction in levels of short-lived anti-apoptotic proteins and activation of either the 
intrinsic or extrinsic pathway (Blagosklonny, 2007).  
Paclitaxel can also cause the phosphorylation and inactivation of anti-apoptotic Bcl-2 
through Raf-1, pushing the balance of pro- and anti-apoptotic proteins towards 
mitochondria mediated apoptosis (Blagosklonny et al., 1996). Orth et al. (2012) showed 
that prolonged mitotic arrest in breast cancer cells can also cause DNA damage and a 
p53-dependent damage response. In addition, paclitaxel can initiate necrosis in breast 
cancer cells, at least at higher than therapeutic levels (Yeung et al., 1999), and can 
generate an autophagic response (Eum and Lee, 2011) although it is unclear whether 
this protects against or promotes apoptosis.  
Docetaxel is a semisynthetic analogue of paclitaxel that binds β-tubulin with greater 
affinity and has a longer retention time in tumour cells (Gligorov and Lotz, 2004). 
Abraxane is a form of paclitaxel bound to albumin as a nanoparticle delivery vehicle. 
The presence of albumin aids drug delivery by binding to the cell surface receptor gp60 
on vascular endothelial cells to make an albumin-gp60 complex which induces 
caveolae formation, transcytoses across the blood vessel wall into the stroma, and 
binds to secreted protein acid rich in cysteine (SPARC) often expressed by cancer cells 
(Miele et al., 2009). Binding to SPARC releases the hydrophobic cargo paclitaxel which 
then diffuses into the tumour cell (Miele et al., 2009). Breast cancer patients can 
tolerate 70% higher doses because higher levels of paclitaxel are found in the tumour 
than surrounding cells, and the antitumour effect is greater (Miele et al., 2009). 
The vinca alkaloid drugs vincristine and vinblastine and their derivatives vindesine and 
vinorelbine target microtubules by inhibiting polymerisation. Vinblastine binds to tubulin 
27 
 
polymers and dimers inducing self-association in dimers and prolonging the time a 
microtubule spends neither growing nor shortening (Jordan and Wilson, 2004). It 
seems to perturb microtubule dynamics sufficiently to delay anaphase leading to mitotic 
block at the SAC and apoptosis (Jordan and Wilson, 2004). In a study of the effects of 
vincristine and vinblastine, at doses which caused just less than 50% growth arrest, 
spindles looked almost normal, with the exception of some unusually long astral 
microtubules, yet 50% of cells were arrested in metaphase of mitosis (Jordan et al., 
1991). At doses that caused 70-90% mitotic arrest some cells had star-shaped 
microtubule arrangements instead of a spindle while in others some chromosomes 
were found at the poles instead of at the metaphase plate, yet polymerisation was only 
inhibited at still higher doses when microtubules in the star shapes became shorter 
(Jordan et al., 1991). Despite the differences in taxanes’ and vinca alkaloids’ binding to 
tubulin, their mechanisms of action in preventing tubulin turnover, perturbing 
microtubule dynamics and leading to mitotic block are similar.  
Cancers that are unresponsive to taxanes or vinca alkaloids can be treated with drugs 
that target microtubules in other ways. Eribulin (Halaven) is a microtubule inhibitor 
antimetabolite that appears to operate by end-poisoning, or preventing growth of 
microtubules during mitosis, and by forming aggregates with free tubulin, reducing the 
available pool of tubulin for microtubule growth (Jordan et al., 2005). It was approved in 
2010 by the USA Food and Drug Administration (FDA) for use on metastatic breast 
cancer that has already been treated with two other chemotherapy regimens involving 
taxanes and anthracyclines (FDA, 2010). The newer epothilone group of microtubule 
inhibitors, which includes ixabepilone, appears to have a similar mode of action to the 
taxanes, but binds to a different binding pocket on the β-tubulin subunit (Boehnke 
Michaud, 2009). In both cases, as with the taxanes, treated cells enter mitotic block 
and cell death (Boehnke Michaud, 2009). 
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Cancers that develop resistance to taxanes and vinca alkaloids do so with two primary 
mechanisms. Some cancers with mutated β-tubulin genes form α-β subunits less 
readily which slows the growth of microtubules, making them more vulnerable to 
instability through hydrolysis of the end cap of GTP-tubulin, a situation reversed by 
taxanes which confer normal microtubule growth on these cells (Orr et al., 2003). 
Others develop ATP transporter drug efflux pumps that remove paclitaxel and vinca 
alkaloids from the intracellular space (Gottesman et al., 2002). Despite some cross-
resistance between the two taxanes, paclitaxel can be successful in MBC patients who 
have developed resistance to docetaxel, therefore mechanisms of resistance are not 
identical (Yonemori et al., 2005).  
1.4.4 Actin filaments in cell motility  
Most of the changes associated with movement are performed by the actin 
cytoskeleton (Wehrle-Haller and Imhof, 2003). Excessive cell motility enables cancer 
cells to migrate inappropriately and form invasive or metastatic tumours. Cells either 
adopt an amoeboid crawling motion led by broad lamellipodia, or extend narrow 
filopodia and follow them with the rest of the cell body (Chhabra and Higgs, 2007). The 
most important F-actin structures in cell motility are mesh, a complex structure 
involving actin binding proteins (ABPs) and regulatory proteins, and stress fibres, thick 
bundles of unbranched actin (Tojkander et al., 2012).  
A cross-linked mesh of branched or dendritic actin filaments (Figure 1-8), supported by 
many ABPs with differing functions, forms the cell cortex near the plasma membrane 
which shapes the cell (Olson and Sahai, 2009). The ARP2/3 complex acts as a 
nucleation point for actin filaments and initiates branching in lamellipodia (Yamaguchi 
and Condeelis, 2007). The formin family of ABPs provide actin nucleation points 
without branching, and travel with the plus or barbed end, preventing end-capping 
proteins from binding in a movement called processive capping (Zigmond, 2004). 
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Profilin adds actin monomers to the barbed ends of microfilaments by binding to ADP-
actin monomers and catalysing hydrolysis to ATP-actin (Kang et al., 1999). The actin 
depolymerising factor (ADF)/cofilin family of severing proteins are depolymerising 
proteins that bind to GDP-F-actin in the filament and sever it, creating more ends for 
polymerisation and encouraging turnover (Chen et al., 2000). Gelsolin is a severing 
and capping protein that caps filaments at the barbed end to prevent growth but can 
sever and cap existing filaments (Remedios et al., 2003). Formins mediate nucleation 
of a new actin filament in an unbranched network such as in filopodia. When formins 
are activated into their open conformation by Rho family GTPases they bind the actin 
polymer and the monomer with profilin, providing a supply of new actin monomers to 
extend the strand (Olson and Sahai, 2009). Cross-linking proteins α-actinin in 
lamellipodia and fascinin in filopodia anchor bundles together (Tseng et al., 2005) and 
stress fibres are cross-linked with α-actinin (Pellegrin and Mellor, 2007).  
                        
Figure 1-8: Simplified model of growth of branched actin. ABP: actin binding protein. ATP: 




Both branched and unbranched actin may be contractile. Contractility is generated by a 
dimer of myosin II molecules made of a myosin II light chain (MLC) and a myosin 
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heavy chain (MHC) with a globular head and a coiled-coil domain tail (Figure 1-9). On 
phosphorylation of MLC by Rho associated coiled-coil containing kinase (ROCK), citron 
kinase or MLC kinase (MLCK), the MHC tail is released, allowing interaction of myosin  
 
 
Figure 1-9: Myosin II dimer structure (A), actomyosin structure (B) and contractility mechanism in 
minifilament. ROCK: Rho associated coiled-coil containing kinase. MLC: myosin light chain. MHC: 
myosin heavy chain. MLCK: MLC kinase. P: phosphorylation. +: plus/barbed end of actin filament. 
Red arrows in B show contraction of myosin. Adapted and redrawn from Levayer and Lecuit (2012). 
 
 
II with the actin filament in an actomyosin complex (Levayer and Lecuit, 2012). During 
stress fibre formation, ROCK phosphorylates LIM kinase (LIMK) which phosphorylates 
and inactivates the severing protein cofilin (Olson and Sahai, 2009). Several 
actomyosin fibres associate tail to tail to make a minifilament. Using energy from ATP, 
the myosin head progresses along the actin filament towards the barbed end. When 
two myosin filaments associate with opposite polarities they move relative to one 
another, creating contractile force (Olson and Sahai, 2009). Tropomyosins (TMs) 
polymerise to form filaments that lie in the major groove of actin filaments and regulate 
the binding of ABPs to actin (Gunning et al., 2005). The family of ~40 TMs have 
isoform-specific, cell type-specific effects (Gunning et al., 2005). When stimulated by 
calcium, TM5NM1 moves to uncover the myosin binding site of actin and permit 
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actomyosin formation. In breast epithelial cells, TM1 stabilises stress fibres by 
protecting them from severing by gelsolin and ADF/cofilin, and is often absent in breast 
cancer cells (Gunning et al., 2005). In neurons, TMBr3 promotes gelsolin and 
ADF/cofilin binding to actin and their severing activity, reduces stress fibres and 
increases lamellipodia formation (Bryce et al., 2003). 
The mechanisms for cell migration are specific to cell type and substrate. In a 
stationary fibroblast on a 2D adhesive surface stress fibres are prominent but in a 
migrating fibroblast (Figure 1-10) stress fibres are disassembled to provide a pool of G-
actin for polymerisation in a lamellipodium or filopodium (Lauffenburger and Horwitz, 
1996). Migration is a cycle of protrusion and retraction at the leading edge (Giannone 
et al., 2007). Polymerisation of branched actin mesh attached to a substrate at 
stationary focal complexes provides sufficient force to push the leading edge of the cell 
forward (Giannone et al., 2007). This is followed by retraction as, behind the actin rich 
leading edge, actomyosin contracts to pull the lamellipodium backward and generate 
downward pressure on the substrate where a new focal contact forms (Giannone et al., 
2007). Meanwhile, at the rear, stress fibres contract to pull the tail forward and focal 
contacts slide (Wehrle-Haller and Imhof, 2003) or break off and are left on the 
substrate (Lauffenburger and Horwitz, 1996). As more prominent stress fibres are seen 
in less motile cells, they may inhibit cell migration (Pellegrin and Mellor, 2007), whereas 
in fast moving cells such as some cancer cells, stress fibres are finer or absent 
(Wehrle-Haller and Imhof, 2003). Possibly due to loss of polarity, cancer cells may 
develop lamellipodia at two membrane locations, resulting in equal pull and 
immobilisation (Wehrle-Haller and Imhof, 2003). In some cancer cells a continuous 
extension and retraction of lamellipodia is seen without attachment in a process called 




Figure 1-10: Schematic of actin fibres in a migrating fibroblast and the protrusion and retraction 
cycle. Adapted and redrawn from Levayer and Lecuit (2012); Wehrle-Haller and Imhof (2003). 
 
 
The three Rho GTPase families Rho, Rac and Cdc42 catalyse the hydrolysis of GTP to 
GDP and act as molecular switches in control of actin cytoskeleton remodelling during 
mitosis and cell migration (Hall, 2009). Rho GTPases are activated by a family of more 
than 70 guanine nucleotide exchange factors (GEFs) and inactivated by more than 80 
GTPase activating proteins (GAPs) responding to extracellular signals (García-Mata 
and Burridge, 2007). Activated Rac1 induces the formation of lamellipodia and is found 
in membrane ruffles (Wehrle-Haller and Imhof, 2003). For nucleation of a new filament 
in a lamellipodium, Rac at the leading edge determines the position of the scaffold 
Wiskott–Aldrich syndrome proteins (WASPs) which have a closed conformation until 
Cdc42 and the phospholipid signalling molecule phosphatidylinositol 4,5-bis-phosphate 
(PIP2) bind to change them to an open, active conformation (Olson and Sahai, 2009). 
Activated Cdc42 induces the polymerisation of branched actin in lamellipodia where 
WASPs have binding sites for actin, profilin and ARP2/3, bringing them into close 
proximity and increasing the rate of actin binding (Olson and Sahai, 2009). Activated 
RhoA is found at the rear of the cell and induces stress fibre formation (Wehrle-Haller 
and Imhof, 2003). The polarisation is maintained by activated Rac1 blocking RhoA and 
activated RhoA blocking Rac1 activity (Wehrle-Haller and Imhof, 2003); however, in 
cancer cells both Rac1 and RhoA are found in membrane ruffles (Kurokawa and 
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Matsuda, 2005). The GAPs and GEFs regulating the Rho GTPases in cell migration 
are not fully understood. 
1.4.5 Actin filaments in cell division 
The actin cytoskeleton is involved at several stages of mitosis (Table 1-5). The 
contractile ring, consisting of actomyosin, forms at the cell equator and tightens to 
induce cytokinesis (Miller, 2011). If the contractile ring fails to form, cytokinesis does 
not take place and the cell becomes binucleated (Davies and Canman, 2012). 
Positioning of the contractile ring is partly controlled by microtubules through the GEF 
GEF-H1, localised to microtubules and itself activated by microtubule depolymerisation, 
which activates RhoA at the equator (D’Avino, 2009). Activated RhoA-GTP induces 
formation of actin filaments for the contractile ring and linkage with myosin II via ROCK, 
citron kinase, nucleation via the formin mDia and inactivation of cofilin in a similar way 
to the formation of stress fibres (Figure 1-9) (Glotzer, 2001). Myosin II promotes 
alignment of actomyosin bundles and provides contractile force in the contractile ring 
(Glotzer, 2001). GAPs and GEFs may control cycling of active and inactive RhoA 
during mitosis to ensure a constant supply of activated RhoA (Heng and Koh, 2010).  
Table 1-5: Actin involvement in stages of the cell cycle 
1
. 
Stage Event Role of microfilaments 
Mitosis 
Prophase Rounding, to facilitate spindle 
positioning 
Loss of adhesion and increased cortex rigidity. Separation 
of centrosomes for correct spindle positioning. 
Retraction fibres maintain attachment. 
Metaphase Spindle attachment to chromosome 
kinetochores 
Associate with microtubules, possibly for correct spindle 
orientation  
Anaphase Spindle separates chromosomes 
Cytokinesis Split into two daughter cells Actin-myosin filament assembly forms contractile ring. 
Contraction of ring. Cortex reassembled to pull daughter 
cells apart 
Interphase Spreading  Regain adhesion 
1 





1.4.6 Drugs that target the actin cytoskeleton  
Many of the actin cytoskeleton proteins are deregulated in cancer cells, and in breast 
cancer cells these include ARP2/3, Cdc42, Rac1, RhoA, N-WASP, profilin, gelsolin, 
and MLCK (Olson and Sahai, 2009). Metastatic breast cancer has increased actin 
filaments and reducing the actin structure reduces cell motility (Trendowski, 2014). 
There are no drugs approved for use that target the actin cytoskeleton and two recent 
reviews of drug targets for metastasis did not include the actin cytoskeleton (Eckhardt 
et al., 2012; Weber, 2013). However, some natural product compounds target actin 
directly. They either inhibit polymerisation or depolymerise actin filaments; or enhance 
polymerisation or stabilise actin filaments (Table 1-6) (Foerster et al., 2014). Many of 
them have been investigated as potential anticancer drugs.  
Table 1-6: Some natural product compounds targeting actin directly 
1
.  






Binds to filaments and prevents addition of monomers. 
Latrunculin A Sequesters G-actin: binds to the ATP-binding cleft and prevents 
monomers polymerising by inhibiting the necessary conformational 
change. 
Kabiramide C Sequesters G-actin: Binds to surface of barbed end of G-actin creating 






Interacts with three actin monomers in filament to stabilise filament. 
Dolastatin Interacts with two actin monomers in filament to stabilise filament. 
1
Based on data from Allingham et al. (2006); Trendowski (2014); Dhar et al. (2015). 
 
 
Cytochalasin B can disrupt the contractile ring in cancer cells leading to unsuccessful 
mitosis and large multinucleated cells (Trendowski, 2014). Kabiramide C, a trisoxazole 
toxin, has a large hydrophobic ring that contacts a hydrophobic patch in the barbed end 
of monomeric G-actin such that its long tail lies in the cleft and prevents monomers 
from attaching (Allingham et al., 2006). The natural products that stabilise actin, 
including cyclic peptides jasplakinolide and phalloidin, bind to more than one actin 
subunit in the polymer to reinforce the intrafilament binding, and it is likely that they 
induce conformational changes with effects that stabilise the filament at a distance from 
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the binding sites (Allingham et al., 2006). Both jasplakinolide and phalloidin appear to 
have cell type specific effects. In prostate cancer cells at non-lethal doses 
jasplakinolide caused cell rounding, membrane blebs, aggregation of filamentous actin 
and reduced cell motility, and it inhibited cell division leading to the formation of 
multinucleated cells (Senderowicz et al., 1995). At non-lethal doses jasplakinolide 
increases actin polymerisation and cell migration in breast cancer and leukaemia cells 
(Hayot et al., 2006; Kothakota et al., 1997; Stingl et al., 1992). In cervical cancer cells 
phalloidin causes aggregation of actin and reduced cell motility and cell division 
(Wehland et al., 1977). 
Some drugs target the cytoskeleton accessory proteins. A synthetic triterpenoid has 
been tested on Rat2 fibroblasts where it led to reduced ARP3 expression and ARP2/3 
dependent branching, and knocking down ARP3 with a small interfering RNA reduced 
cell motility (To et al., 2010). Tropomyosins are differentially expressed in cancers with 
TM5NM1 upregulated in melanoma and neuroblastoma cells and TM1 expressed at 
low levels or absent in most cancers including breast cancer (Gunning et al., 2008; 
Stehn et al., 2013). The anti-tropomyosin synthetic compound TR100 targets 
TM5NM1/2 (Stehn et al., 2013). Raval et al. (2003) found that TM1 had a tumour 
suppressor function and expressing TM-1 in breast cancer cells could inhibit growth 
and sensitise cells to apoptosis in anchorage independent conditions. However, 
targeting the tropomyosins may prove challenging as their activity is dependent on the 
availability and activity of other ABPs in each cell type and intracellular location 
(Gunning et al., 2008). Due to the ubiquity of the actin cytoskeleton in all cells and the 
difficulty of specifically targeting cancer cells, and the complexity in the cytoskeleton 
which permits alternative pathways when one is blocked, there is still much to discover 
about targeting the proteins in the actin cytoskeleton.  
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1.4.7 The need for new drugs 
Breast cancer is heterogeneous. The choice of therapy and the specific agents 
selected as monotherapy or in combination depend on the nature and stage of the 
disease, and each patient’s cancer response. In a breast cancer classification of 537 
tumours based on gene expression microarray analysis, Guedj et al. (2012) found that 
breast cancer tumours clustered into six subgroups which they suggest could generate 
new prognostic markers and therapeutic targets. They validated the classification 
against external datasets of >3000 tumours and found distinct differences between 
groups in clinical outcome (Guedj et al., 2012). However, others including Green et al. 
(2013) dispute the validity of using microarray analysis for classification, preferring 
immunohistological classification on grounds of clinical relevance, repeatability and 
cost. Green et al. (2013) classified 93% of tumour specimens into six subgroups using 
10 biochemical markers. Genetic classification is allowing drugs to be developed for 
sub-groups of patients but the cost per patient is high. Currently, even drugs that target 
sub-populations do not have an entirely predictable response: for example, tamoxifen 
is only effective in 70% of ER positive cases (Hoskins et al., 2009). Drugs aimed at less 
specific targets, that would be effective in more patients, would be more cost effective.  
Very effective, if burdensome, treatments exist for early stage breast cancer, with the 
exception of triple negative patients. Hormone therapy, chemotherapy and biological 
therapy, used alone and in combination, offer huge benefit to patients and can prevent 
or considerably delay the progress of disease. However, in advanced breast cancer, 
after disease recurrence, metastasis and drug resistance, eventually palliative care is 
the only option. There are currently no drugs available that target the process of cell 




1.5 Sources of new drugs 
1.5.1 Introduction 
The goal of drug discovery is to develop effective and safe treatments for human 
diseases. In the last 25 years target-based approaches which attempt to modify the 
behaviour of molecular targets with a key role in disease have been the main focus of 
commercial drug discovery (Zheng et al., 2013). Phenotypic screening, a traditional 
approach that needs no initial knowledge of the target molecule but relies on an assay 
that represents a disease model, continues to be used (Zheng et al., 2013). Both rely 
on large databases of potential drug candidates that may include natural products, 
which have supplied many of the drugs in use today. Of the 1355 new chemical entities 
(NCEs) introduced between 1981 and 2010, 27% were a natural product or derived 
from a natural product, and a further 13% were synthetic but with a pharmacophore 
derived from a natural product (Figure 1-11). Natural product drug discovery strategies 
form a third approach to drug discovery. 
 
Figure 1-11: Sources of new chemical entities introduced worldwide excluding Russia and China, 
1981-2010 (A) and (B) example anticancer drugs of each type. N=1355. B: biological. N: natural 
product. ND: natural product derived semi-synthetic. S: synthetic. S*: synthetic with a 
pharmacophore derived from a natural product. V: vaccine. Compiled from information in Newman 







1.5.2 Target-based and phenotypic drug discovery 
Since early work in the 1950s and 1960s on enzyme kinetics, it has become possible to 
identify a molecular target with a key role in disease. The target-based methodology 
(Figure 1-12) was adopted as it appeared to offer a more direct and efficient route to 
finding effective NCEs. Genome analysis and recombinant DNA technology are two of 
the many new methods available to assist development of assays that test whether a 
drug interaction with a target will cause a change in the progress of a disease, and 
miniaturization and robotic automation have allowed fast high-throughput screens for 
activity of a range of compounds on a molecular target using large libraries of 
compounds (typically 0.4-2 million) (Zheng et al., 2013). Lead identification can be 
assisted with x-ray crystallography, computational modelling and virtual screening 
(Swinney and Anthony, 2011). Nonetheless, drug discovery is an expensive process. 
The average cost to develop a new drug over 10-12 years is accepted as around $1 
billion and recent estimates place it at $2.5 billion when the losses from unsuccessful 
drugs are included (Mullin, 2014). The recently elevated cost is attributed to more 
complex clinical trials, additional testing to meet requirements for insurance and a 
greater focus on difficult-to-treat chronic and degenerative diseases such as 
Alzheimer’s, where animal models are not representative and trials require large 
numbers of subjects to be followed for a longer time (Mullin, 2014; Cook et al., 2014). 
 
 
Figure 1-12: Schematic of the conventional approach for drug discovery, either target-based (A) or 
phenotypic (B). ID: identification. HTS: high-throughput screening. Adapted and redrawn from 





There is a high attrition rate: between 2005-2010 the industry median for success in 
bringing candidate drugs to market was 6% (Figure 1-13). Meanwhile, the number of 
new chemical entities has declined from an average of 51 per year (1981-1990) to 40 
per year (2001-2010) (Newman and Cragg, 2012). The target-based strategy has also 
come into question as invalidation of drug targets is a significant cause of failure. In an 
analysis of 142 projects in Astra Zeneca’s drug pipeline from 2005-2010, where more 
than half were halted because of safety issues, lack of efficacy was the second highest 
reason for failure (Cook et al., 2014). The reasons were complex, but lack of target 
validation – the drug’s engagement with the target not having the predicted benefit in 
patients – was the main reason for failure due to lack of efficacy (Cook et al., 2014). 
This was attributed to an incomplete knowledge of the molecular mechanism, using 
animal models as an imperfect representation of human disease, and the genetic 
variation in patient populations (Zheng et al., 2013). 
 
    
Preclinical development Clinical trials 
Phase I Phase II Phase III 
From toxicology testing to 
investigational new drug 







studies. Normally in 
healthy volunteers. 
Trials in patient 
population aimed at 
evaluating candidate 
drug efficacy and 
leading up to clinical 
proof of concept. 
Trials in large groups to 
confirm efficacy, monitor 
side effects, compare to 
other treatments, and 
collect information that 
will allow safe use 
Figure 1-13: Industry success rates at each preclinical and clinical phase of candidate drug 
development 2005-2010 (A) and description of phases of drug development (B). A, data from NIH, 







The impact of this data is that alternative strategies are being sought. Among many 
other initiatives, there is an increase in phenotypic drug discovery (Figure 1-12 B). 
Phenotypic screening relies on an assay that represents a disease model, usually a 
physiologically relevant cell based assay such as a cell viability assay. As in target-
based approaches, large libraries of compounds are screened for activity in the assay. 
After a candidate molecule is found, the target must be identified for lead optimization 
and structure activity relationship work (Zheng et al., 2013). Among the first-in-class 
small molecule drugs approved by the US FDA between 1999-2008, 28 were 
discovered in a phenotypic screening approach and 17 in a target-based approach 
(Swinney and Anthony, 2011).  
1.5.3 Natural product drug discovery  
Natural product drug discovery strategies have run in parallel alongside more 
commercial target-based and phenotypic drug discovery. The term natural product 
includes whole organisms, parts of organisms such as leaves, extracts made from 
biological organisms, and pure chemicals isolated from extracts. Strategies for finding 
useful natural products may focus on screening a natural product extract for chemicals, 
and may quickly isolate and identify components of a natural product extract without 
testing for bioactivity or isolating the compounds (Dias et al., 2012). For example, in a 
recent study 24 hydroxycinnamates were isolated and identified from the leaf, and 26 
compounds from the stem, of the grass Miscanthus × giganteus by liquid 
chromatography-mass spectrometry (Parveen et al., 2011). To avoid isolating every 
compound, fractions of extracts are also stored in libraries and used in high throughput 
screening (Harvey et al., 2015). In some zones of biodiversity, for example Costa Rica, 
all species are being documented which will facilitate scientific use including screening 
for useful chemicals (INBio, 2014). Alternatively, in a bioassay-led approach to natural 
product drug discovery, work concentrates on identification of bioactive components 
with potential medicinal benefit from a natural product extract (Sarker and Nahar, 
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2012a). A recent bioassay-led approach to antifungal activity in turmeric and nutmeg 
led to the isolation and identification of six potentially useful compounds (Radwan et al., 
2014). Spectroscopy techniques permit identification of novel compounds, and 
metabolomics are being used to analyse medicinal products in traditional Chinese 
medicine (Luo et al., 2012). The type of organism being studied has widened, for 
instance to include more microorganisms and marine organisms, but 48% of drugs 
from natural products are derived from plants (Harvey, 2008) (examples of sources in 
Table 1-7).  
Natural products offer a range of compounds with different chemical characteristics 
from synthetics, offering potential advantages: they tend to have more fused and 
bridged ring systems, offering some rigidity and binding to widely spaced targets; they 
have more chiral centres, more carbon-oxygen bonds, fewer carbon-nitrogen bonds, 
fewer aromatic atoms and more scaffold diversity (Drewry and Macarron, 2010). These 
factors can introduce more diversity into screening libraries. They often bind with high 
affinity to their targets, requiring minimal modification (Driggers et al., 2008). In addition 
they tend to be more hydrophilic than synthetic drugs, potentially facilitating uptake into 
cells (Ganesan, 2008). One disadvantage is that they can present challenges for 
synthetic chemists in synthesis, preventing their inclusion in libraries, but advances in 
synthesis techniques are changing this (Drewry and Macarron, 2010). There is a move 
towards using smaller libraries based on a class of natural product such as flavonoids 
or alkaloids, or based on chemically related scaffolds, and pooling structure data from 
different institutions to facilitate virtual screening before obtaining the compound from 
the institution that has isolated or synthesised it (Harvey, 2008). 
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Table 1-7: Sources of selected drugs derived from natural products in current use or being studied. 




Paclitaxel Bark of Taxus brevifolia, Pacific yew, and its endophytic fungus Taxomyces 
andreanae 
Vincristine, vinblastine  Catharanthus roseus, Madagascar periwinkle
 
Aspirin Bark of Salix alba, white willow 
Withaferin Root of Withania somnifera, winter cherry 
Reserpine Root of Rauwolfia serpentine, Indian snakeroot 
Bacteria 
Everolimus Synthetic analogue of rapamycin, isolated from Easter Island soil bacteria 
Streptomyces hygroscopicus 
Mitomycin C Streptomyces caespitosus 
Ixabepilone  Synthetic analogue of epothilone B isolated from soil bacteria Sorangium 
cellulosum 
Fungus  
Phalloidin Amanita phalloides, death cap mushroom 
Cytochalasin B  Helminthosporium dematioideu 
Animal: marine sponge 
Eribulin Synthetic analogue of halichondrin B, isolated from Halichondria okadai 
Latrunculin B Negombata magnifica, toxic-finger sponge 
Kabiramide C Ircinia sp. 
Jasplakinolide Jaspis johnstoni 
Animal: marine mollusc 
Dolastatin Dolabella auricularia, wedge sea hare 
 
 
The conventional approach to bioassay-led development from natural products can be 
viewed in three stages (Figure 1-14). The bioassay driven approach leads to selection 
of lead compounds after which the drug development proceeds as for the phenotypic 
approach once sufficient quantity of the active compound is available. 
The aim of the selection stage is to obtain extracts with useful bioactivity, either from 
different candidate organisms, or from one organism using different solvent systems 
(Sarker and Nahar, 2012a; Brusotti et al., 2013). The bioassay is normally cell-based 
and related to the disease in question (Gray et al., 2012). Separation requires the use 
of a chromatography system, usually liquid or gas chromatography (Sarker et al., 




Figure 1-14: A generic strategy for drug development from natural products in three stages. ID: 
identification. SAR: structure activity relationship study. Adapted and redrawn from Sarker et al. 
(2005); Koehn and Carter (2005); Suvarna (2010). 
 
 
the most bioactive are selected for further fractionation with iterative steps until the 
bioactive material is isolated to sufficient purity for structural elucidation (Brusotti et al., 
2013). At any fractionation stage the activity may be lost, either because it is a 
combinatory effect of two compounds widely separated on the chromatogram, or 
because there is too little material, when the active compound becomes too dilute in 
the bioassay (Brusotti et al., 2013). Structural elucidation proceeds using one or more 
identification technologies. Nuclear magnetic resonance confirms structure but requires 
around 500 µg of compound and large quantities may not be available from isolation of 
compounds from natural products, therefore many authors rely on the more sensitive 
mass spectrometry for identification (Vukics and Guttman, 2010). If the compound is 
known it may be possible to confirm the identity by comparison with a standard (Sarker 
and Nahar, 2012b). Obtaining the larger quantities required for drug development 
(~100 g) can be a bottleneck for development if the source organism is not available in 
large quantities and cannot be cultured, for example with marine organisms or plant 
material with a minute percentage of the active substance (Koehn and Carter, 2005). 
Chemical synthesis or biosynthesis with organisms such as yeast (Saccharomyces 
cerevisiae) may provide sufficient material (Cannell et al., 2005). 
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There is an enormous variety of chemical entities in natural product extracts, with each 
plant extract containing potentially 700 different chemicals of which many are non-
essential secondary metabolites that enable a plant to influence its environment and 
compete for survival (Gray et al., 2012; Field et al., 2006). It has been estimated that 
the higher plants collectively synthesise 100,000 secondary metabolites (The 
Arabidopsis Genome Initiative, 2000), but with only around 10% of the higher plants 
having been screened for bioactivity (Gransalke, 2011), there is a need to conserve 
ecosystems as resources. The United Nations Convention on Biological Diversity 
(United Nations, 1992) came into force in 1993. Recognising that natural resources 
must be used by humans, two of its goals were conservation of biological diversity and 
sustainable use of its components (United Nations, 1992). 25 biodiversity hotspots 
representing 1.4% of the world land surface have been identified as conservation 
priorities based on the species of plants they contain and the degree of threat (Myers et 
al., 2000). Each hotspot contains at least 0.5% or 1,500 of the world's 300,000 vascular 
plant species as endemic and has lost at least 70% of its primary vegetation (Myers et 
al., 2000). Plants were chosen as a measure of biodiversity because of the available 
data and the dependence of other species on plants, for instance as predator, 
pollinator or symbiont (Myers et al., 2000). Paradoxically, the obligations that the 
Convention imposes to reach its third goal, fair and equitable sharing of the benefits 
arising from natural resources (United Nations, 1992), have been quoted as a reason 
that pharmaceutical companies have moved away from natural products (Koehn and 
Carter, 2005; Kirsop, 1996; United Nations, 1992). Nonetheless, pharmacognosy 
based investigations where local medicinal products, usually from plants, are surveyed, 
continue to be a rich source of starting material for natural product drug discovery 
(Sarker and Nahar, 2012a). For example, the antiviral drug prostatin, which derives 
from the bark of the mamala tree, was discovered in a Samoan therapy for hepatitis 
(Wender et al., 2008). 
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1.6 Traditional medicine systems 
The World Health Organisation estimated in 2002 that 60-80% of people in developing 
countries rely on traditional medicine (TM) for primary healthcare (WHO, 2002). 
Western medicine is inaccessible to many on grounds of cost or geography and strong 
cultural beliefs favour TM. In sub-Saharan Africa in 2000 TM practitioners outnumbered 
Western medicine practitioners 100:1 and the cost of a Western course of anti-malarial 
treatment in Ghana in 2002 was more than the annual state health expenditure per 
person ($6) (WHO, 2002). Traditional, complementary and alternative therapies are 
also popular in developed countries, with 40% of Americans having used at least one in 
the 12 months to 2007, the most common category being non-vitamin natural products 
(18%) (Barnes et al., 2008). 
1.6.1 Traditional Chinese Medicine 
In 2002 around 40% of Chinese people in both rural and urban areas were reported to 
prefer traditional Chinese medicine (TCM) to Western medicine for their healthcare (Qi 
et al., 2011). TCM has been followed in China for at least 3000 years and includes 
herbal medicines, massage and acupuncture (Konkimalla and Efferth, 2008). 22% of 
Chinese clinics specialise in TCM, but 95% of Western style Chinese hospitals also 
offer a TCM service (Qi et al., 2011). In 2012 Chinese spend on TCM was 515 billion 
yuan (£56 billion) and 36% of the total healthcare spend (LCB, 2014). It is growing in 
popularity abroad: $280 million was spent on TCM in the USA and $393 million in 
Japan in 2012 (Jie and Hongyi, 2013). In the Beijing declaration on the modernisation 
and internationalization of Chinese medicines, the Chinese government recognised the 
need to modernise TCM, combine it with other medical sciences and improve its 
scientific understanding while improving safety and quality control (MOST, 2007). TCM 
treatments have generated drugs either in use or clinical trials, including the cancer 
treatments camptothecin from the bark of the Chinese Camptotheca tree Camptotheca 
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acuminata and its analogue topotecan (Patwardhan et al., 2005), and indirubin from a 
herbal mixture used for leukaemia (Hoessel et al., 1999). The antimalarial artemisinin 
was discovered in 1971 in the bark of the wormwood tree in a study of 2000 TCM 
antimalarial remedies (Miller and Su, 2011).  
TCM products are prescribed for cancer patients either alone or alongside Western 
treatments (Hsiao and Liu, 2010). Many TCM herbal extracts have cytotoxic effects on 
cancer cells in vitro (Hsiao and Liu, 2010). Although many studies have taken place, 
there is little research on the effectiveness of TCM compared to Western medicine in 
randomised clinical trials (Hsiao and Liu, 2010). A study of 115 trials of TCM products 
for pain relief in cancer showed that TCM may provide pain relief as effectively as 
Western analgesics, with few adverse side-effects, but most of the studies were 
described as having methodological flaws (Xu et al., 2007). As many Chinese 
treatments are mixtures of 4-14 different natural products (example in Table 1-8) and 
the activity is attributed to synergistic effects, the active chemicals in Chinese formulae 
are being researched with a systems biology approach (Luo et al., 2012). In the 
process, a chemical fingerprint can be established for quality control (Zhang et al., 
2004).  
Table 1-8: Components of the traditional Chinese medicine Qingkailing injection, used widely in 
China after stroke and cerebral edema to reduce brain damage
1
. 
Component Traditional source Modern alternative 
Niuhuang Bovis calculus, gallstones of cattle Taurocholic acid and hyodesoxycholic 
acid, extracted from bovine bile 
2 








Banlangen root of Coptis chinensis, goldthread 
flower 
Isatidis radix, root of Isatis tinctoria, 
woad 
3 
Shuiniujao, hydrolyzed rhinoceros horn Bubali Cornu, buffalo horn 
3 
Zhenzhumu, hydrolysed  Margaritifera usta, shell of shellfish 
including Pteria martensii 
3 
 





Data extracted from Luo et al. (2012).
2
 NZP (2011). 
3





1.6.2 Indian traditional medicine 
In India around 80% of the population relies on traditional medicine (TM) for healthcare, 
either exclusively or in combination with Western medicine, and for 65% TM is the only 
available option (Dargan et al., 2008; WHO, 2002). Indian TM systems comprise 
Ayurveda, Yoga & Naturopathy, Unani, Siddha and Homeopathy, administered by 1.5 
million practitioners, with Ayurveda most widely used (WHO, 2007; Mukherjee and 
Wahile, 2006). There is a belief that natural therapies are safer than Western medicine, 
although cases of toxicity and adulteration occur, with the result that the Indian 
Government in 2002 launched a National Policy on Indian Systems of Medicine & 
Homeopathy to improve safety and efficacy and to promote research (Dargan et al., 
2008; WHO, 2007). Ayurveda has been practiced since 5000 BCE and its main texts 
date from the 6th century BCE (Mukherjee and Wahile, 2006). Today, over 25,000 
herbal medicinal preparations are used but only 6% of species used in medicines have 
been investigated scientifically (Mukherjee and Wahile, 2006). 600 Indian medicinal 
plant species are found in Assam province in North-East India (Borthakur, 2012) which 
forms part of the Indo-Burma biodiversity hotspot (Myers et al., 2000). 
A number of Indian institutes are actively engaged in characterising Indian herbal 
medicines and identifying the bioactive agents (Patwardhan et al., 2005). The 
successful antipsychotic and antihypertensive drug reserpine originated from an 
Ayurvedic remedy for insanity, fever and snakebite, extracted from root of Rauwolfia 
serpentina (Indian snakeroot) (Plummer et al., 1954). Artrex is a combination of four 
Ayurvedic medicines, extracts of Withania somnifera (winter cherry), Boswellia serrata 
(Indian frankincense), Zingiber officinale (ginger) and Curcuma longa (turmeric), has 
undergone clinical trials in India for the treatment of arthritis and is now sold in the USA 
as a food supplement although not licensed as a drug (Chopra et al., 2004; 
Patwardhan et al., 2005). Many compounds from Indian TM are being researched, for 
instance withaferin from Withania somnifera may have anti-angiogenesis effects in 
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breast cancer (Thaiparambil et al., 2011) and andrographolide, found in Andrographis 
paniculata (Nees), a TM treatment for infectious disease, may be cytotoxic to breast 
and colon cancer cells and anti-asthmatic (Jada et al., 2008).  
1.7 Aims and objectives of this study 
The subject of this thesis is the cytotoxic or cytostatic effects of three plant extracts 
chosen through collaboration with Gauhati University, Guwahati, Assam Province, 
India: root of Clitoria ternatea, seed of Mucuna pruriens and rhizome of Cheilocostus 
speciosus (Figure 1-15).  
1.7.1 Clitoria ternatea 
Clitoria ternatea (Butterfly pea, Aparajita) is a fast-growing climbing legume in the 
Fabaceae family, native to Indonesia but naturalised in India, Asia, Africa, America, 
China and Australia. It is used for cover in Africa, ornamentally in USA (Morris, 2009) 
and as a forage crop in Brazil (Abreu et al., 2014) and the edible flowers make a blue 
coloured drink in Thailand (Suwan, personal communication). All parts of the plant are 
used in Ayurvedic medicine. When treating female infertility the root is ground and 
mixed with goat’s milk and drunk for 21 days (Kalita, 2012). Extracts of the root, called 
Shankapushpi, are also used to avert abortion; as a laxative; for indigestion, ascites, 
constipation, fever, arthritis, eye and ear ailments, sore throat, skin diseases, 
bronchitis, snakebite, rheumatism; for epilepsy and insanity; and the bitter fresh root is 
given to children with honey and ghee as a general tonic and to improve mental 
faculties, muscular strength and complexion (Mukherjee et al., 2008). Its use in 
Ayurvedic cancer treatment appears to be restricted to a decoction of leaves of Clitoria 
and two other herbs administered for purification after surgery to remove a major or 
benign tumour, defined differently from Western medicine (Balachandran and 




Figure 1-15: Flowers of (A) Clitoria ternatea, (B) Mucuna pruriens, (C) Cheilocostus speciosus. 
Images from (A) tropicalforages (2015); (B) JungleSeeds (2015); Kinsey (2105). 
 
 
Non-root parts of the plant show cytotoxic activity in studies. The leaf extract is 
cytotoxic to brine shrimp (Das and Chatterjee, 2013; Rahman et al., 2006) and cervical 
cancer and Dalton’s lymphoma cells (Ramaswamy et al., 2011), the aerial parts to 
cervical cancer cells (Sarumathy et al., 2011) and the flower extract to Dalton’s 
Lymphoma ascites cells (Kumar and Bhat, 2011), ovarian cancer cells and breast 
cancer cells (Neda et al., 2013). Much of the research on the root extract concerns 
effects on brain and memory. Aqueous, methanolic and ethanolic root extracts have 
been shown in rats to reduce memory impairment (Taranalli and Cheeramkuzhy, 2000) 
and enhance dendritic branching in amygdala neurons (Rai et al., 2005), to be 
antipyretic, anti-inflammatory (Parimala Devi et al., 2003) and analgesic (Kamilla et al., 
2014) and to reduce immune response to a challenge (Taur and Patil, 2011). However, 
root extracts contain compounds that when tested alone are cytotoxic or growth-
inhibitory (Table 1-9). Other compounds found in Clitoria are identified in Appendix A. 
A B C 
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Table 1-9: Compounds in Clitoria root extract with cytotoxic or growth-inhibitory properties.  
Compound 
1 


























Peptides Chemosensitise lung cancer cells to paclitaxel treatment 
13 
Cytotoxic to cervical cancer cells 
12 
1 
Reference is to publication linking compound with Clitoria root. 
2 
Reference is to publication describing cytotoxic effect. 
3
 Kumar et al. (2008). 
4 
Takasaki et al. (1999).
 5
 Chauhan and Singh (2011). 
6
 Tan et al. (2011). 
7 
Swain et al. (2012).
 8
 
Ahmed et al. (2010). 
9 
Barik et al. (2007).
 10 
Kelemu et al. (2004).
 11
 Kelemu et al. (2004). 
12
 Nguyen et al. (2011). 
13
 Sen 
et al. (2013).  
 
 
1.7.2 Mucuna pruriens 
Mucuna pruriens (Velvet bean, Kapikachchhu) is a legume of the Fabaceae family. Its 
beans are consumed by humans and its leaves used as fodder. Originally from China 
and Eastern India, it now grows in America, Asia and Africa (Lampariello et al., 2012). 
The seeds have been a commercial source of L-Dopa, a Western therapy for 
Parkinson’s disease, and the seed extract is an Ayurveda treatment for Parkinson’s 
(Lampariello et al., 2012). Indian medicinal uses of the seed include female infertility, to 
promote menstrual flow, as a male aphrodisiac, for snakebite (Deka and Kalita, 2013), 
as anti-inflammatory, for intestinal worms (Misra and Wagner, 2004) and anti-tumour, 
although this may not mean anti-cancer in Western terms (Sayed et al., 2006). When 
treating infertility the seed is ground, mixed with goat’s milk and drunk daily for one 
month (Kalita, personal communication). Research into the seed extract has shown 
that it has an estrogenic effect in increasing uterine weight of ovariectomised mice 
(Deka and Kalita, 2013), a hypoglycemic effect in rats (Bhaskar et al., 2008), protease 
inhibitory activity (Hope-Onyekwere et al., 2012) and anti-fungal activity (Nidiry et al., 
2011). Some components have anti-proliferative effect (Table 1-10) although it also 
contains nicotine which is anti-apoptotic (Heusch and Maneckjee, 1998). Other 
compounds found in Mucuna are identified in Appendix A. 
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Table 1-10: Compounds in Mucuna seed extract with growth-inhibitory properties. 
Compound 
1 












Reference is to publication linking compound with Mucuna seed. 
2 






Misra and Wagner (2007).
 6 
Kable et al. (1989). 
 
  
1.7.3 Cheilocostus speciosus 
Cheilocostus speciosus (Crape ginger, Kebu), formerly Costus speciosus, is an 
ornamental ginger native to South East Asia and now growing in India and Australia. Its 
rhizome is an Indian commercial source for diosgenin, a steroid used in the 
manufacture of contraceptives (Pandey et al., 2011). When pressed to extract juice, or 
dried and ground, the rhizome is used for female infertility and for diabetes, as 
aphrodisiac and as diuretic (Najma et al., 2012), for intestinal worms, leprosy, skin 
diseases, asthma, bronchitis and to reduce fever (Joy et al., 1998). A rhizome extract 
has been investigated for stimulating rat uterine contractions (Lijuan et al., 2011). 
Although several components of the rhizome extract have cytotoxic or growth-inhibitory 
effect (Table 1-11), most research interest is focussed on the anticancer activity and 
suppression of cholesterol absorption seen with diosgenin (Cayen and Dvornik, 1979). 
Other compounds found in Cheilocostus are identified in Appendix A. 































Pentacyclic triterpene Inhibits growth in skin cancer and prostate cancer cells 
12 
1 
Reference is to publication linking compound with Cheilocostus rhizome. 
2 
Reference is to publication describing cytotoxic effect. 
3
 Dasgupta and Pandey (1970). 
4 
Shishodia and Aggarwal (2005). 
5 
Duraipandiyan et al. (2012).
 6
 Whipple et al. (2013).  
7 
Joy et al. (1998).
 8
 Hu and Yao (2003). 
9 
Inoue and Ebizuka (1996).
 10 
Bhuyan and Zaman (2008).
 11
 Vásquez et al. 
(2012). 
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1.7.4 Specific aims 
The aims of the project are: 
(1) Confirm cytotoxic or cytostatic effects of Clitoria, Mucuna and Cheilocostus 
and select one for further study. 
(2) Characterise cytotoxic or cytostatic effects. 
(3) Elucidate biological mechanism. 
(4) Isolate bioactive agents for further investigation. 
(5) Identify the bioactive agents. 
1.7.5 Objectives 
The objectives have been chosen to meet the aims of the project: 
(1) Using cell-based assays, quantify the cytotoxic or cytostatic effects on cancer 
cells. Use this data as a basis for selecting the most interesting extract for 
further study. 
(2) Establish with cell-based assays whether effects (i) are cytotoxic (ii) are dose-
dependent (iii) are time-dependent (iv) are cell type specific. 
(3) Observe treated cells with live cell imaging and use immunohistochemistry to 
gain information on the mechanism. 
(4) Using High Performance Liquid Chromatography (HPLC) in a bioassay-driven 
approach, fractionate the extract and test fractions with cell-based assays to 
isolate the smallest bioactive fractions possible. 
(5) Using structural elucidation methods, identify the chemical formula of the 




1.7.6 How this thesis is organised 
Chapter 1: Introduction 
Contains background for understanding breast cancer and current treatments 
for breast cancer, the cytoskeleton, drug discovery from natural products and 
the aims and objectives of this study. 
Chapter 2: Materials and methods 
Contains materials and methods that apply to the whole thesis. 
Chapter 3: Cytotoxicity in Clitoria root extract 
Contains results of cell-based assays used to confirm the cytotoxic and 
cytostatic effects of Clitoria, Mucuna and Cheilocostus and further 
characterisation of the cytotoxic effects of Clitoria. 
Chapter 4: High Performance Liquid Chromatography fractionation of extracts 
Contains method development for fractionation of Clitoria, Mucuna and 
Cheilocostus, results of bioassay-driven fractionation of Clitoria from preparative 
HPLC and initial fractionation of Cheilocostus with analytical HPLC. 
Chapter 5: Mechanism of action 
Contains results of live cell imaging and fluorescence microscopy investigations 
into the mechanism of the cytotoxic effect of Clitoria. 
Chapter 6: Alternative sources of Clitoria 
Contains results of analysis of Clitoria extracts from plant material sourced in 




Chapter 7: Identification of bioactive agents in Clitoria root extract 
Contains structural elucidation of the bioactive agents in bioactive fractions of 
Clitoria. 
Chapter 8: Discussion 
Contains a discussion of the impact of the results in this thesis in the context of 





Chapter 2 Materials and methods 
2.1 Preparation of plant extracts 
2.1.1 Sources of plant material 
The first plant extracts for this project originated from plants grown in India. Roots of 
Clitoria ternatea, blue flowered form, and matured seeds of Mucuna pruriens were 
collected from gardens and forest respectively in Guwahati, Assam, India and 
authenticated in the Department of Botany, Gauhati University, Assam. Cheilocostus 
speciosus rhizome was obtained and authenticated in Assam. None of the species are 
listed as at risk on the UN Convention on International Trade in Endangered Species of 
Wild Fauna and Flora list or the International Union for Conservation of Nature Red List 
of endangered species (CITES, 2000; IUCN, 2014). Indian export restrictions allow the 
export of medicinal extracts “in unrecognizable and physically inseparable form” 
(Embassy of India, Beijing, 1992). 
Further supplies of Clitoria extract were requested from India, but could not be supplied 
within the timescale of this study, therefore alternative sources were investigated. 
Fresh Clitoria root was obtained in Jakarta, Indonesia, by Sri Murhandini, Research 
Center for Drug and Food, The National Agency of Drug and Food Control of the 
Republic of Indonesia, Jakarta, and authenticated by Dr Joeni Setijo Rahajoe, 
Indonesian Institute of Sciences, Jakarta. Clitoria seeds (Thompson & Morgan) were 
germinated in 9 inch pots in May 2013 in a greenhouse in Marlow, UK by Geoff 
Swinburn. The plants were transferred to 18 inch pots and moved in June to a 
sheltered outdoor area. When the leaves died in October 2013, the plants were lifted 
and the roots were washed in water and dried in a greenhouse. The plants were not 
formally authenticated, but from photographic evidence they resemble Indian Clitoria.  
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2.1.2 Preparation of extracts 
The Indian plant extracts were prepared in the laboratory of Professor Jogen Chandra 
Kalita, Department of Zoology, Gauhati University, India. Clitoria root, Mucuna seed 
and Cheilocostus rhizome were washed immediately after collection in tapwater and 
scrubbed with hands. Lesions and dead tissue were removed from root and rhizome 
with a knife. The plant material was left to dry overnight in the laboratory in the shade 
at 25-35°C, then root and rhizome were cut with knife and scissors into 0.5 cm pieces 
to aid drying. The material was left to dry further over four days without sun exposure in 
the laboratory, then was ground in a mechanical grinder and 20 g was extracted with 
200 mL Analar grade methanol (Fisher Scientific) for 18 hours in a Soxhlet extractor at 
reflux (64°C) and dried in a Büchi R-205 rotary evaporator at 60°C. In November 2012 
the initial Clitoria root extract (CE) was exhausted and a second vial supplied from 
Assam, CE(B), was used in subsequent experiments.  
Indonesian Clitoria root was washed and dried before shipping to the UK. UK Clitoria 
root was washed with water and dried immediately after harvesting. On arrival at 
Brunel, Indonesian and UK root was washed in ethanol (Fisher Scientific), dried and 
ground in a coffee grinder to a coarse powder and extracted in 200 mL methanol 
(Fisher Scientific) (Table 2-1). Indonesian and UK extracts and the material was 
weighed, resuspended in ethanol (Table 2-2) and filtered. Yields were calculated for 




Table 2-1: Extractions of Clitoria performed at Brunel.  
Origin Extract Extraction 
apparatus 
Weight of 







































Brown solid.  






Brown oil.  









Golden brown oil. 
1
 Büchi R-205 rotary evaporator. 
2
 Eppendorf centrifugal concentrator 5301. 
 
Table 2-2: Yields and resuspensions from extractions of plant material. 
Extract Amount 
recovered (g) 





Extractions performed in India 
Clitoria root CE
 1
 0.87 4.3 4.83 180 
Clitoria root CE(B)
 2 
0.45 2.3 5  90 
Mucuna seed
 
2.0276 10.1 11.26 180 
Cheilocostus rhizome
 
0.45 2.3 5 90 
Clitoria root extractions performed at Brunel
 3
 
CE(E) 0.96 9.6 5 192 
CE(F) 1.98 19.8 5 396 
CE(G) 1.31 16.2 5 262 
CE(H) 0.42 5.3 3 140 
CE(J) 0.69 8.6 3 230 










 See Table 2-1. 
 
  
2.2 Tissue culture 
2.2.1 Cell lines 
Breast cancer epithelial cells, normal breast epithelial cells, normal fibroblasts and 




Table 2-3: Sources of cell lines. 
Cell line Origin Reference Gift from 
MCF-7 Breast cancer epithelial cells from pleural 
effusion. 
Soule et al. (1973). A. Harvey (Brunel). 
 
MDA-MBA-231 Breast cancer epithelial cells from pleural 
effusion. 
Cailleau et al. (1974). 
MCF-10A Breast epithelial cells from fibrocystic 
disease. 
Cailleau et al. (1974). 
2DD Normal dermal fibroblasts from juvenile 
foreskin. 
Bridger et al. (1993). C. Eskiw (Brunel). 
HMEC 240L Primary human mammary epithelial cell 
derived from reduction mammoplasty in a 
21-year old patient. 
Hammond et al. (1984); 




Primary human mammary epithelial cell 
derived from reduction mammoplasty in a 
16-year old patient. Immortalised with 
hTERT plasmid at Brunel. 
Stampfer et al. (2001). 
 
 
2DD normal fibroblasts in culture gradually cease active growth, until around passage 
33 only ~5% are regularly dividing (Eskiw, Personal communication). When received at 
passage 10, approximately 75% of cells had proliferative ability and they were assayed 
at passages 14-26 as noted in all results. 240L human mammary epithelial cells 
(HMECs), commonly used as normal primaries, cease active growth around passage 
14-25 and were assayed at passage 12. 
2.2.2 Cell maintenance 
Cell culture work was performed in aseptic conditions in a tissue culture hood. Cells 
were maintained at 37°C and 5% CO2. All cells except HMECs were maintained in 
DMEM/F12 (Life Technologies (LT)) with 10% fetal bovine serum (FBS) (Invitrogen) 
and 1% Glutamax (LT). 5-10 ng/mL epidermal growth factor (EGF) (LT), 5 µg/mL 
insulin (LT) and 1 µg/mL hydrocortisone (Sigma) were added to medium for MCF-10A. 
Cells were maintained without antibiotics until May 2013 and thereafter with penicillin-
streptomycin (LT). Cells were grown in 100 mm Cell+ cell culture dishes (Sarstedt).  
HMECs were maintained in a 50:50 mixture of DMEM/F12 (LT) and Mammary 
Epithelial Cell Growth Medium (Lonza). Supplements added were 1% glutamine (LT), 
35 μg/mL bovine pituitary extract (LT), 7.5 μg/mL insulin (LT), 5 x 10-5 M isoproterenol 
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(LT), 0.1 μg/mL hydrocortisone (LT), 2.5 μg/mL apotransferrin (LT), 0.1 nM oxytocin 
(LT), 0.5 ng/mL cholera toxin (LT), 5 ng/mL EGF, 5 x 10-10 M β-estradiol (LT), 5 x 10-9 
M tri-iodothryonine (LT), 0.1% albumax (LT). 
2.2.3 Passaging 
MCF-7 and MDA-MB-231 cells were passaged at or before confluence. Cells were 
washed in Versene buffer (0.02% ethylenediaminetetraacetic acid chelating agent 
(Fisher) in phosphate buffered saline (PBS) (Sigma), dissociated from the dish surface 
within 2-8 min in 2 mL of pre-warmed TrypLE Express (Invitrogen) dissociation reagent 
at 37°C and transferred to a 50 mL tube. The dish was washed with 3 mL of Versene 
which was added to the tube. An amount of the suspension appropriate for the required 
split ratio was transferred to another 50 mL tube. Medium was added to the tube to 
make up to 15 mL for each culture dish and the mixture was poured into a new culture 
dish.  
2DD cells were passaged twice per week and plated out at 3,000 cells/cm2. Cells were 
washed and dissociated as described above. Cells were counted following the cell 
counting protocol. An amount of the suspension appropriate for the required number of 
cells was transferred to a 50 mL tube, medium was added to the tube to make up to 15 
mL for each culture dish and the mixture was poured into a new culture dish. 
HMECs were passaged when 60-70% confluent. Cells were dissociated in 0.05% 
trypsin in saline base (LT) for 3-5 minutes. The dish was washed in PBS which was 
added to the cell suspension. After spinning down at 1000 r.p.m. for 2 min, the pellet 
was resuspended in medium. 20 µL of the suspension was mixed in an Eppendorf tube 
with 20 µL of 0.4% Trypan blue (LT). 20 µL of the mixture was pipetted into a Countess 
cell counting chamber (LT). The cells were counted in a Countess cell counter (LT). 
The number of cells required was calculated for a density in flasks of 2500 cells cm-2, 
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the correct amount of cell suspension was transferred to a new 50 mL tube and 
medium was added to make 15 mL of cell suspension per 100 mm culture dish. This 
was poured into new culture dishes. 
2.2.4 Cell storage, freezing and recovery 
Cell stocks were stored in a liquid nitrogen freezer. For freezing, cells were washed 
and dissociated as described in Section 2.2.3 and spun down at 1500 r.p.m. for 5 min. 
The supernatant was aspirated, the pellet was resuspended in freezing medium 
consisting of 10% dimethyl sulfoxide (DMSO) (Sigma) in FBS and the cell suspension 
was placed in cryovials, each containing 5 x 105 cells. Cells were frozen in a controlled 
rate freezing container before moving to liquid nitrogen. To recover frozen cells, the 
cryovial was warmed in a water bath at 37°C, before cells were transferred into 
warmed medium and the cell suspension placed in a culture dish. The following day, 
medium was aspirated to remove residual freezing medium, cells were washed with 
Versene and fresh medium was added to the dish. 
2.2.5 Cell counting 
MDA-MB-231, MCF-7 and 2DD cells were washed and dissociated as described in 
Section 2.2.3 and spun down for 5 min at 1500 r.p.m. The supernatant was aspirated 
and the pellet was resuspended in a known amount of Versene or medium. 20 µL of 
the cell suspension was pipetted into a hemocytometer chamber. Cells in five of the 
hemocytometer regions were counted under a microscope. This figure was divided by 
100 to give the cell number as a multiple of 105 cells mL-1. The required amount of cell 
suspension was calculated and transferred to a tube for use. HMECs were washed, 
dissociated and counted as described in Section 2.2.3. 
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2.3 Cell doubling times 
Cell doubling times for 2DD and MDA-MB-231 cells were established for Brunel 
laboratory conditions over a 5 day time period. MDA-MB-231 cells and 2DD cells at 
passage 26 were seeded at density of 2,740 cells cm-2 and 2,700 cells cm-2 
respectively in 60 mm culture dishes (Sarstedt). Cells were counted 1, 2, 3 and 4 days 
after settling. Three dishes were counted at all timepoints except day 4 when 2 dishes 
were counted for MDA-MB-231 cells. Medium was changed 2 days after seeding for 
MDA-MB-231 and 3 days after seeding for 2DD cells. Doubling time was calculated 
from mean cell counts (Roth, 2006). Human fibroblast cell growth has been shown to 
decline linearly (Kill et al., 1994). When received at passage 10, ~ 75% of cells had 
proliferative ability and at around passage 33 ~5% are regularly dividing (Eskiw, 
Personal communication). From this data it was calculated that at passages 18 and 26 
~ 50% and ~30% of 2DD cells could be expected to be actively proliferating. Cell 
numbers for 2DD cells at passage 18 were estimated by multiplying the cell numbers 
for cells at passage 26 by 5/3. Cell doubling times for HMECs were calculated from 
growth of a continuously growing batch over 3 months (Yasei, personal 
communication). 
2.4 Cell viability assays 
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT), PrestoBlue and 
methylene blue cell viability assays were used to measure the cytotoxicity of plant 
extracts and biochanin A on cells. MTT was used for assays with crude extract, 
PrestoBlue for assays with crude extract, fractions and biochanin A, and methylene 
blue for a resuspension of remixed fractions. MTT and PrestoBlue rely on a colour 
change reaction in a reducing environment induced by active mitochondria, which is 
quantified by reading absorbance. Methylene blue stains cells that remain alive and 
adherent to the culture dish at the end of the treatment. When the dye is resuspended, 
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its absorbance provides a means of measuring cell viability. Unless stated, maximum 
ethanol concentration in treatments was 1%. 
2.4.1 MTT protocol 
MTT (Millipore) is a tetrazolium dye that measures the activity of living cells via 
mitochondrial dehydrogenase activity. In the presence of mitochondrial activity, MTT is 
reduced from a yellow solution to purple insoluble crystals which can be dissolved in 
acidified isopropanol and measured spectrophotometrically. 
The MTT protocol was followed as described by the supplier (Millipore). Day 1: Cells 
were seeded with a multichannel pipette in 96-well plates at 10,000 cells per well in 
100 µL medium. Plates were incubated for 24 hours. Day 2: Each extract was diluted in 
medium to obtain a dilution series from 1:100 to 1:32000. The medium was aspirated 
from each well with a pastette and diluted extract was placed in each well using a 
multichannel pipette. Control wells held medium, cells treated with ethanol vehicle at 
1%, or cells in medium. The plate was incubated for 48 or 72 hours. Day 4 (48 hours 
incubation) or day 5 (72 hours incubation): Medium was removed from each well using 
a pastette. 100 µL of MTT reagent diluted 10x in medium was added to each well using 
a multichannel pipette. The plate was incubated for 3 to 4 hours at 37°C. After 
incubation, the medium was removed using a pastette and 100 µL of 0.1 N HCl 
solubilising solution (Sigma) was added to each well. The solution was pipetted up and 
down to aid solubilisation. The plate was read within 30 min on an Xmark Microplate 
Spectrophotometer 96-well plate reader at 562 nm (absorbance) and 630 nm 
(background). 
To calculate fold proliferation, for each well, the reference reading was subtracted from 
the absorbance reading. The mean of wells with medium only (blank) was calculated 
and subtracted from all readings (A). The mean for ethanol treated cells (control mean) 
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was calculated. A was divided by the control mean to obtain fold proliferation. The 
mean for each set of fold proliferation values with the same treatment was divided by 
the control to give a normalised fold proliferation. 
2.4.2 PrestoBlue protocol 
PrestoBlue cell viability reagent (LT) is a resazurin-based solution that is reduced from 
a blue resazurin to a red resorufin in the presence of mitochondrial activity. The 
PrestoBlue protocol was followed as described by the supplier (LT). Day 1: Cells were 
seeded and incubated as described for MTT. Day 2: Cells were treated with plant 
extract as described for MTT and incubated for 48 hours or 72 hours. Day 4 (48 hours 
incubation) or day 5 (72 hours incubation): Medium was removed from each well using 
a pastette. 100 µL of PrestoBlue reagent diluted 10x in medium was added to each 
well using a multichannel pipette. The plate was incubated for 3 hours at 37°C and was 
read within 30 min at 570 nm (absorbance) and 600 nm (reference) on an Xmark 
Microplate Spectrophotometer 96-well plate reader. Fold proliferation was calculated as 
described for MTT. The alternative molar extinction coefficient calculation 
recommended by the supplier was trialled and gave similar results to the subtraction 
method above.  
2.4.3 Methylene blue assay protocol 
Day 1: Cells were seeded with a multichannel pipette in 96-well plates at 15,000 cells 
per well in 100 µL medium, a seeding density of 45,000 cells cm-2. Plates were 
incubated for 24 hours. Day 2: Cells were treated with 1 µL of the remixed fraction 
solution (see Section 2.13.7), or 1 µL of a 1:20 dilution of Clitoria extract CE in ethanol. 
Control wells held medium. The plate was incubated for 72 hours. Day 5: Medium was 
removed from each well using a pastette. Cells were washed gently with tapwater, 
drained and air-dried. Cells were fixed by placing 100 µL ethanol in each well. After 5 
min the wells were washed in tapwater and air-dried. A 10% solution of methylene blue 
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dye (Sigma) in distilled water was dropped into each well to cover the bottom surface, 
left 5 min for staining, then drained. The wells were washed with tapwater, drained and 
air-dried. 100 µL ethanol was added to each well to resuspend dye and the plate was 
left on a rocker for 30 min. Dye density was read in an Xmark Microplate 
Spectrophotometer 96-well plate reader at 668 nm (absorbance) and 425 nm 
(reference). Calculation of fold proliferation was performed as for MTT assays.  
2.4.4 Dilution of biochanin A for cell viability assays 
A stock solution of 154.8 mM biochanin A in DMSO was diluted in cell culture medium 
to obtain a dilution series of 1.5 mM to 23 µM. Concentration of DMSO was not more 
than 1% in any treatment. 1% DMSO did not affect cell growth (data not shown).  
2.4.5 Calculation of estimated half maximal inhibitory concentration 
from cell viability assays  
Estimated half maximal inhibitory concentration (IC50) was calculated from cell viability 
assay results. Using the line of cell viability between the two points either side of 50% 
viability (AB in Figure 2-1), the extract dilutions were converted to concentration and 
the x-coordinate (xa) for the point at which the line crosses 50% viability (C) was 
calculated, assuming linear response between A and B, using the principle of 
mathematically similar triangles, as follows.  
Taking triangles AEC and ADB, these are mathematically similar because they have 
the same angles. Therefore the ratio of the lengths of the sides of AEC is the same as 
the ratio of the lengths of the corresponding sides of ADB.  
Therefore AE/AD = EC/DB 
Since EC = DF, this can be written as AE/AD = DF/DB 
Therefore DF=DB x (AE/AD) 




Figure 2-1: Diagram for calculating half maximal inhibitory concentration (IC50) (xa). A,B: cell 
viability values established experimentally either side of 50%. C: point at which line of cell viability 




2.4.6 Method development for cell viability assays 
Method development took place to establish the optimum seeding density and the 
vehicle concentration for MTT and PrestoBlue cell viability assays, and the optimum 
incubation time for PrestoBlue assays. 
2.4.6.1 Establishing optimum seeding density for MTT and PrestoBlue 
assays 
In MTT and PrestoBlue assays a low seeding density gives low absorbance readings, 
reducing reliability of readings. A seeding density was needed that was high enough for 
consistent absorbance readings after cell death in treated wells. To find this density for 
MTT, two normal cell lines were seeded at densities of 1,000-32,000 cells per well of a 
96-well plate and allowed to grow untreated for 72 hours before being assayed with 
MTT (Figure 2-2). A linear increase in absorbance was seen up to 0.15 AU with little 







Figure 2-2: Seeding density in MTT assays for measurement of cell death. MCF-10A normal breast 
epithelial cells and 2DD normal fibroblasts seeded at different densities and left untreated for 72 




A similar test was run with MDA-MB-231 cancer cells and 2DD cells using PrestoBlue, 
but taking readings at 0 hours (24 hours after seeding), 48 hours and 72 hours (Figure 
2-3). Absorbance increased linearly up to 0.5 AU, suggesting the sensitivity of the 
assay is in the range 0-0.5 AU. At a seeding density of 10,000 cells per well, growth is 
visible at 48 hours in both cell lines, but may be under-represented because the 
absorbance is at the maximum for the assay. However, as these assays are used in 
this project to report cell death, it was decided that 10,000 was an appropriate number 
of cells per well. This is consistent with (Boncler et al., 2014) who chose 10,000 cells 
per well as the optimum seeding density that would allow some growth in control 
human umbilical vein endothelial cells, but would show significant difference in MTT 
assays after cell death in treated cells.  
  
Initial cell number per well 
5,000        10,000       15,000        20,000       25,000       30,000       35,000 
2DD 
MCF-10A 











Figure 2-3: Seeding density in PrestoBlue assays for measurement of cell death. Absorbance 
measured in PrestoBlue assays at 0 hours (24 hours after seeding), 48 hours and 72 hours with (A) 




2.4.6.2 Establishing vehicle concentration 
Extracts were suspended in ethanol for treatments. It was necessary to establish what 
concentration of ethanol in medium could be used without toxicity. Cell growth in 2DD 
and MBA-MB-231 cells was reduced by only 7% and 6% respectively when treated 
with 1% ethanol (Figure 2-4 A). To confirm that readings in PrestoBlue assays were not 
affected by 1% or 1.5% ethanol, actual measurements were compared across a 
number of assays (Figure 2-4 B, C). The means of absorbance readings in PrestoBlue 
assays where ethanol was used as a control over 48 or 72 hours were at the maximum 
for the assay as established in Figure 2-3 (>0.5 AU). There was no difference between 
ethanol treated and untreated cells, except for 2DD cells treated with 1.5% ethanol for 
A 
Initial cell number per well 
Initial cell number per well 
B 







 0          5,000       10,000     15,000      20,000      25,000    30,000      35,000 
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72 hours where there was a small (12%) reduction in viability compared to untreated 
cells. 1% vehicle concentration was used for all assays except where indicated. 




   
 
 Treatment    72H 1.5%      72H 1%          48H 1%                         72H 1.5%      72H 1%          48H 1% 




25 20  9 9  56 32 
No of  
values (N) 25 17  24 21  43 28 
No of 
expts 

















     
 
Figure 2-4: Cells’ sensitivity to vehicle. A: MDA-MB-231 breast cancer epithelial cells and 2DD 
normal fibroblasts treated with ethanol and assayed with PrestoBlue after 48 hours. Values 
represent means ± SD of 4 replicates. B, C: Means of absorbance readings in PrestoBlue assays 
where ethanol was used as a control over 48 or 72 hours. MDA-MB-231 breast cancer epithelial 
cells (B) and 2DD normal fibroblasts (C) treated with 1% or 1.5% ethanol and assayed with 
PrestoBlue after 48 or 72 hours. N=number of readings included in means. *: p<0.02, control to 
medium (student’s t-test). 
 
 
2.4.6.3 Establishing optimum incubation time for PrestoBlue assay 
As PrestoBlue had not been used before in this research group, it was necessary to 
establish the optimum incubation time to see consistent results. The product protocol 
0.1     0.25    0.5      1       2        3       4       5      10     20 
Ethanol treatment (%) 










specifies that absorbance readings can be taken from 20 min to 2 hours after adding 
the reagent (Invitrogen, 2011). MCF-7 cells, seeded at 10,000 cells per well in a 96-
well plate, were treated with serial dilutions of Clitoria and Cheilocostus, assayed with 
PrestoBlue after 48H and read at different incubation times. At timepoints from 2 to 6 
hours, normalised absorbance readings had low variability (Clitoria, Figure 2-5; 
Cheilocostus, data not shown). 3 hours was chosen as a convenient timepoint for all 
assays.  
             
 
Figure 2-5: Comparison of different incubation times for PrestoBlue assay. Incubation times from 2 
to 6 hours, assaying Clitoria treated MCF-7 cells. **: 20 min to all other points, p<0.02. Values 
represent means ± SD of 4 replicates. 
 
 
2.5 Cell counting assay 
Cells were counted as described in Section 2.2.3. Cells were seeded at 105 cells per 
dish in 60 mm cell culture dishes with 2 mL tissue culture medium and incubated for 24 
hours. The following day, 3 dishes were treated with 2 µL of crude Clitoria extract CE 
and 3 dishes were treated with 2 µL ethanol as a control. After 24 hours, 48 hours and 
72 hours, one treated dish and one control dish were washed in 1 mL Versene. 1 mL 
TrypLE Express was placed in each dish and cells were incubated at 37°C for 2-4 min 
until cells had dissociated. Cell suspension was moved to a 2mL tube. The dish was 
washed with 1 mL Versene which was added to the 2 mL tube. Cells were spun down 
in a microcentrifuge at 1500 r.p.m for 5 min and resuspended in a volume of Versene 
** 
** 













as in Table 2-4. 20 µL of the resuspension was pipetted into a hemocytometer 
chamber. Cells in five of the hemocytometer regions were counted under a 
microscope. This figure was divided by 100 to give the cell number as a multiple of 105 
cells mL-1 and the total number of cells in the resuspension volume was calculated. 
Table 2-4: Resuspension volumes for cell counting assay. 
Timepoint Control dish CE treated dish 
24H 250 µL 250 µL 
48H 250 µL 100 µL 
72H 250 µL 50 µL 
 
 
2.6 Metaphase spread preparation and counting 
Metaphase spreads were prepared with Temitayo Owoka and Dr Abdulbasit Naiel 
(Brunel). Cells were grown to 60% confluence and assayed when some cells could be 
seen to be undergoing mitosis. 1 µL of 0.01ug/ml Gibco © KaryoMAX Colcemid (LT) 
per mL was added to growth medium in the culture dish to arrest cells in metaphase. 
The dish was incubated at 37°C for 30 minutes. The supernatant was transferred to a 
50 mL tube and the cells were washed and disassociated as described in Section 
2.2.3. All wash liquid and TrypLE Express was collected in the 50 mL tube. The tube 
was centrifuged for 5 min at 1500 r.p.m. before removing 70% of the supernatant, 
resuspending the cells and transferring the cell suspension to a 15 mL tube. The tube 
was centrifuged again for 5 min at 1500 r.p.m. 
All but 0.5 mL of the supernatant was removed and the cells were resuspended by 
vortexing. 10 mL of hypotonic solution (0.075 M KCl) (Fisher Scientific) prewarmed to 
37°C was added dropwise while tapping the bottom of the tube to avoid nuclei 
clumping. The tube was incubated for 10 min at 37°C. Ten drops of fixative solution 
(3:1 methanol (Fisher Scientific):acetic acid (Fisher Scientific)) at room temperature 
was added to avoid clumping during the centrifugation steps. The tube was centrifuged 
at 1000 r.p.m. for 5 min and supernatant was discarded. 
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The pellet was resuspended in 1 mL of fixative solution by vortexing and 9 mL of 
fixative solution was added slowly. The tube was incubated for 15 min at room 
temperature, centrifuged at 1000 r.p.m. for 5 min and supernatant was discarded. This 
stage was repeated twice omitting the incubation step. 
Almost all the solution was removed without disturbing the pellet. The pellet was 
resuspended in around 1 mL of fixative solution. 8-20 µL of solution was dropped onto 
a slide and the slide was left in a tray lined with damp tissue. Slides were allowed to dry 
and cure overnight in a dry black box at room temperature. The following day, slides 
were stained with Vectashield mounting medium with DAPI (Vector) and covered with a 
coverslip. Slides were imaged at 1000x magnification on an Olympus BX41 or on a 
Leica DM4000 fluorescence microscope. Images were processed in ImageJ and 
metaphases were counted manually by one person.  
2.7 Fluorescence microscopy 
2.7.1 Protocol 
13 mm coverslips, rinsed in ethanol and then in PBS, were placed in the wells of a 24-
well plate and covered with 250 µL medium, then allowed to equilibrate at 37°C for 15 
min. Cells were seeded either by adding 250 µL cell suspension to medium already in 
the wells, or by aspirating the medium and replacing it with 250 µL cell suspension. 
Plates were incubated for 24 hours to allow cells to adhere to the coverslips. Cells were 
treated by replacing medium with extract diluted in medium and incubated for the 
experiment’s treatment time at 37°C. 
MDA-MB-231 breast cancer epithelial cells were first seeded at 40,000 cells per well 
(20,000 cells cm-2) but when control cells appeared overgrown, they were seeded at 
20,000 cells per well (10,000 cells cm-2) to avoid confounding effects of cell-cell 
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contact. The larger 2DD normal fibroblasts were seeded at 12,000 cells per well (6,000 
cells cm-2).  
For actin staining, coverslips were washed three times in PBS in the wells, then fixed 
with 4% paraformaldehyde (PFA) electron microscopy grade (TAAB) for 10 min. They 
were washed three times in PBS then left in 5% FBS in PBS (wash). Coverslips fixed in 
PFA were permeabilised in permeabilisation buffer (20 mM (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) (HEPES) (pH 7.0 (NaOH)) (Sigma), 300 mM sucrose 
(Sigma), 50 mM NaCl (Sigma), 3 mM MgCl2 (Sigma), 0.5% Triton (Roche)) on ice for 5 
min, then washed three times in PBS. For tubulin staining, coverslips were washed 
three times in PBS in the wells, then fixed and permeabilised with ice cold methanol for 
30 sec (Fisher). They were washed three times in PBS then left in wash until staining. 
Coverslips were blocked in wash for 30 min. Primary antibodies (Table 2-5) were 
prepared immediately before use by dilution in 0.25% FBS in PBS. Coverslips were 
removed from the wells, blotted on paper and placed on parafilm (Fisher) in an 
incubation chamber lined with wet tissue. 30 µL of primary antibody solution was 
dropped onto each coverslip. The incubation chamber was incubated for 60 min at 
room temperature. Coverslips were blotted, dipped in wash, blotted and dipped again 
and replaced on the parafilm. They were covered with wash using a dropper and left in 
the chamber for 30 min at room temperature. Secondary antibodies (Table 2-5) were 
prepared immediately before use. If using Hoechst, a 1:10,000 solution of Hoechst 
(Invitrogen) in 0.25% FBS in PBS was prepared in an Eppendorf tube. Secondary 
antibody was added to the Eppendorf tube which was vortexed to mix. The wash was 
aspirated from the coverslips and 30 µL of antibody mixture was placed on the 
coverslips. The incubation chamber was left for 30 min in the dark at room 
temperature. The coverslips were washed three times in wash on the parafilm and the 
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last wash was left on. The incubation chamber was left for 30 min in the dark at room 
temperature. 
The coverslips were blotted and placed right way up on a slide, three or four to a slide. 
10 µL of AF1 antifadent (CitiFluor) was placed on each coverslip before covering with 
one large coverslip for each slide. The slides were viewed on an Olympus BX41 
fluorescence microscope at 400x magnification. 
Table 2-5: Antibodies used in fluorescence microscopy. 
Primary/secondary Name Supplier Dilution used 
Primary Anti-Ki-67 rabbit polyclonal Abcam 1:200 
Anti-tubulin rat monoclonal Abcam 1:1000 
488 phalloidin Alexa Fluor 1:100 
Secondary 546 goat anti-rabbit IgG Alexa Fluor 1:100 
488 goat anti-rat IgG Alexa Fluor 1:100 
 
 
2.7.2 Apoptosis assays  
Apoptosis assays were performed with FITC Annexin V Apoptosis Detection Kit I (BD 
Biosciences) and with Cell Meter Apoptotic and Necrotic Detection Kit (Stratech). 
Phosphatidylserine (PS) is a membrane phospholipid that moves to the extracellular 
surface of the plasma membrane during early apoptosis (Martin et al., 1995). The BD 
Biosciences kit employs annexin V, a phospholipid binding protein that binds to PS with 
high affinity (van Engeland et al., 1998) and when conjugated to a fluorescent marker 
such as FITC can be viewed with fluorescence microscopy, and propidium iodide, a red 
membrane impermeable dye that binds to nucleic acid of cells with compromised 
membrane integrity and is a marker for late apoptosis. The Stratech kit employs the 
phospholipid binding protein Apopxin™ Green, with membrane impermeable red 7-
Aminoactinomycin D (7-AAD) which binds to DNA, and CytoCalceinTM Violet 450 which 
stains cytoplasm in live cells. Staurosporine (STS) is a kinase inhibitor and inducer of 
apoptosis commonly used as a positive control in apoptosis assays. 
74 
 
13 mm coverslips were prepared as described in the protocol for fluorescence 
microscopy. When using the BD Biosciences kit, MCF-7 cells were seeded at 40,000 
cells per well with 250 µL medium added, and allowed to settle for 24 hours. Cells were 
treated with Clitoria extract CE at 1:2000 dilution in ethanol and incubated for 24 hours, 
or 0.5 µM STS (Invitrogen) and incubated for 16 hours as positive control. Vehicle 
control was 1% ethanol with 24 hours incubation. After incubation, coverslips were 
removed, stained with a drop of reagent solution (200 µL 1X binding buffer (0.01 M 
HEPES/NaOH (pH 7.4), 0.14 M NaCl, 2.5 mM CaCl2 in distilled water (BD 
Biosciences)), 1 µL 1X Annexin V (BD Biosciences), 1 µL propidium iodide (BD 
Biosciences)), and incubated for 15 min in the dark at room temperature. They were 
replaced in the wells, washed twice in PBS, and 4% PFA in PBS was added to each 
well. The plate was incubated for 5 minutes in the dark for fixing. The coverslips were 
washed in PBS, placed right way up on a microscope slide (3 per slide) and covered 
with a large coverslip before viewing on a Nikon Eclipse TE2000-S confocal 
microscope. 
When using the Stratech kit, MDA-MB-231 breast cancer epithelial cells were seeded 
at 40,000 cells per well with 250 µL medium added, and allowed to settle for 48 hours. 
Cells were treated with Clitoria extract CE at 1:2000 dilution in ethanol and incubated 
for 24 hours, or 1.5 µM STS and incubated for 2 hours as positive control. Vehicle 
control was 1% ethanol with 24 hours incubation. After incubation, 2 µL of 100X 
Apopxin Green (Stratech) was added to 200 µL assay buffer (Stratech). 1 µL of 200X 
7-AAD (Stratech) was added to the mixture, followed by 1 µL of 200X CytoCalceinTM 
Violet 450 (Stratech) in DMSO. Coverslips were removed, stained with 25 µL of 
reagent solution and incubated for 30 min in the dark at room temperature. They were 
replaced in the wells and washed in PBS, placed inverted on a microscope slide (3 per 




2.8 Actin density measurement 
ImageJ was used to measure actin density and to count the number of cells on each 
image. On a red channel (actin) 8-bit image, the threshold was adjusted to include actin 
filaments and to exclude rounded cells in mitosis. The unit of length was set to “pixel”. 
The Measure feature was used to obtain the integrated density between thresholds for 
the image. Integrated density results were copied into MS Excel. Cell nuclei were 
counted on a blue channel (DAPI) 8-bit image. The threshold was adjusted to include 
nuclei and nuclei were counted with the Analyze Particles feature set to show overlay 
outlines. Nuclei count results were copied into Excel. The nuclei count data were 
compared with the overlay outline image and adjustments were made where a particle 
included more than one cell, where one cell had more than one measurement or where 
a particle was an artefact. Rounded cells in mitosis were excluded. In Excel, the 
integrated density was divided by the number of cells to obtain a mean actin density 
per cell for each image, and means of two images were calculated. 
2.9 Live cell imaging 
Cells were seeded at 5,000-6,000 cells cm-2 in Falcon 12- or 24-well plates (VWR) in 
their normal cell culture medium and incubated for 24 hours to attach. HEPES was 
pipetted into the medium to make 35 mM dilution. Treatment was pipetted into the 
medium and mixed by gentle agitation of the plate. The plate was immediately sealed 
with parafilm and placed in a custom-made metal insert on the darkened stage of a 
Nikon Eclipse TE2000-S confocal microscope. The stage was pre-warmed and 
maintained at 37°C. Cells were observed at 200x magnification and phase contrast 
images were captured at 5 min intervals for 24 or 48 hours. The acquisition software 
was NIS-Elements AR version 3.22.11. Movies were transferred to Microsoft Windows 
8 and edited in Windows Live Movie Maker version 2011.  
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2.10 Movement tracking 
Movement tracking in movies was performed by Ashutosh Temang (Brunel). Cells that 
remained within the field of view and did not enter cell division during the entire 48 hour 
period observed were selected for tracking. Using the ImageJ Manual Tracking plug-in, 
a new track was started. The centre of a cell nucleus was located manually and 
clicked, the movie was played one frame at a time and and the location of the nucleus 
centre was clicked for each frame. The 48 hour duration was recorded as 659 frames. 
This provided a set of 659 xy coordinates in pixel units. The distance between adjacent 
coordinates was calculated by the plug-in in μm. The track data was copied into MS 
Excel and the distances between steps were summed to obtain a total distance moved. 
2.11 Membrane ruffling 
Movies of cells treated with Clitoria and control cells were viewed in ImageJ. From a 48 
hour movie consisting of 659 frames, five sets of four frames were selected for 
analysis: frames 1-5, 100-104, 200-204, 300-304 and 400-404. Cells were selected at 
random in the first frame of each set from cells that had least contact with other cells.. 
A visual estimate was made of the amount of plasma membrane that ruffled as a 
proportion of the exposed (not touching other cells) plasma membrane during the four 
frames. Four control and four treated cells were viewed at each timepoint. It was not 
possible to perform image analysis on movement of plasma membranes as in van 
Larebeke et al. (1992) because movement of intracellular structures dominated the 
signal. 
Movies of cells treated with Clitoria fraction F17 and control cells and control cells were 
viewed in ImageJ. From a 24 hour movie consisting of 289 frames, three sets of four 
frames were selected for analysis: frames 1-5, 30-34, 60-64. Cells were selected and 
the plasma membrane ruffling was estimated as described above. After frame 64, 
exposed plasma membrane was minimal in control cells due to cell division.  
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2.12 Phase contrast imaging  
Phase contrast images were taken on an Olympus IX71 microscope running IPLab 
Scientific Image Processing 3.6.3 (Scanalytics, Inc.) on an Apple Mac OS 9.2. 
2.13 High Performance Liquid Chromatography 
2.13.1 Chemicals 
The chemicals used for High Performance Liquid Chromatography (HPLC) were HPLC 
grade methanol (Cat. M/4056/17), HPLC grade acetonitrile (ACN) (Cat. A/0627/17), 
trifluoroacetic acid (TFA) (Cat. T/3258/PB05) and HPLC grade water, 18.2 MΩcm, from 
a Purite Select Fusion 40 water purification system. All chemicals except water were 
purchased from Fisher Scientific.  
2.13.2 System 
The system and analytical column are described in Table 2-6, Table 2-7 respectively. 
The preparative column was recommended by the supplier (Waters) as the closest 
match to the analytical column when scaling up to preparative HPLC and is described 
in Table 2-7.  
Table 2-6: HPLC system components. 
HPLC Separations module Waters Alliance W2690/5  
HPLC Photodiode array detector  Waters W2966 




Table 2-7: Analytical column used for HPLC method development and semi-preparative HPLC and 
preparative column used for preparative HPLC. 
 Analytical column Preparative column 





Waters X-Bridge BEH Column, part N
o
 186003256 with PKG 
10x10 mm Cartridge Holder, part N
o
 289000779 and XBridge 
BEH C18 Prep Guard Cartridge, part N
o
 186002972   
Column dimensions 150 mm 
1 




 x 10.0 mm 
2 
Stationary phase C18 C18 
Particle type Silica Silica 
Particle size 3.5 µm 5 µm 










2.13.3 Instrument method 
In the instrument method for analytical HPLC, the injection volume was 10 µL, the flow 
rate was 0.6 mL/min, the stroke volume was 50 μL, the column temperature was 50°C, 
the column high pressure limit was 5000 psi, the degas mode was set to Vacuum 
degasser and the photodiode array range was 230-400 nm. See Chapter 4, High 
Performance Liquid Chromatography fractionation of extracts, for details of method 
development. 
2.13.4 Analytical HPLC 
The crude extracts were diluted in methanol for analytical HPLC (Table 2-8). See 
Chapter 4, High performance liquid chromatography fractionation of extracts, for details 
of method development for analytical HPLC. 




Dilution of crude extract in methanol 1:50 1:5  1:50  
Concentration of diluted sample (µg/µL) 3.6  36 1.8 
Injection volume (µL) 10 10 10 
Loading (ug)  36 360 18 
 
 
2.13.5 Semi-preparative and preparative fraction collection 
The analytical column was used for semi-preparative fractionation and the preparative 
column for preparative fractionation. Fractions were collected by hand in 2.0 mL vials 
(semi-preparative fractionation) and 10.0 mL vials (preparative fractionation). The 
HPLC drain tubing to waste was disconnected and an 81 cm length of tubing was fitted 
to transfer the eluent to the collection bottles. The time taken for the eluent to flow 
through the tubing (2 s for semi-preparative, 0.3 s for preparative HPLC) was allowed 
for during fraction collection.  
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2.13.6 Fraction drying and weighing 
Fractions were dried in an Eppendorf centrifugal concentrator 5301. When more than 
one fractionation run was combined, eluent for each fraction was combined by pipetting 
the eluent from several HPLC vials to one vial during drying down. 
Vials were weighed before fraction collection on a Sartorius 160A MPB-1 balance. To 
ensure the fraction was fully dried, the vial containing the fraction was weighed 
repeatedly during drying down until the weight did not change between weighings. 
2.13.7 Preparing remixed fractions after HPLC 
In order to test whether the crude extract retained its bioactivity during HPLC, fractions 
were collected and recombined as follows. The 19-min method for fractionation on the 
analytical column was run with a 10 µL injection of Clitoria extract CE diluted 1:10 in 
methanol. All eluent was collected in two 10 mL vials and dried in a centrifugal 
concentrator, combining into one 2 mL vial during drying. The solid material was 
resuspended in 20 µL ethanol. 
2.13.8 Method scale-up from semi-preparative to preparative fractionation 
The 28 minute method used in semi-preparative fractionation on the analytical column 
was scaled up for preparative fractionation on the preparative column (Table 2-9, Table 
2-10).  
Table 2-9: Scale-up for method for preparative fractionation. 
 Method 
 Semi-preparative fractionation on 
analytical column 
Preparative fractionation  
Gradient (min)  24 57 
Total run time (min) 28 61 









Table 2-10: HPLC solvent flow for fractionation with preparative column. 





1 0 25 75  
2 0-57 100 0 Linear 
3
 
57-61 25 75 Linear 
1
 Trifluoroacetic acid (TFA). 
 
 
2.13.9 Calculation of retention factor 
Retention factor (Rf) from HPLC was calculated as follows: 
Rf = retention time of substance (min) / length of method (min). 
 
2.14 Liquid chromatography-mass spectrometry analysis 
Liquid chromatography-electrospray ionisation-tandem mass spectrometry (LC-ESI-
MSn) was performed in collaboration with Dr. Ifat Parveen at Aberystwyth University. 
The Thermo Finnigan HPLC/MSn system (Thermo Electron Corporation, USA) included 
an online degasser, an auto-sampler, a column temperature controller, a photodiode 
array detector and a linear ion trap with ESI source, coupled to an analytical 
workstation. The configuration consisted of a Waters C18 reversed phase Nova-Pak 
column (4.0 µm, 3.9 x 100 mm). The analytical software was Thermo Xcalibur 3.0 
(Thermo Scientific). The conditions were as in Table 2-11 and the ionisation modes 
and fragmentation were as in Table 2-12. 
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Detection wavelength 240-400 nm 
Flow rate  1.0 mL min
-1
 with 100 µL min
-1
 to mass spectrometer 
Auto-sampler tray temperature 4 °C 
Column temperature 30 °C 
Mobile phase Purified water (A) and HPLC grade methanol (Fisher) with 0.01% 
formic acid (B) 
Gradient A:B 95:5 linearly to 0:100  
Run time 60 min 
Injection volume 10 µL 
Dilution of Indian Clitoria extract 
CE(B) 




Sheath and auxiliary gas N2 
Collision gas He 
Interface and mass selective 
detector parameters 
Sheath gas, 30 arbitrary units; auxiliary gas, 15 units; spray 
voltage, 4.0 KV; capillary temperature, 320 °C; capillary voltage, 1 
V; tube lens offset, 68 V. 
1 





Table 2-12: Tandem mass spectrometry for structural elucidation of Clitoria extract CE(B). 
Ionisation mode Fragmentation Ions fragmented 
Negative  data dependent MS
1 
 
MS/MS for fraction F17 ions 623, 357, 311 
MS/MS for fraction F18 ions 683, 404, 387, 341 
Positive data dependent MS  
MS/MS for fraction F17 ions 625, 313, 295, 267, 253 
MS/MS for fraction F18 ions 685, 343, 325, 283, 219 
1
 Mass spectrometry (MS). 
 
 
2.15 Fourier transform infrared spectroscopy 
Samples were scanned on a Perkin Elmer Spectrum One Fourier transform infrared 
spectroscopy (FTIR) spectrometer, using a Specac Golden Gate Single Reflection 
attenuated total reflectance accessory, consisting of a Diamond crystal at a fixed angle 
of 45°. Spectra were collected over the 4000 cm-1 to 650 cm-1 wavenumber range, at a 
resolution of 4 cm-1. 16 accumulations were collected for each sample. The software 
used for analysis was Perkin Elmer Spectrum version 10.02. 
2.16 Chemical databases  
The Reaxys database (Elsevier) was used at the University of Bath to search for 
previous reports of the compounds identified from structural elucidation. The Kegg 
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Ligand database (Kanehisa Laboratories, 2012) was used to search for candidate 
compounds. 
2.17 Statistics 
Correlation coefficients were calculated in Microsoft Excel and one-tailed p-values for 
correlation coefficients were calculated using Statistics Calculators online calculator 
(Soper, 2015). Two-tailed, two-sample unequal variance student’s t-tests were 




Chapter 3 Cytotoxicity in Clitoria root extract 
3.1 Introduction 
It has been estimated that plants produce over 100,000 different secondary 
metabolites, which are of sufficient importance to plants for large resources to be 
concerned with their synthesis. 12.2% of the Arabidopsis genome, for example, is 
concerned with plant defence (The Arabidopsis Genome Initiative, 2000) and 
Arabidopsis synthesises over 170 of these chemicals (D’Auria and Gershenzon, 2005). 
It is not surprising therefore that traditional medicine exploits the bioactivity of natural 
product extracts, and many secondary metabolites have cytotoxic activity that is 
retained in a medicinal extract. 
In pharmacognosy work prior to this study, infertility therapies based on medicinal plant 
extracts from Assam were proposed for investigation into estrogenic activity. During 
this earlier work, in which breast cancer epithelial cells were used as a model, low 
growth or cell death was observed in cells treated with three of the plant extracts. This 
serendipitous observation led to preliminary studies on the three extracts, Clitoria, 
Mucuna and Cheilocostus, which demonstrated cytotoxic activity in breast cancer cells 
(Figure 3-1). Clitoria root extract and Cheilocostus rhizome extract had dose related 
toxicity. Mucuna seed extract was cytotoxic only at the highest concentration. 
A strategy for natural product drug discovery was proposed that would build on the 
preliminary work (Figure 3-2). This chapter concerns bioassays with the three crude 
extracts that were conducted to confirm which of the three had properties that justified 
further study, and more extensive bioassays with Clitoria, conducted in order to 




Figure 3-1: Cytotoxicity of Clitoria and Cheilocostus on breast cancer cells. Adapted from (Rand-
Weaver, personal communication). MTT cell survival assay on MCF-7 breast cancer epithelial cells 
treated with Clitoria extract CE, Mucuna extract or Cheilocostus extract for 72 hours. Survival is 
expressed as % of control (=100%). *: p<0.04,**: p<0.01, extract to control (student’s t-test). Values 





Figure 3-2: Strategy for isolation of natural products showing the approach taken in this study with 
Indian plant extracts. This chapter covers the steps in the outlined box. Adapted and redrawn from 
Sarker and Nahar (2012a); Koehn and Carter (2005). 
 






As supplies of extract were scarce, quantitative assessment of cytotoxicity in this study 
was principally performed with the MTT and PrestoBlue cell survival assays in which 
replicates can be obtained with small quantities of extract. MTT is a yellow substance 
that is reduced by mitochondrial dehydrogenases to a purple formazan precipitate 
which needs to be dissolved before measuring. The absorption reading for the 
redissolved formazan correlates with the number of live cells, but if cells are killed by a 
cytotoxic agent, the remaining cells reduce less of the MTT to formazan and the 
absorption reading is lower (Ulukaya et al., 2008). Similarly, PrestoBlue is a blue 
resazurin dye that is reduced by mitochondrial activity to a red resorufin whose 
absorbance reading corresponds to the number of live cells, but PrestoBlue has the 
advantage of not requiring dissolution (Boncler et al., 2014). In both cases the 
absorbance of treated cells after a timepoint, usually 24-96 hours, is compared to that 
of untreated control cells and an estimated half maximal concentration (IC50) can be 
calculated (Cree, 2011). Cell counting assays were also used to support the cell 
survival assay results. 
Approximately 75% of breast cancers are ER positive (Hoskins et al., 2009), where 
blocking the ER pathway with an estrogen antagonist can reduce tumour growth. All 
three Indian plant extracts had been shown to induce an estrogenic response in a 
yeast based assay for activation of the estrogen receptor (described in Arnold et al., 
1996), and with MCF-7 breast cancer epithelial cells, which are ER positive (Kalita and 
Rand-Weaver, personal communication). There is also evidence in the literature for 
estrogenic activity in extracts from the plants. Estrogenic activity with a yeast based 
estrogen screen was seen in an extract of Clitoria aerial parts (El-Halawany et al., 
2011), and treatment with Mucuna seed extract (Deka and Kalita, 2013) and 
Cheilocostus rhizome extract (Najma et al., 2012) induced an increase in mouse 
uterine weight, an effect also seen in estrogen controls. In the current study, comparing 
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results from ER positive and ER negative breast cancer cells would indicate whether 
cell killing was related to ER status. 
3.2 Results 
3.2.1 Cytotoxicity of the three Indian extracts 
To see if cytotoxicity was dependent on the ER pathway Clitoria, Mucuna and 
Cheilocostus extracts were assayed with MTT on ER negative MDA-MB-231 cells 
(Figure 3-3). Clitoria (Figure 3-3 A) and Cheilocostus (Figure 3-3 B) killed cells in a 
dose dependent fashion, while Mucuna (Figure 3-3 C) only killed cells at 1:100 dilution, 
an effect attributed to general toxicity. This agreed with the response of MCF-7 cells 
seen in Figure 3-1. Cheilocostus was not significantly more cytotoxic than Clitoria. The 
additional growth seen in MCF-7 cells at low doses of Clitoria (Figure 3-1) was not 
seen in MDA-MB-231 cells. The maximum ethanol concentration in the extract dilutions 
throughout this study was 1%, which cells tolerated (see Figure 2-4). 
When the extracts’ effects on MCF-7 cells were validated during this study under the 
same conditions as for MDA-MB-231 cells, it was confirmed that Clitoria and 
Cheilocostus killed cancer cells in a dose dependent fashion (Figure 3-4 A, B). Survival 
in ER positive MCF-7 cells appeared to be significantly lower than MDA-MB-231 cells 
when treated with Clitoria (Figure 3-4 A). This may suggest greater sensitivity to Clitoria 
in MCF-7 cells, but the spread of data makes this unlikely and there was not enough 
evidence for an ER related effect. No additional growth was seen with Clitoria at low 
doses, unlike in Figure 3-1, likely due to the different conditions in which cells were 
maintained. There was no difference in cytotoxic response to Cheilocostus between ER 






Figure 3-3: Cytotoxicity of Clitoria and Cheilocostus on ER negative breast cancer cells. MTT cell 
viability assay with MDA-MB-231 estrogen receptor (ER) negative breast cancer epithelial cells 
treated with (A) Clitoria extract CE, (B) Cheilocostus extract or (C) Mucuna extract for 72 hours. 
Viability is expressed as % of control (=100%). **: p<0.01, extract to control (student’s t-test). 
Values represent means ± SD of 4 replicates in each of 3 independent experiments. 
Dilution of crude plant extract 
Dilution of crude plant extract 






In order to find out whether normal cells would respond similarly to Clitoria to cancer 
cells, MCF-10A normal breast epithelial cells and 2DD normal foreskin fibroblasts were 
assayed with MTT after treatment with the extracts. Observations on treated cancer 
cells suggested an effect was seen after 48 hours, therefore treatment time for the MTT 
assays on normal cells was 48 hours. There was considerably higher survival in normal 
cells over 48 hours (Figure 3-5 A) than in cancer cells over 72 hours (Figure 3-4 A). 
There was no significant difference between the two normal cell lines’ response to 
Clitoria. The size of the difference between normal cells treated for 48 hours and 
cancer cells treated for 72 hours (Table 3-1) was unexpected and it was hypothesised 
that the cytotoxic effect might be related to the number of cell cycles undergone during 
the different treatment times.  
In contrast, although a dose response was seen in all cell lines treated with 
Cheilocostus extract, there was no difference in cytotoxic response between cancer 
cells treated for 72 hours and normal cells treated for 48 hours, (Figure 3-4 B, Figure 
3-5 B). The MCF-10A data points were consistently above those for 2DD, and at 
1:2000 dilution there was a significant difference between the two. This may suggest 
greater sensitivity to Cheilocostus in 2DD cells, but the spread of data makes this 
unlikely. Cytotoxicity of Cheilocostus appeared not to be related to the cell cycle. There 
was no difference in the two cancer cell lines’ responses to Cheilocostus (Figure 3-4 






   
 
 
Figure 3-4: Cytotoxicity of Clitoria and Cheilocostus on ER positive and ER negative breast cancer 
cells. MTT cell viability assays with estrogen receptor (ER) positive MCF-7 and ER negative MDA-
MB-231 (data from Figure 3-3) breast cancer epithelial cells after 72 hours’ treatment with (A) 
Clitoria extract CE or (B) Cheilocostus extract. Viability is expressed as % of control (=100%). **: 
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Figure 3-5: Cytotoxicity of Clitoria and Cheilocostus on normal cells. MTT cell viability assays with 
2DD normal fibroblasts and MCF-10A normal breast epithelial cells after 48 hours treatment with 
Clitoria extract (CE) (A) or Cheilocostus extract (B). Viability is expressed as % of control (=100%).  
2DD compared to MCF-10A, **: p<0.02 (student’s t-test). 2DD cells assayed at passages 14, 18 and 
18 (A) and passages 14 and 18 (B). Values represent means ± SD of 4 values in each of in 3 (A) and 
2 (B) independent experiments. 
 
 
Table 3-1: Estimated half maximal inhibitory concentration (IC50) of Clitoria root extract CE on 
normal and breast cancer cells in MTT assays. 
Cell line IC50 (μg/mL) after 
48 hours 
IC50 (μg/mL) after 
72 hours 
2DD 240  
MCF-10A 214  
MDA-MB-231  53.9 
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There was no cytotoxic response to Mucuna extract in normal cells other than at the 





Figure 3-6: Absence of cytotoxicity in Mucuna. MTT cell viability assay with MCF-10A normal breast 
epithelial cells after 48 hours treatment with Mucuna extract. Viability is expressed as % of control 
(=100%). Values represent means ± SD of 12 replicates in 3 independent experiments. 
 
 
3.2.2 Selective killing in Clitoria  
As Clitoria assays had shown a cytotoxic effect that might be related to cell cycling, and 
Cheilocostus assays had not, Clitoria was investigated further. Natural product 
compositions can vary between extractions, therefore a second vial of Clitoria root 
extract obtained from India, CE(B) with concentration of 90 mg/mL, was tested to see if 
it gave similar results to the CE extract with concentration of 180 mg/mL. This extract 
produced a similar dose response on MCF-7 breast cancer cells to that observed 
previously but survival at a 1:2000 dilution was around 3-fold higher than with the 
original extract CE (Figure 3-7), suggesting it was less potent. This broadly agreed with 
the known concentrations, and when IC50 values were calculated they were similar 
(Table 3-2). 





Figure 3-7: Difference in potency between Clitoria extracts CE and CE(B). PrestoBlue cell viability 
assay with MCF-7 breast cancer cells after 48 hours’ treatment with either CE or CE(B), different 
extractions of Clitoria root from India. **:p<0.0008, student’s t-test. Viability is expressed as % of 




Table 3-2: Estimated half maximal inhibitory concentration (IC50) of Clitoria root extracts CE and 












Ratio of IC50 
CE:CE(B) 
CE 180 0.5 42.9 0.7 
CE(B) 90 62.0 
1
 from Chapter 2, Materials and methods. 
 
 
When cancer and normal cells were compared side by side in the same assay, MCF-7 
breast cancer epithelial cells were 5.5-fold more sensitive to CE(B) than MCF-10A cells 
when treated for 48 hours (Figure 3-8, Table 3-3). CE(B) was around half as potent as 
CE on MCF-10A normal breast epithelial cells, with 60% surviving a 1:500 dilution of 
CE(B) (Figure 3-8) while 60% had survived a ~1:1000 treatment of CE (Figure 3-5 A). It 
appeared that cancer cells were more sensitive than normal cells to this extract of 
Clitoria. 
Table 3-3: Estimated half maximal inhibitory concentration (IC50) of Clitoria extract CE(B) on normal 
and breast cancer cells. 
Cell line IC50 (μg/mL) after 
48 hours 
Ratio of IC50 
MCF-10A:MCF-7 





 data from Table 3-2. 
 







Figure 3-8: Difference in sensitivity to Clitoria between cancer and non-cancer cells. PrestoBlue 
cell viability assay with MCF-7 breast cancer cells (data from Figure 3-7) and MCF-10A normal 
breast epithelial cells after 48 hours’ treatment with Clitoria extract CE(B). **: p<0.0001 (student’s t-
test). Viability is expressed as % of control (=10%). Values represent means ± SD of 4 replicates. 
 
 
Direct comparisons between cancer and normal cells are also possible by combining 
data from later assays on Clitoria fractions where crude extract CE(B) was used as a 
positive control at 1:2000 dilution. In these experiments survival in 2DD cells was 
generally 2-4 fold higher than in MDA-MB-231 cells. (Figure 3-9). The apparent 
increase in the extract’s toxicity over ~12 months is likely to be due to gradual ethanol 
evaporation and corresponding higher concentration, despite its being kept at -20°C. 
                  
 
 
Figure 3-9: Consistent difference in cell viability between cancer and normal cells after Clitoria 
treatment. Data from PrestoBlue cell viability assays where extract CE(B) was used as a positive 
control at 1:2000 dilution over 72 hours with 2DD normal fibroblasts and MDA-MB-231 breast 
cancer epithelial cells. Viability is expressed as % of control (=100%). 2DD passage numbers 
shown above data points. Assays are plotted in time sequence and took place over ~12 months. 
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A further evaluation of assays where extract CE(B) was used as a positive control 
demonstrates that survival in MDA-MB-231 cells after 48 hours’ treatment with extract 
CE(B) at 1:1000 dilution was around two fold greater than after 72 hours’ treatment 
(Figure 3-10).  
         
 
 
Figure 3-10: Cytotoxicity of Clitoria extract CE(B) on cancer cells compared to treatment time. 
PrestoBlue cell viability assays with MDA-MB-231 breast cancer epithelial cells using Clitoria crude 
extract CE(B) as positive control at 1:1000 dilution. Viability is expressed as % of control (=100%). 
48H: N=3. 72H: N=4. Bars indicate mean for each group. **: p= 0.0025 (student’s t-test). 
 
 
In order to determine the effect of treatment duration on non-cancer cells, primary 
human mammary epithelial cells (HMECs) were treated with CE extract for 48 and 72 
hours Figure 3-11). There was almost two fold difference in sensitivity between 48 and 
72 hours in treated HMECs compared to untreated cells, consistent with data from 
cancer cells (Figure 3-10).  
Taking all this data together, Clitoria is consistently more toxic to cancer cells than 
normal, non-cancer cells when assayed over the same time period, and the ratio of 
survival of normal:cancer cells is between 2:1 and 5.5:1, although in most assays 
between 2:1 and 3:1. To confirm whether cells were more sensitive when assayed for a 
longer time, treatment time was investigated further in a cell counting assay. Figure 
3-12 demonstrates that treatment time does affect survival, with 28% survival at 48 






   48H                                         72H 
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more pronounced difference than seen previously (Figure 3-4), but a direct comparison 
between cell counting and cell viability assays is not possible and the sensitivity limit of 
the absorbance assay underestimates the difference between control and treated. Cell 
counting was impractical for the number of assays planned, therefore cell viability 
assays continued to be used as they were sensitive enough to detect major differences 
in cell numbers. 
         
 
 
Figure 3-11: Cytotoxicity of Clitoria on primary breast epithelial cells compared to treatment time. 
PrestoBlue cell viability assay with 240L primary human mammary epithelial cells (HMECs) 
comparing 48 and 72 hours’ survival after treatment with Clitoria extract CE(B). **: p<0.0002 




        
 
 
Figure 3-12: Cytotoxicity of Clitoria extract on MDA-MB-231 cancer cells compared to treatment 
time. Cell counting assay after treatment with CE at 1:2000 dilution for 48 and 72 hours. Values 
represent one replicate. 
 
 
Taken together, the data indicates that cancer cells are 2-3 fold more sensitive to 
Clitoria than normal cells over 48 hours, and that extending treatment time from 48 to 
Treatment time 
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72 hours increases toxicity by around two fold compared to untreated controls. Further 
explanations were sought for the better survival in normal cells. Additionally, the cell 
counting results suggest that CE treatment kills, and not merely inhibits growth; at 48 
hours MDA-MB-231 cells’ number had reduced by 54% of the original seeded number, 
which extended to 80% reduction by 72 hours. 
3.2.3 The relationship between cell doubling time and sensitivity  
It was suspected that cancer cells might be more sensitive to Clitoria extract because 
the extract was targeting a process that contributes to cell division. A shorter doubling 
time in MDA-MB-231 breast cancer epithelial cells (20.4 hours) than in 2DD fibroblasts 
at passage 26 (36.0 hours) was confirmed with cell doubling time assays (Figure 3-13, 
Table 3-4).  
          
 
 
Figure 3-13: Growth of MDA-MB-231 breast cancer epithelial cells and 2DD normal fibroblasts. Cell 




Using the data from Figure 3-13, MDA-MB-231 cell growth was 2.2-fold 2DD cell 
growth after 48 hours (Table 3-4). This is within the range of the 2-3 fold difference in 
survival seen between cancer and normal cells over 48 hours. Differences in 
proliferative fractions can influence apparent doubling times. ~100% of cells in some 
cancer cell lines in culture may be proliferative, whereas the fraction of actively 
Hours after settling 
4000 









proliferating cells in a normal population reduces with each passage. Between 
passages 18 and 26 the percentage of actively proliferating cells could be expected to 
change from 50% to 30%. Using this data, growth in MDA-MB-231 cells would have 
been approximately 1.4-fold growth in 2DD fibroblasts at passage 18 after 48 hours 
(Table 3-4). Therefore, growth in cancer cells in the assays in this study would be in the 
range of 1.4- to 2.2-fold growth in fibroblasts after 48 hours and 2.0- to 3.3-fold after 72 
hours.  



















Number at start after 24 
hours settling (x 10
3
 cells) 
77.3 49.3 49.3   




800.0 225.7 376.2   
Factor increase in 48 hours 10.3 4.6 7.6 2.2 1.4 




1565.3 305.0 508.3   
Factor increase in 72 hours 20.2 6.2 10.3 3.3 2.0 
1
 Established by experiment in this study. 
2








Figure 3-14: Cytotoxicity of Clitoria on primary breast epithelial cells with different doubling times. 
PrestoBlue cell viability assay with 240L primary human mammary epithelial cells (HMECs) and 
184hT hTert immortalised primary HMECs after 48 hours’ treatment with Clitoria extract CE(B). 
Viability is expressed as % of control (=100%). *: p<0.03, **: p<0.0002 (student’s t-test). 240L values 
represent means ± SD of 4 replicates. 184hT values represent means ± SD of 8 replicates. 
 
 
Further evidence that faster dividing cells are more sensitive to Clitoria extract came 
from assays on HMECs. Primary HMECs (240L) and hTert immortalised HMECs 
Dilution of crude plant extract 
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(184hT) have doubling times of 20 hours and 36 hours respectively (Yasei, personal 
communication). When treated with Clitoria extract CE(B) over 48 hours, the faster 
dividing 240L cells were twice as sensitive to the extract as 184hT cells (Figure 3-14). 
Although the cell lines were derived from different patients, this data suggests that cells 
that divide more quickly are more sensitive to killing by Clitoria extract. 
 
3.2.4 Karotypes of cell lines tested  
As this study frequently compared normal fibroblasts and cancer cells, it was 
necessary to demonstrate that the normal cell line had not developed instability in 
culture. Metaphase spreads from 2DD fibroblasts were compared with a sample from 
one of the cancer cell lines, MDA-MB-231. The fibroblasts appeared largely normal 
with 90% of the metaphase spreads analysed composed of 46 chromosomes (Table 
3-5, Figure 3-15 A). In contrast, the karyotype of the MDA-MB-231 breast cancer cells 
ranged from 65 to 221 chromosomes and no two metaphases had the same number 
(Table 3-5, Figure 3-15 B). Interestingly, the level of cell death in treated 240L HMECs 
(Figure 3-14) was similar to MCF-7 cancer cell death seen in Figure 3-8 with 60% of 
cells surviving a treatment of 1:2000 dilution over 48 hours. It was surprising that 
HMECs did not survive as well as other non-cancer cells studied, but other cultures of 
HMECs are unstable and frequently aneuploid (Romanov et al., 2001) and HMECs 
may thus be more comparable to cancer cells in their response. To confirm this with 
the cells in this laboratory, HMEC primary epithelial cells were also spread and imaged. 
Only 30% of the 240L HMECs analysed had 46 chromosomes (Table 3-5) and many 
were dicentric (Figure 3-15 C). 
Data was available from other research groups for the two other cell lines used in this 
study, MCF-10A and MCF-7 (Table 3-5). It appeared that the MCF-10A immortalised 
breast epithelial cells had some abnormalities but were stable with 47 chromosomes in 
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the most recent paper (Marella, 2009). Cells with low levels of abnormality were less 
sensitive to Clitoria cytotoxicity than cells with high levels of abnormality. 
Table 3-5: Comparison of metaphase spreads of normal and cancer cells. 
Cell line Chromosome count data  
 Mode Range Mean Median N 
Established in this study 
2DD normal fibroblasts 
1
 46 46-49 46.8 46 10 
HMEC 240L primary human 
mammary epithelial cells 
46 40-46 43.3 44 9 
MDA-MB-231 breast cancer 
epithelial cells 
73 65-221 92.7 73.5 10 
Data obtained from other sources 














   




82 66-87    
MDA-MB-231 breast cancer 
epithelial cells 
4 
64 52-68    
1 
2DD cells assayed at passage 18. 
2 
Data extracted from Soule et al. (1990).
 3 
Data extracted from Marella et al. (2009). 
4





Figure 3-15: Example metaphase spreads. A: 2DD normal fibroblasts at passage 18. B: MDA-MB-
231 breast cancer epithelial cells. C: 240L primary human mammary epithelial cells (HMEC), 
suspected dicentric chromosomes arrowed. A, C imaged on Leica DM4000 microscope, 1000x 
magnification. B imaged on Olympus BX41 microscope, 1000x magnification. Scale bars: 10 μm. 
 
 




Three Indian extracts were proposed for study after they had been shown to have 
cytotoxic activity on cancer cells in preliminary work. In this study, two of the extracts, 
Clitoria and Cheilocostus, were seen to be highly cytotoxic to cancer cells while 
Mucuna was only cytotoxic at the highest concentration tested. From a series of assays 
on two breast cancer cell lines and two normal, non-cancer cell lines, it could be seen 
that Clitoria killed cancer cells selectively whereas Cheilocostus was equally cytotoxic 
on all cell lines tested. A 2-3 fold difference in cytotoxicity between cancer and normal 
cells was consistently observed over a 48 hour treatment time, although this may be an 
underestimate as cell viability assays underestimate the reduction in cell growth 
compared to controls. Cells were around 2-fold more sensitive when assayed for 72 
hours than 48 hours, and this was confirmed with breast cancer cells in a cell counting 
assay. 
Cells that divide faster were more sensitive to Clitoria treatment. This was seen both in 
the comparison between MDA-MB-231 cancer cells and 2DD fibroblasts for which 
doubling time was established, and in primary and immortalised HMECs where 
doubling times were available from another source. Doubling times for MCF-7 (24 
hours (Sutherland et al., 1983)) and MCF-10A cells (17.8 hours (Liu and Lin, 2004)) 
have been established but cannot be compared because protocols varied. The greater 
sensitivity of faster dividing cells to Clitoria suggests that the extract targets cells during 
cell division. Cancer cells divide more frequently than normal cells, so over any time 
period are more vulnerable to agents that target mitosis. This hypothesis is supported 
by the lower survival seen with a longer treatment.  
Cancer cells appeared more sensitive to Clitoria than normal cells, yet human primary 
mammary epithelial cells (HMECs), chosen as normal controls, were as sensitive as 
the breast cancer cell line MCF-7. Although full karyotype analysis was not undertaken, 
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in analysis of 9 spreads, HMECs appeared abnormal, with fewer than 46 chromosomes 
on average. HMECs at the passage used are known to have chromosomal 
abnormalities despite often being used as an example of normal primary cells 
(Romanov et al., 2001). The cancer cells used here were aneuploid. From analysis of 
10 spreads MDA-MB-231 breast cancer cells had a modal chromosome count of 73 
and wide variation, broadly in agreement with published data, and MCF-7 is known to 
be an abnormal cell line with modal number 82 (ATCC, 2014). The two normal cell 
lines appeared stable. MCF-10A breast epithelial cells’ karyotypes were seen to be 
stable with 48 chromosomes although with some binucleation by the group that was 
responsible for their establishment as an immortal non-tumourigenic cell line (Soule et 
al., 1990) and more recently to be stable with 47 chromosomes (Marella et al., 2009). 
For confirmation, the MCF-7 and MCF-10A stocks held in this laboratory would need to 
be analysed. However, it appeared in this study that cancer cell lines were more 
sensitive to Clitoria extract and the less abnormal cell lines were less sensitive.  
The cell lines were chosen to explore any difference in sensitivity owing to ER status. 
Although a p-value of 0.003 between ER positive MCF-7 cells and ER negative MDA-
MB-231 cells was obtained for cell viability in MTT assays, there were no significant 
differences that could be borne out by the wide variability in the data. MCF-10A breast 
epithelial cells are also ER negative (Soule et al., 1990) and survived better than MDA-
MB-231 cells. ER is generally expressed in skin fibroblasts (Hall and Phillips, 2005) 
such as 2DDs, which survived better than MCF-7 cells. HMECs are ER negative (Soule 
et al., 1990) yet their response was close to that of MCF-7 cells. There was therefore 
no conclusive evidence that the difference in sensitivity to Clitoria was due to ER 
status.  
Others have found cytotoxic activity when extracts from different parts of Clitoria were 
assayed on cells. Neda et al. (2013) found that a methanolic Clitoria flower extract had 
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a dose related cytotoxic effect on breast cancer and ovarian cancer cells, and survival 
in normal fibroblasts was around 4-fold that of breast cancer cells. Sarumathy et al. 
(2011) saw a dose response with an extract of aerial parts on cervical cancer cells and 
Ramaswamy et al. (2011) found a Clitoria leaf extract to be cytotoxic on cervical cancer 
and Dalton’s Lymphoma cells. These findings are broadly in agreement with the current 
study.  
Two methods were used to assess cytotoxicity: cell survival assays and cell counting 
assays. When the same Clitoria treatment was compared using both techniques, 
results appeared different. Survival in a cell counting assay appeared considerably 
lower (4% of controls) than in MTT assays (23% of controls) after MDA-MB-231 cells 
were treated for 72 hours with the same dilution of Clitoria, which demonstrates how 
results can vary between techniques. Angst et al. (2013) used the same techniques to 
study the effect of quercetin on pancreatic cancer cells and obtained widely differing 
results where survival in MTT assays was consistently higher than in cell counting. The 
cell survival assays give a percentage survival result for treated cells compared to an 
untreated control, based on the amount of reduced dye, which is read as absorbance. 
Because absorbance in control wells at the start of these cell survival assays was very 
near maximum for the range of sensitivity of the assay, increases in control cell 
numbers were not reflected in higher absorbances at the end of the assay. Therefore, 
the difference between controls and treated cells at the end of the assay is likely to be 
underestimated. Cell killing may be greater than these figures indicate and the 
difference between cancer and non-cancer cells may also be underestimated by these 
figures. In contrast, in cell counting, the number of live cells is calculated from a 
counted sample for treated and control cells, which gives a truer indication of the effect 
of treatment on numbers of live cells. 
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MTT is used widely for cell proliferation assays (Cree, 2011), for instance by 
deGraffenried et al. (2004) in a study of mTOR inhibition on tamoxifen resistant MCF-7 
breast cancer cells, and Fan et al. (1995) on sensitizing breast cancer cells to cisplatin 
and pentoxifylline. Other methods based on mitochondrial activity are also used, 
including PrestoBlue, for example by Sandi et al. (2014) when assessing susceptibility 
to oxidative stress in mouse fibroblasts. Microplate assays based on dye that can be 
read with fluorescence such as CyQuant which binds to nucleic acid may be more 
sensitive and have greater range than absorbance based assays (Jones et al., 2001; 
Cree, 2011). CyQuant was used by Olesen et al. (2008) in testing the small molecule 
CHS-28 for cytotoxicity on small cell lung cancer cells. Equipment for fluorescence 
based assays was not available to this study.  
For cell survival assays conducted in microplates, absorbance can be read 
simultaneously for many replicates whereas cell counting is not feasible for many 
replicates. Boulay et al. (2005) used cell counting for assessing cell survival in MCF-7 
breast cancer cells after treatment with mTOR inhibitor RAD001 but the results are 
limited to three treatments with three replicates, whereas their cell proliferation assays 
with automated plate reading include results from serial dilution assays with 9 dilutions. 
Dye exclusion based on the impermeability of live cells to a dye such as Trypan blue, 
may be used with counting to distinguish live from dead cells (Longo-Sorbello et al., 
2005). Countess, a semi-automated cell counter, was used with Trypan blue by Kim et 
al. (2014) to produce counts of live mesenchymal stem cells transfected with 
microRNAs, but using Countess slides for counting was also not feasible with the 
number of replicates in this study. 
Flow cytometry offers a fully automated means of counting cells (Shapiro, 2005) and 
information about their response to treatments can be gathered at the same time by 
means such as annexin V staining to indicate apoptosis, or DNA content to show cell 
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cycle stage, as performed by Angst et al. (2013) on quercetin treated pancreatic cancer 
cells. However, it requires greater quantities of treated cells than cell survival assays, 
and method development is necessary. Flow cytometry was not attempted due to 
limitations on the supply of extract. 
Clonogenic assays, in which cells are seeded at low density, treated, and allowed to 
grow over a time period normally of 7-10 days, after which the number of colonies is 
scored, are sensitive over a wide range (Pomp et al., 1996) and although they are 
primarily a cell growth assay they are used by many groups as a longer term 
cytotoxicity assay. For instance, Siddique et al. (2011) tested the long-term effects of 
lupeol on prostate cancer cells over 14 days in a clonogenic assay and Stehn et al. 
(2013) used clonogenic assays to confirm that knockdown of one gene did not impact 
survival. However, clonogenic assays are not suitable for all cell lines, and, like MTT, 
they do not differentiate between growth inhibition and cell death, as absence of colony 
formation could be due to either (Hoffman, 1991). Besides, clonogenic assays could 
not be used in this study because they require a large quantity of bioactive agent for 
treatments which was not available in this study. 
Theoretically, cell survival assays do not differentiate between cell growth inhibition and 
cell death. However, in this study, initial seeding density was selected so that 
absorbance was near the top of the range for the sensitivity of the assay at the point 
when cells were treated. Consequently, any absorbance reading that is lower than the 
control after 48 or 72 hours indicates cell death. Therefore these cell survival assay 
results show cell death and are confirmed by the cell counting assay. This approach 
agrees with Tyring (2012) who used cell counting after cell survival assays to confirm 
cell killing. The same cell density as in the current study was used by Prabhakaran et 
al. (2012) for evaluating cytotoxicity of nickel complexes on cancer cell lines.  
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With time (after around one year of experiments) bacterial contamination was noted in 
Clitoria extract CE(B). Initially this was thought to be contamination introduced during 
the project. Later, extractions made from Indonesian and UK Clitoria root (refer to 
Chapter 6 for full details) were also discovered to be contaminated. The possibility of 
endophytic bacteria including rhizobia, closely associated with nitrogenous plant root 
cells, being co-extracted, was considered. A number of methods were tried to remove 
the bacteria, which were tolerating an ethanolic extract of pH 3-4: Filtering twice with 
0.2 µm filter; treatment with antibiotics penicillin, streptomycin, gentamicin and 
amphotericin; and heating to 70°C for one hour. After this, use of the crude extracts 
was limited, although assays with fractions continued. No bacterial infection was seen 
in the fractions or in cells treated with the fractions. 
Rhizobia are nitrogenous, endophytic bacteria which form symbiotic relationships that 
are often specific to a small number of plant species (Mylona et al., 1995). They are 
Gram-negative (Franche et al., 2009) and non spore-forming (Graham et al., 1963). 
They respond to flavonoid chemoattractant signals from legume plant roots by moving 
towards the root (Dharmatilake and Bauer, 1992), entering plant cells and expressing 
Nod factors which cause the plant to initiate the formation of root nodules, where the 
bacterial enzyme nitrogenase catalyses the fixation of nitrogen (Mylona et al., 1995). 
There is no evidence that bacteria can produce flavonoids, which are thought to be 
exclusively of plant origin (Pinheiro and Justino, 2012). Rhizobia can respire 
anaerobically as well as aerobically (Daniel et al., 1980) and a very small percentage 
are persister cells, which can resist desiccation and antibiotics (Denison and Kiers, 
2011). In laboratory conditions some species have been shown to survive 60°C for 6 
hours (Kulkarni and Nautiyal, 1999) and some are acid tolerant to pH 4.0 (Correa and 
Barneix, 1997). Without DNA characterisation it is not possible to confirm the species 
of the bacterial contaminant, but their appearance after one year of using the legume 
extract and their persistence suggest that they may be rhizobia. If work were to 
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continue with Clitoria crude extract, methods for obtaining sterilised extracts without 
affecting bioactivity would be required. 
3.4 Next steps 
Clitoria, as the extract with a differential killing effect, was considered the most 
promising of the three Indian medicinal extracts for anti-cancer activity. Subsequent 
stages of the work concerned fractionation and identification of the bioactive fraction 





Chapter 4 High Performance Liquid Chromatography fractionation of 
extracts 
4.1 Introduction 
Practitioners of traditional medicine systems administer plant extracts which are 
complex mixtures of compounds, and Traditional Chinese Medicine (TCM) formulations 
are often combinations of more than one extract, but quality control on such mixtures is 
challenging (Efferth et al., 2007). This is a recognised problem in TCM, where 
substantial effort is going into ways of improving standardisation and consistency in 
TCM products, for example using High Performance Liquid Chromatography (HPLC) 
for fingerprinting, whereby a number of marker compounds are identified from peaks in 
traces for each component and used to compare formulations (Yang et al., 2014).  
Alternative and complementary treatments in the USA and Europe are often made from 
natural product extracts or mixtures. Natural product medicines are sold in the USA as 
dietary supplements with legally specified controls on the claims they can make, 
including a statement that the U. S. Food and Drug Administration (FDA) has not 
validated the product for safety or efficacy (Bent and Ko, 2004). One example is Artrex, 
a mixture of four Ayurvedic plant extracts which is sold in the USA in capsule form as a 
food supplement (Patwardhan, 2012). In the USA, quality control is the responsibility of 
the manufacturers, some of whom use chemical fingerprinting techniques to monitor 
levels of what are thought to be the active agents, and some standardise their product 
by blending several batches (Bent and Ko, 2004). However, in a survey of 25 ginseng 
products on sale in the USA, the levels of the active ingredients, ginsenosides and 
eleutherosides, varied by 15 to 36 and 43 to 200-fold in capsules and liquids 
respectively (Harkey et al., 2001). Heavy metals which are added to some Ayurvedic 
medicines have caused cases of poisoning in the UK from products bought in India 
(Dargan et al., 2008) and in a survey of 175 Ayurvedic medicines on sale via the 
internet from American suppliers, 20% contained lead, arsenic or mercury (Saper et al., 
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2008). Batches of PC-SPES, a treatment for prostate cancer based on TCM herbs and 
manufactured in the USA, were found to be adulterated with Western drugs including 
the anticoagulant drug warfarin (Ko et al., 2003), and PC-SPES has been withdrawn 
(Cassileth and Deng, 2004).  
Western medicine treatments are based on single bioactive compounds, not crude 
extracts or formulations from natural products, as without a standard product, clinical 
outcomes are unpredictable, therefore it is essential with a natural product extract to 
isolate and identify the active compound which will become the lead compound in drug 
discovery (Zheng et al., 2013). During lead optimization, the compound is evaluated 
and optimised for absorption, distribution, metabolism, excretion, and toxicity and 
shown to be safe and effective, without which data the drug cannot progress to clinical 
trials or gain approval from regulatory bodies (Corson and Crews, 2007). Polyphenon E 
is a rare example where the FDA has approved a combination of compounds, but this 
is a defined mixture of four green tea catechins and not a complex natural product 
extract (Chen et al., 2008). Polyphenon E was approved in 2006 as an ointment for 
genital warts (Chen et al., 2008) and is being investigated for treatment of cancers 
including neuroblastoma (Santilli et al., 2013).  
Bioassay-led analysis of a natural product extract to identify the active compound is 
performed by chemical separation using one of the available chromatography methods 
(Harvey et al., 2015). The crude extract is separated into fractions with less complexity 
than the whole extract according to the time taken to elute, and fractions are tested for 
bioactivity in an assay relevant to disease (Harvey et al., 2015). Before fractionation, 
extracts can be pre-processed to remove classes of compounds and reduce the 
complexity of the chromatogram, for instance partitioning in hexane to remove lipids 
(Jones and Kinghorn, 2012). Bioassay results inform the selection of fractions for 
further iterative fractionation until a pure substance is obtained (Sarker and Nahar, 
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2012a). Following this methodology, compounds with bioactivity are prioritised for 
investigation, leading to quicker, more efficient and more cost-effective hit discovery of 
candidate compounds for drug candidates (Harvey et al., 2015). 
The chemotherapy drugs camptothecin, the vinca alkaloids and paclitaxel were all 
identified in bioassay-led fractionation (Wall and Wani, 1995). In the discovery of 
camptothecin, wood and bark of Camptotheca acuminata were extracted in ethanol 
and found to be effective in a mouse leukemia life prolongation assay model by Wall 
and Wani (1995). The isolation and purification of camptothecin required several steps. 
After extractions in heptane and chloroform, and fractionation in counter current 
chromatography,11 fractions were obtained, of which 6 had activity on human oral 
carcinoma cells (Wall and Wani, 1995). Camptothecin was crystallised from the 6 
recombined fractions (Wall and Wani, 1995).  
In this study a strategy for isolation and purification was followed, based on a 
conventional bioassay-guided approach (Figure 4-1). Several chromatographic 
techniques were considered for analysis and fractionation. Thin Layer Chromatography 
(TLC) confirmed that Clitoria, Mucuna and Cheilocostus were mixtures of many 
different visible and UV active components. However, TLC requires method 
development to find the best solvent system for separation, and the supply of extract 
was not sufficient. Gas Chromatography (GC) was trialled, but no significant peaks 
were detected, which was attributed to the compounds not being volatile at the 
temperature used. It was decided that HPLC, a sensitive and non-destructive technique 
for separating natural products that requires small quantities for analysis and can easily 
be scaled up for fractionation (Wolfender, 2009), would be the best technique with the 
limited supply of extract. In liquid chromatography, solutes in solvent (liquid phase) are 
passed through a column packed with particles (stationary phase), and are separated 
based on the time taken to elute, which depends on their affinity to the particles (Skoog 
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et al., 1992). HPLC uses particles of size 5 µM or less for high resolution and requires 
high pressure to pump the solvent through the densely packed column (Skoog et al., 
1992). A detector coupled to the HPLC system registers a signal for compounds as 
they leave the column, which shows as a peak on a chromatogram (Wolfender, 2009).  
 
Figure 4-1: Strategy for isolation of natural products showing the approach taken in this study with 
Indian plant extracts. This chapter covers the steps in the bold outlined box. Adapted and redrawn 
from Sarker and Nahar (2012a); Koehn and Carter (2005). 
 
 
Reversed phase HPLC (RP-HPLC) uses a column packed with a non-polar stationary 
phase of silica particles bonded to long chain carbon molecules (Nawrocki, 1997) 
through which a solute is passed in a relatively polar solvent, allowing the more polar 
substances in the solute to elute before the less polar (Skoog et al., 1992). RP-HPLC is 
the most popular type of column for natural product separation (Sarker and Nahar, 
2012b). In this study RP-HPLC was coupled to a UV absorbance detector with 
photodiode array (UV-DAD), which was appropriate as its range of wavelengths, 190-
800 nm (Waters, 2001), includes the 200-550 nm range at which most bioactive 
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substances from natural sources absorb UV radiation, and the stored UV data can be 
analysed by peak distribution to assess purity (Wolfender, 2009). 
The conventional approach to HPLC separation when the target compounds are 
unknown is to begin with method development in analytical HPLC to obtain a 
chromatogram with well resolved peaks, for which a very small quantity of sample is 
sufficient (Sarker and Nahar, 2012a). Once analytical HPLC is satisfactory, coarse 
fractions with similar polarities are collected and evaluated in bioassays, as performed 
by Koehbach et al. (2013) on an extract of Oldenlandia affinis. Sections of the 
chromatogram can then be excluded from further testing and the broad bioactive 
fractions are subfractionated into less complex fractions, normally by running the 
fraction through the column again with a modified solvent gradient (Harvey et al., 
2015). With a preparative column, a larger quantity of extract can be injected, resulting 
in more concentrated fractions (Latif and Sarker, 2012). At any fractionation stage the 
activity may be lost, either as it is a combinatory effect of two compounds widely 
separated on the chromatogram, or because fractions that are too small can dilute the 
target compound beyond the point at which bioactivity is seen (Harvey et al., 2015). For 
example, Orhan and Sener (2003) partitioned extracts from Amaryllidaceae bulbs with 
anticholinesterase activity to isolate the alkaloid fraction, which retained the activity. 
However, when 8 alkaloids were isolated, identified and tested in bioassays, activity 
per µg of material was halved, prompting the authors to attribute the alkaloid fraction 
activity to a synergistic effect of more than one alkaloid (Orhan and Sener, 2003). 
Clitoria was the most promising of the three extracts that are the subject of this study 
due to the selectivity of its crude extract in bioassays, and it was prioritised for 
separation. The aim was to fractionate as finely as possible so that the bioactive 
fractions were pure enough to be presented for structural elucidation. Methods for 
separation for Mucuna and Cheilocostus were established at the same time as for 
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Clitoria, and preliminary bioassays were conducted with Cheilocostus fractions. The 
bioassay was the same as those used for crude extracts (see Chapter 3) so that results 
could be compared. 
4.2 Results 
4.2.1 Method development: Establishing optimum separation methods in 
analytical HPLC 
Before fractionation could begin, HPLC methods had to be developed to separate 
compounds effectively in each of the three extracts Clitoria, Mucuna and Cheilocostus. 
An incremental approach to HPLC method development was adopted for each of the 
extracts. The solvents for the mobile phase were initially methanol with 0.05% 
trifluoroacetic acid (TFA) and water with 0.05% TFA in a rising gradient of methanol 
(Table 4-1) which is a typical choice for separation of natural products with RP-HPLC 
(Latif and Sarker, 2012) with a UV detector (Wolfender, 2009). TFA was used to reduce 
peak tailing through silanol interactions with the mobile phase and to encourage ion-
pairing for longer retention times of charged compounds (Dolan, 2015).This method 
generated the chromatograms in Figure 4-2. 
Method development for Clitoria was conducted by testing a methanol starting 
percentage of 25%, a methanol gradient of 25-100% over 22 min, a gradient of 70-
100% methanol over 3 min, using pure methanol, and returning to start conditions over 
0.5 min. The developed method achieved good peak resolution while shortening the 




Table 4-1: Initial HPLC solvent flow for all extracts. 











1 0 2.0 98.0  
2 0-30  100.0 0 Linear  
3 30-40  100.0 0 Isocratic  
4 40-45  2.0
 
98.0 Linear  
5 45-50 
 
2.0 98.0 Isocratic  
1
 Trifluoracetic acid (TFA). 
 
        
 
 
         
 
 
         
 
 
Figure 4-2: Chromatograms from initial method with (A) Clitoria, (B) Mucuna, (C) Cheilocostus.        
* methanol contaminant. Waters X-bridge column, 150 x 3.0 mm, flow rate 0.6 mL/min, column 
temperature 50°C, injection volume 10 µL. Gradient of methanol (MeOH) and water with 0.05% 
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Table 4-2: HPLC solvent flow for method developed for Clitoria. 
Step Time (min) % methanol
 





1 0 25 75  
2 0-14 70 30 Linear 
3 14-16 100 0 Linear 
4 16-16.5
 
25 75 Linear 
5 16.5-19
 
25 75 Isocratic 
1
 Trifluoroacetic acid (TFA).  
 
 
            
 
 
Figure 4-3: Chromatogram for separation method developed for Clitoria. Waters X-bridge column, 
150 x 3.0 mm, flow rate 0.6 mL/min, column temperature 50°C, injection volume 10 µL. Gradient of 
methanol (MeOH) and water with 0.05% trifluoroacetic acid seeTable 4-2. Maxplot, 230-400 nm. 
 
 
Mucuna extract contained more polar components that eluted early with the initial 
method (Figure 4-2 B). Method development was conducted by testing a methanol 
starting percentage of 0%, a methanol gradient of 0-40% over 20 min, a methanol 
gradient of 40-100% over 3 min, adding a 0% methanol isocratic step of 2 min at the 
start and returning to start conditions over 0.5 min. Solvent systems tested were pure 
methanol and water with 0.05%TFA, acetonitrile and water with 0.05% TFA, and 
acetonitrile and pure water. The developed method achieved better peak resolution 
while shortening the run from 50 min to 26 min (Table 4-3, Figure 4-4).  
Method development for Cheilocostus was conducted by testing a methanol starting 
percentage of 60%, a methanol gradient of 60-100% over a range of 3-10 min, using 
methanol without TFA and returning to start conditions over 0.5 min. The developed 
method achieved better peak resolution while shortening the run from 50 min to 10 min 
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Table 4-3: HPLC solvent flow for method developed for Mucuna. 
Step Time (min) % ACN 
1 
% water + 0.05% TFA
2
 v/v Profile 
1 0 0 100  
2 0-2 0 100 Linear  
3 2-20 40 60 Linear  
4 20-23  100 0 Linear  
5 23-23.5 
 
0 100 Linear  
6 23.5-26 
 
0 100 Isocratic 
1
 Acetonitrile (ACN). 
2 
Trifluoroacetic acid (TFA). 
 
 
              
 
Figure 4-4: Chromatogram for separation method developed for Mucuna. Waters X-bridge column, 
150 x 3.0 mm, flow rate 0.6 mL/min, column temperature 50°C, injection volume 10 µL. Gradient of 
acetonitrile (ACN) and water with 0.05% trifluoroacetic acid, see Table 4-3. Maxplot, 230-400 nm. 
 
 
Table 4-4: HPLC solvent flow for method developed for Cheilocostus. 





1 0 75 
2 
25  
2 0-6 100 0 Linear 
3 6-6.5
 
75 25 Linear 
4 6.5-10
 
75 25 Isocratic 
1
 Trifluoroacetic acid (TFA). 
 
 
               
 
 
Figure 4-5: Chromatogram for separation method developed for Cheilocostus. Waters X-bridge 
column, 150 x 3.0 mm, flow rate 0.6 mL/min, column temperature 50°C, injection volume 10 µL. 



























As expected with extracts from different natural products, the chromatograms with well 
separated peaks showed different constituents and were generated by different 
methods. 
4.2.2 Semi-preparative fractionation of Clitoria with HPLC analytical 
column 
Clitoria crude extract had been seen in bioassays to be the most interesting due to its 
differential killing on cancer and normal cells and was prioritised over Mucuna and 
Cheilocostus for fraction testing with semi-preparative HPLC. The rationale for dividing 
the chromatograms into fairly coarse fractions was to isolate the relevant region of the 
chromatogram to determine the region of bioactivity. This region could then be further 
subdivided into a number of smaller subfractions. First, to find out whether bioactivity 
was lost during the HPLC fractionation process, a full set of Clitoria fractions was 
collected, remixed, dried down and resuspended in ethanol, and tested in a bioassay. 
Crude Clitoria extract was used as a control. The bioassay confirmed that bioactivity 
was still present (Figure 4-6). The methylene blue assay was used for early qualitative 





Figure 4-6: Bioactivity is retained after HPLC. Cell viability in MDA-MB-231 breast cancer epithelial 
cells after 72 hours’ treatment with remixed fractions of Clitoria extract CE, dried down and 
resuspended in ethanol. Methylene blue assay. Viability is expressed as % of control (=100%). 
Values represent means ± SD of 4 replicates.  
 
 
The treatment dose for a bioassay of coarse fractions from semi-preparative HPLC on 













placed on the column (see Appendix B). In this bioassay, Clitoria fractions F5 and F6, 
tested together, had cytotoxic effect on both cancer and normal cells while fraction F10 
killed cancer cells selectively over normal cells (Figure 4-7).  
 
 
        
 
 
Figure 4-7: Bioassay after semi-preparative fractionation of Clitoria on analytical column. A: Cell 
viability in MDA-MB-231 breast cancer epithelial cells and 2DD normal fibroblasts after 72 hours’ 
treatment with fractions of Clitoria extract CE(B). PrestoBlue assay. Ethanol concentration in 
treatments =1.5%. Viability is expressed as % of control (=100%). Values represent means ± SD of 2 
replicates in each of 2 independent experiments. 2DD cells assayed at passage 23 and 24. B: 
Chromatogram showing fractions F1-F10 collected by peak in semi-preparative fractionation. 
Waters X-bridge column, 150 x 3.0 mm, flow rate 0.6 mL/min, column temperature 50°C, injection 
volume 10 µL. Gradient of methanol (MeOH) and water with 0.05% trifluoroacetic acid, seeTable 4-2. 
See Appendix B for details of extract concentration. Maxplot, 230-400 nm. 
 
 
Fraction F10 was the most interesting fraction due to its clear selectivity. To separate 
F10 further, the crude extract was fractionated using a method with a run time 
extended from 19 to 28 min and a shallower gradient in the F10 region of the 
chromatogram, and subfractions of fraction F10 were collected (Figure 4-8 B). In a 
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Figure 4-8: Bioassay after semi-preparative fractionation of Clitoria on analytical column. A: Cell 
viability in MDA-MB-231 breast cancer epithelial cells and 2DD normal fibroblasts after 72 hours’ 
treatment with fractions of Clitoria extract CE(B). PrestoBlue assay. Ethanol concentration in 
treatments =1.5%. Viability is expressed as % of control (=100%). Values represent means ± SD of 2 
replicates. 2DD cells assayed at passage 24.  B: schematic of fractions F9-F10.6. Maxplot, 230-400 
nm. C: Chromatogram with scale expanded in 18-28 min region. Waters X-bridge column, 150 x 3.0 
mm, flow rate 0.6 mL/min, column temperature 50°C, injection volume 10 µL. Gradient of methanol 
(MeOH) and water with 0.05% trifluoroacetic acid: 25-100% methanol over 24 min, return to start 
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When the scale was expanded for the chromatogram at the active region, each of the 
fractions F10.3, F10.4 and F10.5 was seen to contain peaks representing UV-
absorbent compounds (Figure 4-8 C).  
4.2.3 Fractionation of Clitoria with preparative HPLC 
Semi-preparative fractionation of Clitoria extract with the analytical column required 
pooling three fractionation runs for one bioassay. This approach had worked well, but 
larger volumes of fractions were needed for testing on cells. Moving to a preparative 
column allowed more extract to be fractionated and provided enough material for both 
bioassays and an investigation into the mechanism of action, described in Chapter 5. 
The method for semi-preparative fractionation on the analytical column was scaled up 
for preparative fractionation. The run time was extended from 28 to 61 minutes, the 
gradient was made shallower to maintain the same profile over a longer run time, the 
flow rate was increased from 0.6 mL/min to 4.67 mL/min and the stroke volume was 
increased from 50 to 130 µL.  
Theoretically a scale-up from 10 µL injection volume to 180 µL was possible, but the 
HPLC loop size restricted the injection volume to 100 µL. With a concentration of 
Clitoria extract CE(B) of 9 µg/µL, 60 µL was the most appropriate injection volume for a 
well resolved chromatogram. Fractions were collected at 1-minute intervals, each 
containing 4.67 mL of eluent before drying down, and numbered F1 to F61 according to 
retention time. The chromatogram for preparative HPLC showed well resolved peaks 
and the major peaks from fractions F5 and F6 on the semi-preparative fractionation 
were identifiable on the chromatogram from preparative fractionation as fractions F17 
and F18 from shape and approximate % methanol (Figure 4-9). The major peaks also 
had similar UV spectra with both peaks having λmax1=323.8 nm and λmax2=285.6 nm on 
both chromatograms.  
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Approximate peak area presented a means of estimating the amount of material in 
each fraction when moving from an analytical to a preparative column. In order to 
estimate how much ethanol to resuspend the fractions in, the peak height at 323 nm 
(λmax) multiplied by the fraction eluent volume was used to give an indication of the 
amount of material in the fraction (see Appendix B). From this it was concluded that 
when the material from one preparative fractionation run was resuspended in 4.5 µL 
ethanol, 1 µL would be sufficient to treat one well and would theoretically have around 
70% of the bioactive effect seen in the bioassays after semi-preparative fractionation.  
          
 
 




Figure 4-9: Comparison of chromatograms from semi-preparative and preparative fractionation of 
Clitoria extracts. A: from semi-preparative fractionation of Clitoria extract CE(B). Waters X-bridge 
column, 150 x 3.0 mm, flow rate 0.6 mL/min, column temperature 50°C, injection volume 10 µL. 
Gradient of methanol (MeOH) and water with 0.05% trifluoroacetic acid: 25-100% methanol over 24 
min, return to start conditions over 4 min. B: from preparative separation of Clitoria extract CE(B). 
Waters X-Bridge BEH column, 250 x 10 mm, flow rate 4.67 mL/min, column temperature 50°C, 
injection volume 60 µL. Gradient of methanol (MeOH) and water with 0.05% trifluoroacetic acid: 25-
100% methanol over 57 min, return to start conditions over 4 min. Maxplot, 230-400 nm. See 
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As expected, there was bioactivity in some fractions from preparative fractionation 
(Figure 4-10). From observation of cells under the microscope before the bioassay was 
conducted, those treated with fraction F17 had rounded up and appeared dead (Figure 






          
 
 
Figure 4-10: Bioassay after preparative fractionation of Clitoria. A: Cell viability in MDA-MB-231 breast cancer epithelial cells after 72 hours’ treatment with 
fractions of Clitoria extract CE(B). PrestoBlue assay. Viability is expressed as % of control (=100%). Values represent means ± SD of 2 replicates. B: 
Chromatogram employed for separation. Fractions were collected at 1 min intervals. Waters X-Bridge BEH column, 250 x 10 mm, flow rate 4.67 mL/min, 
column temperature 50°C, injection volume 60 µL. Gradient of methanol (MeOH) and water with 0.05% trifluoroacetic acid: 25-100% methanol over 57 min, 
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Figure 4-11: Images of cells treated with Clitoria fraction F17. Phase contrast images of MDA-MB-
231 breast cancer epithelial cells. A, C: ethanol control. B, D: treated with Clitoria fraction F17. A, B, 
0H, 40x magnification. Scale bar: 40 μm. C, D: 72H, 200x magnification. Scale bar: 20 μm. Images of 
cells in 96-well plates used in the same assay shown in Figure 4-10. 
 
 
All bioactive fractions from preparative fractionation colocated with bioactive fractions 
from semi-preparative fractionation on the analytical column (Figure 4-12 A). Bioactive 
fractions F14, F17 and F18 colocated with peaks representing UV absorbent 
compounds whereas F46 and F48 did not (Figure 4-12 B). Although there were UV 
peaks in the fractions that corresponded to fractions F10.4 and F10.5 from semi-
preparative fractionation, these fractions were not bioactive in preparative fractionation 






        
 
 




Figure 4-12: Comparison of bioactive fractions from Clitoria semi-preparative and preparative 
fractionation. A: Chromatogram employed in preparative fractionation showing bioactive fractions 
with 60% cell viability or less on cancer cells (blue; data from Figure 4-10) and with 20% cell 
viability or less on cancer cells after semi-preparative fractionation on analytical column (red; data 
from Figure 4-7, Figure 4-8) aligned by peak. B: 43-60 minute region of chromatogram in A 
enlarged. Waters X-Bridge BEH column, 250 x 10 mm, flow rate 4.67 mL/min, column temperature 
50°C, injection volume 60 µL. Gradient of methanol (MeOH) and water with 0.05% trifluoroacetic 
acid: 25-100% methanol over 57 min, return to start conditions over 4 min. See Appendix B for 
details of extract concentration. Maxplot, 230-400 nm.  
 
 
The fractions that contained the major peaks (hereafter called fractions F17 and F18 
from preparative fractionation) had previously killed both cancer and normal cells. To 
find out whether this was because more material was in the fractions than in others, 
and whether they would be selective if diluted, fractions F17 and F18 were tested in a 
dilution series in a bioassay with the same cell lines that were used to test the crude 
extract in Chapter 3, Figure 3-5: MCF-10A breast epithelial cells, 2DD normal 
fibroblasts, and breast cancer epithelial cells MDA-MB-231 and MCF-7 (Figure 4-13). 
Cytotoxicity with the highest concentration of fraction F17 was around 8 fold higher on 
MDA-MB-231 cancer cells than normal cells, and around two fold higher on MCF-7 
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4-13 B). Around the same amount of material was collected in fractions F31 and F46 
as in fraction F17. Fraction F31, which had not shown bioactivity before and was  
                                                                   
 
     
 
 




Figure 4-13: Cytotoxicity in Clitoria extract fractions F17 and F18. Cell viability in MCF-10A normal 
breast epithelial cells, 2DD normal fibroblasts assayed at passage 17, MDA-MB-231 breast cancer 
epithelial cells and MCF-7 breast cancer epithelial cells after 72 hours’ treatment with fraction F17 
(A), F18 (B), F31 (C) or F46 (D) of Clitoria extract CE(B). PrestoBlue assay. Estimated fraction 
concentrations calculated from weight of fraction material before resuspension in ethanol, see 
Table 4-5. Viability is expressed as % of control (=100%). **: p<0.02, fraction to control (student’s t-
test) for MCF-10A, MDA-MB-231, MCF-7. *: p=0.0498, fraction to control (student’s t-test) for MDA-
MB-231. Values represent means ± SD of 2 replicates. Waters X-Bridge BEH column, 250 x 10 mm, 
flow rate 4.67 mL/min, column temperature 50°C, injection volume 60 µL. Gradient of methanol 
(MeOH) and water with 0.05% trifluoroacetic acid: 25-100% methanol over 57 min, return to start 
conditions over 4 min. Fractions were collected at 1 min intervals. 
 
 
included as a control, still showed no effect in dilution series on any of the cell lines 
(Figure 4-13 C). Fraction F46 was also assayed in dilution series on all four cell lines 
because it was the most cytotoxic fraction in Figure 4-10, and in semi-preparative 
fractionation as fraction F10.3 had shown selectivity (Figure 4-8 A). At the highest 
** 
** ** 
Fraction F17 treatment (ng/µL)
 






Fraction F18 treatment (ng/µL)
 
28 57 113 225 450 B 
Fraction F31 treatment (ng/µL)
 
48 97 193 385 770 C 
Fraction F46 treatment (ng/µL)
 




concentration tested (640 ng mL-1) F46 was tending towards significance (p=0.0498 
comparing control to MDA-MB-231 cells).  
The fraction material was weighed before resuspension in ethanol (Table 4-5). There 
was more material in fraction F17 than F18. When diluted in the same amount of 
ethanol, concentrations of fractions F17 and F18 were different. It was thought that 
they might be equipotent. When survival in the two cancer cell lines was compared by 
plotting against the estimated concentration, as expected, there was little difference 
between the potency of the two fractions (Figure 4-14).  
Table 4-5: Approximate yields of bioactive Clitoria fractions from preparative fractionation. 







Figure 4-14: Potency of Clitoria fractions F17 and F18. Cell viability in MDA-MB-231 and MCF-7 
breast cancer epithelial cells after 72 hours’ treatment with fractions F17 or F18 of Clitoria extract 
CE(B). Data from Figure 4-13. Viability is expressed as % of control (=100%). **: p<0.02, fraction to 




To sum up, the two major Clitoria derived peaks from semi-preparative HPLC on the 
analytical column (fractions F5, F6) showed most bioactivity but no selectivity. The 
corresponding fractions from preparative fractionation (fractions F17, F18) underwent a 











































of the chromatogram (85-100% methanol) in semi-preparative fractionation showed 
most selective activity but the activity was not confirmed after preparative fractionation 
and the peaks could not be identified.  




         
 
 
Figure 4-15: Bioassay after semi-preparative fractionation of Cheilocostus fractions. A: Cell 
viability in MDA-MB-231 breast cancer epithelial cells and 2DD normal after 72 hours’ treatment 
with fractions of Cheilocostus extract. PrestoBlue assay. Ethanol concentration in treatments 
=1.5%. 2DD cells assayed at passage 17. Viability is expressed as % of control (=100%). Values 
represent means ± SD of 2 replicates. B: Chromatogram employed for separation with schematic of 
fractions collected by peak. Waters X-bridge column, 150 x 3.0 mm, flow rate 0.6 mL/min, column 
temperature 50°C, injection volume 10 µL. Gradient of methanol (MeOH) and water with 0.05% 
trifluoroacetic acid: , see Table 4-4. See Appendix B for details of extract concentration. 
 
 
The study originally concerned three Indian medicinal crude plant extracts. Clitoria had 
been shown to be the most interesting because of its selective cytotoxic effects on 
cancer and normal cells, while Mucuna and Cheilocostus crude extracts were not 
selective. Mucuna had very low bioactivity and was excluded from further study. To see 
if there was any fraction in Cheilocostus with interesting cytotoxic activity, semi-




























fractions, cancer cells appeared more sensitive than normal cells to Cheilocostus 
fraction F3 (Figure 4-15), although there was no highly UV absorbent peak 
corresponding to fraction F3 on the chromatogram. Based on these results 
Cheilocostus would have been a candidate for bioassay-led fractionation, but there was 
not enough extract available to pursue this line of work. 
4.3 Discussion 
Bioassay-driven HPLC was successful for fractionation of Clitoria extract, leading to the 
isolation of two strongly bioactive fractions (F17, F18) from preparative fractionation 
which were selective in assays on cancer cells in a dose dependent manner similar to 
the crude extract and could be proposed for identification and structural elucidation. 
From initial coarse fractions from semi-preparative fractionation on the analytical 
column, three fractions (F5-F6 combined, F10) were selected for subfractionation, and 
four subfractions of interest (F17, F18, F46, F48) emerged from 61 1-minute 
subfractions in preparative fractionation (Figure 4-16).  
Bioactivity can be a synergistic effect of chemicals in a mixture and can be lost during 
fractionation (Sarker and Nahar, 2012a), but in Clitoria cytotoxic activity was retained in 
individual fractions. Some bioactivity was lost between moving from coarse to 
preparative fractions, for example when subfractionating F10.4 and F10.5, which may 
have been because material was too dilute in the preparative fractions (F49-F53) to 
have a bioactive effect. Fraction 46 was not sufficiently potent for significant bioactivity 
in a dilution series after preparative fractionation. Bioactive fractions F17 and F18 
contained strongly UV absorbent compounds. There was not enough plant material to 
refine each fraction repeatedly, therefore the purity of each fraction is unknown. 
Bioactive fractions F46 and F48 were not strongly UV absorbent, suggesting that the 
bioactive compounds in these fractions have no chromophores or may be UV 





Figure 4-16: Schematic of bioassay led fractionation of Clitoria extract CE(B). Mapping of 10 
fractions from semi-preparative fractionation on the analytical column to 61 fractions in preparative 
fractionation. Shaded boxes: Bioactive fractions. N. S.: not significant. 
 
 
Scaling up from an analytical to a preparative method was effective, as seen by the 
correspondence between the bioactive fractions. The full capacity of the preparative 
column and theoretical scaling factor of 18 were not used but a 5X linear scale-up was 
achieved which represented a real improvement in efficiency of experimental 
procedure. Merging four preparative runs yielded around 1.1 mg of fraction F17 and 0.8 
mg of fraction F18, sufficient for bioassays on fractions and limited investigations into 
the bioactive mechanism. Further trials with different injection volumes and extract 
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concentrations that might have allowed a heavier loading were not conducted due to 
limitations on the amount of crude extract available.  
The differential response between cancer and normal cells that had already been seen 
in the crude extract was also seen with fractions F17 and F18 in a dose dependent 
manner. The limits of sensitivity of the assay prevented selectivity being visible at 
concentrations below 225 ng/µL. Whereas the crude extract had appeared more toxic 
on MCF-7 cells than MDA-MB-231 cells, the fractions seemed more toxic on MDA-MB-
231 cells than MCF-7 cells. However, the number of replicates in these fraction 
bioassays was low (N=2) and it is possible that combining results of more assays 
would have eroded this difference.  
Detection with a UV detector with photodiode array (UV-DAD) was effective as an aid 
to fractionation as it is non-destructive of the sample being collected and detects a wide 
range of UV wavelengths. Active compounds in natural products tend to have 
chromophores with conjugated bonds which are strongly UV absorbent (Wolfender, 
2009). However, UV-DAD is not a universal detection technique. Compounds with 
double bonds without conjugation are weakly UV active in the low end of the UV 
spectrum (< 220 nm) and may not be seen against the methanol mobile phase signal 
(Wolfender, 2009). Some saponins, terpenes, lipids and alkaloids are not UV active 
and would not be detected (Wolfender, 2009). For instance, the active agents in the 
medicinal extract of Gingko are flavonoids and ginkgolides acting synergistically 
(Dubber and Kanfer, 2006). Ginkgolides are terpene lactones with very weak 
chromophores, better detected by other detector systems such as evaporative light 
scattering detection (ELSD) (Dubber and Kanfer, 2006). The alkaloid group includes 
the vinca alkaloid chemotherapy drugs and saponins are also frequently bioactive 
(Cmoch et al., 2008). The weakly UV absorbent bioactive agents in fractions F46 and 
F48 may be alkaloids or saponins, known to be present in Clitoria root (Deka and 
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Kalita, 2011), or belong to other phytochemical classes for which ELSD would be more 
appropriate. 
The two major peaks in fractions F17 and F18 have identical UV maxima and elute in 
close proximity, indicating they are of similar polarity. Although F18 appeared at first 
less bioactive than F17, when similar concentrations were compared, it was equally 
potent. From this, it can be hypothesised that they are closely related compounds. In a 
study on apple pomace, Schieber et al,. (2001) isolated five glycosides of the flavonoid 
quercetin, which differed only in their glycoside, as separately eluting peaks from HPLC 
with a reversed phase column. To do this, they employed a slowly rising gradient of 
ACN against water, achieving separation of peaks eluting closely together (Schieber et 
al., 2001). In a faster rising gradient very closely related compounds would elute as one 
peak and it is possible that fractions F17 or F18 may be composed of more than one 
closely related compound although the good peak resolution argues against this. 
HPLC methods are easily adapted for identification with liquid chromatography-mass 
spectrometry (LC-MS) for identification, for example by Benayad et al. (2014) when 
separating and identifying flavonoid glycosides from Moroccan fenugreek seed extract. 
Moving to LC-MS for identification can require a change to the method to suit the MS, 
for instance not using TFA in the HPLC solvent, which can alter the peak retention 
times, and in any case substances may elute at different times on a different column 
(Garrard, personal communication). Major peaks F17 and F18 were expected to be 
easily identified in a method adapted for LC-MS with the crude extract. Identifying the 
bioactive agents in fractions F46 and F48, potentially non-UV active compounds, would 
be difficult with LC-MS unless a pure fraction for each containing only the bioactive 
compound could be prepared or ELSD can be used.  
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Accounts of natural product isolation in the literature describe starting with 15 kg of 
plant material (Michel et al., 2013) and can use up to 50 kg, although 250 g-1 kg is the 
usual practice (Gray et al., 2012). Clitoria extracts in this study derived from 40 g plant 
material and Mucuna and Cheilocostus from 20 g of plant material. If more extract had 
been available a further iterative fractionation could have taken place, potentially 
isolating the bioactive agents in F46 and F48. For example, Xu et al. (2015) employed 
three fractionation steps to isolate the compound neobractatin, starting with 4.0 kg of 
trunk of Garcinia bracteata. In addition, the extract could have been pre-processed to 
remove classes of compound, for instance removing lipids by partitioning with hexane 
(Jones and Kinghorn, 2012), which can simplify the chromatogram and assist 
purification and identification of the active agents. Clitoria extract had tested positive in 
qualitative analysis for several phytochemical classes including flavonoids, sterols and 
alkaloids (Deka and Kalita, 2011). With more material, the active fractions could have 
undergone similar tests which would have identified their chemical classes. Here, 
however, the small quantity of extract available was used effectively and with positive 
results. 
4.4 Next steps 
The crude Clitoria extract and its strongly bioactive and selective fractions F17 and F18 
were investigated with the aim of finding the bioactive mechanisms (see Chapter 5, 
Mechanism of action). Identification of the bioactive compounds in fractions F17 and 
F18 was performed, and as bioactivity was not confirmed in F46 and lost in F48, but 
present in their parent fraction F10.3, attempts were made to identify the bioactive 





Chapter 5 Mechanism of action 
5.1 Introduction 
During the drug discovery process, once a cytotoxic effect is confirmed and the drug 
target is identified, work proceeds to understand the mechanism of action so that, 
during the lead optimization stage, structure activity relationship work can attempt to 
improve absorption, distribution, metabolism, excretion and pharmacokinetics (Zheng 
et al., 2013). In this study a dose-dependent cytotoxic effect had been seen with 
Clitoria extract and two Clitoria fractions F17 and F18. The next stages of the study 
focussed on identification of the cytotoxic agent (see Chapter 7, Identification of 
bioactive agents in Clitoria root extract) and elucidation of the cytotoxic mechanism, the 
subject of this chapter (Figure 5-1). 
In results from cell viability assays, cancer cells appeared to be 2-3 fold more sensitive 
to the crude extract than normal cells and some difference in sensitivity between 
cancer and normal cells was also seen with fraction F17. The effect with the crude 
extract appeared to be time-dependent and cells with shorter doubling times were more 
sensitive to Clitoria extract. The hypothesis was that Clitoria and its fractions were 
targeting cells during cell division, similar to current chemotherapy drugs. In this 
scenario, cancer cells would be more sensitive due to their faster cycling times and a 
longer treatment would allow the drug to target more cell division events. In order to 
see the effect of treatment, cells were observed and imaged over a 48-hour treatment 
time. It was envisaged that images of morphological changes, cell division, cell death 
and cell movement would provide information about the mechanism of action. In 
particular, observation would reveal whether treated cells entered mitosis and whether 
cell death occurred during mitosis. 
As supplies of extract were limited, assays that used minimal quantities of extract or 
fraction were chosen. Live cell imaging was performed in multiwell plates. In live cell 
134 
 
imaging, cells are maintained in culture conditions on a microscope stage and imaged 
at a chosen time interval over a period of time to obtain a set of images which are 
linked to form a movie (Stephens and Allan, 2003). Cells can be observed in mitosis in 
live cell imaging both at the entry to mitosis when they round up and also at its 
conclusion when they divide, or if mitosis fails, flatten out without dividing (Woods et al., 
1995). Live cell imaging can also show changes in cell movement as in Sugiyama et al. 
(2013).  
 
Figure 5-1: Strategy for isolation of natural products showing the approach taken in this study with 
Indian plant extracts. This chapter covers the step in the bold outlined box. Adapted and redrawn 
from Sarker and Nahar (2012a); Koehn and Carter (2005). 
 
 
Fluorescence microscopy was performed to view the changes to proteins chosen on 
the basis of live cell imaging results. Fluorescence microscopy on fixed cells involves 
staining proteins with substances that can be visualised in fluorescence, such as 
antibodies conjugated to a fluorescent dye. These techniques were employed in work 
to elucidate the mechanism of action of paclitaxel on microtubules (Schiff and Horwitz, 
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1980) and the technique has been employed for many years for viewing the actin 
cytoskeleton and microtubule network (Weber et al., 1974). Dhamodharan et al. (1995) 
used fluorescence microscopy and fluorescence video imaging to see changes to 
microtubules in African green monkey kidney cells treated with vinblastine, having 
injected them with bovine GTP-tubulin, which was visible with both techniques.  
5.2 Results 
5.2.1 Cell division 
In cell viability assays faster dividing cancer cells were more sensitive to Clitoria 
treatment than more slowly dividing normal (non-cancer) cells. It was hypothesised that 
Clitoria targeted cells during cell division and that a non-lethal Clitoria treatment might 
show some cells entering mitosis but dying before completion. To investigate this, 
MCF-7 breast cancer epithelial cells were treated with a 1:2000 dilution of Clitoria 
crude extract and viewed in live cell observation. The treatment had a cytostatic effect 
in treated cells, with no cell division and no rounding for entry into mitosis, while 
untreated controls doubled in number (Figure 5-2).  
 
 
Figure 5-2: Clitoria extract prevents cell division in breast cancer cells. % change in cell number 
over 48 hours (100%=no change). Cell counts made from live cell imaging. 4% cell death in treated 
cells, 3% in untreated controls. MCF-7 breast cancer epithelial cells observed for 48 hours after 
treatment with Clitoria extract CE at 1:2000 dilution. N=number of cells in field of view at start of 



























To see if this response was common to other cell lines, MDA-MB-231 breast cancer 
epithelial cells and 2DD normal fibroblasts were also observed over 48 hours. The 
1:2000 treatment with Clitoria extract CE(B) was expected to be half as potent as the 
1:2000 dose of extract CE used in Figure 5-2 and might show cells attempting cell 
division. Cells that remained within the field of view throughout the duration of the 
experiment without entering mitosis were observed. One cell death was seen in both 
control and treated cancer cells and no death was seen in normal cells. Whereas both 
untreated cell lines trebled in number over 48 hours, just one cell (11%) divided in the 
treated cancer cells and 25% of treated 2DD cells divided (Figure 5-3 A), consistent  
      
 
          
 
Figure 5-3: Reduced cell division and longer duration of mitosis after treatment with Clitoria. 
Counts made from live cell imaging. MDA-MB-231 breast cancer epithelial cells and 2DD normal 
fibroblasts observed for 48 hours after treatment with Clitoria extract at 1:2000 dilution. 2DD cells 
observed at passage 23. A: % change in cell number over 48 hours (100%=no change). N=number 
of cells in field of view at start of observation. B: Median time taken between rounding and 
cytokinesis. Limits: range of values. N=number of cells observed in mitosis. **: p=0.012, student’s 
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with the MTT and PrestoBlue results that showed cancer cells to be more sensitive to 
the extract than normal cells. Therefore cell division was almost prevented by crude 
Clitoria extract treatment in two breast cancer cell lines and reduced in normal cells.  
In fibroblasts that divided, mitosis took place more slowly after treatment. When the 
time between rounding up and cytokinesis was measured, the time in mitosis was 
found to be twice as long in the treated cells compared to the control cells (Figure 5-3 
B). 
To see if the bioactive fractions in Clitoria also reduced cell division, live cell imaging 
was performed with the fractions. Example images only are shown in Figure 5-4. As 
expected, when treated with a non-lethal dose of fraction F17 of Clitoria, both cancer 
and normal cells divided less than controls (Figure 5-5 A). The change was related to 
the dose of F17 and similar in both cell types. As both fibroblasts and cancer cells 
underwent mitosis during the observation, it was possible to compare the time taken in 
mitosis. The time between rounding up and cytokinesis was measured in cells that 
divided normally. As seen with the crude extract, mitosis in fibroblasts was around 
twice as long after treatment with the higher dose of F17. The median time taken in 
mitosis was longer in cancer cells after treatment with F17 and a wide range of times 







Figure 5-4: Images of cancer cells in live cell imaging treated with Clitoria fraction F17. A: 
Untreated controls. B: Example abnormal cell division with blebbing in MDA-MB-231 breast cancer 
epithelial cells treated with fraction F17 of Clitoria extract CE(B) at 88 ng/µL. C: inset of B. Same 
live cell observation as in Figure 5-4. Abnormal cell division arrowed. A, B: 200x magnification. 











       
 
 
Figure 5-5: Reduced cell division and longer duration of mitosis after treatment with Clitoria 
fraction F17. MDA-MB-231 breast cancer epithelial cells and 2DD normal fibroblasts treated with 
fraction F17 of Clitoria extract CE(B) at 44 or 88 ng/µL or fraction F18 at 140 ng/µL. 2DD cells 
observed at passage 16. A: % change in cell number over 48 hours (100%=no change, white 
%=change compared to controls). N=number of cells in field of view at start of observation. B: 
Bars, median time between rounding and cytokinesis in cells that divide normally. Limits represent 




The figures in Figure 5-5 B for timing of cell division did not include cells that rounded 
up and did not undergo cytokinesis, or those that divided abnormally. Any period of 
observation is likely to include cells that enter mitosis but do not complete it by the end 
of the observation. However, more cancer cells than normal cells treated with the 
higher dose of fraction F17 spent an extended period in a rounded state and were still 
in that state at the end of the observation (Figure 5-6). Some cells that completed cell 
division were observed to undergo a protracted cytokinesis with gross blebbing and 































































abnormal cell division was seen occasionally in almost all groups of cells, but was 
substantially increased in cancer cells treated with fraction F17 and appeared to be 
dose related.  
         
 
           
 
        
 
             
 
Figure 5-6: Abnormal and incomplete cell division after treatment with Clitoria fractions. Counts 
made from same live cell observations as in Figures 5-3, 5-4. A, B: 2DD normal fibroblasts 
observed at passage 16. C, D: MDA-MB-231 breast cancer epithelial cells. Supplementary movies 7-
14, see Appendix D. B, D: same data as in Figure 5-3. Supplementary movies 3-6, see Appendix D. 
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5.2.2 Cell movement 
In live cell observation, cells treated with Clitoria extract displayed distinct differences in 
movement compared to controls. The distance travelled (motility) by cells treated with a 
1:2000 dilution of Clitoria extract was 40-50% less than controls in both cancer cells 




Figure 5-7: Reduced motility in cells treated with Clitoria. MDA-MB-231 breast cancer epithelial 
cells and 2DD normal fibroblasts. 2DD cells observed at passage 23. Distance travelled in live cell 
observation movies over 48 hours after treatment with 1:2000 dilution of Clitoria extract CE(B). 
Values represent means ± SD (%=change compared to controls). *: p=0.029 (student’s t-test). N.S.: 
Not significant. Supplementary movies 3-6, see Appendix D. 
 
 
Untreated cancer cells displayed constant membrane ruffling, a characteristic that is 
observed in the majority of cancer cells in culture (Jiang, 1995) which was greatly 
reduced in treated cells. Motility was reduced and ruffling was completely absent in the 
MCF-7 breast cancer cells treated with Clitoria extract CE at 1:2000 dilution shown in 
Figure 5-2, suggesting that these observations might be common to cancer cells. 
Where plasma membrane was exposed in MDA-MB-231 cells, the proportion of plasma 
membrane that was ruffling reduced from 61% in control cells to 31% in cells treated 
with a 1:2000 dilution of Clitoria extract over 48 hours (p=0.00003, student’s t-test). 
However, there were no changes observed in motility and no significant changes in 

















concentrations used. The differences in cell division and cell movement between 
treated and untreated cells were striking and were investigated further. 
5.2.3 Cytoskeletal proteins 
A reduction in cell division and slower cell division in treated cells suggested that 
Clitoria and its cytotoxic fractions could be disrupting microtubules similarly to the 
microtubule inhibitor chemotherapy drugs, while reduced cell motility and membrane 
ruffling suggested inhibition of the actin cytoskeleton. To see the impact of treatment on 
cytoskeletal proteins directly, cells were seeded at 20,000 cells cm-2, similar to the 
density in the cell viability assays, treated with Clitoria for 18 hours and stained with 
phalloidin, which binds to filamentous actin, and with anti-tubulin-β, conjugated to 
fluorescent dyes. The actin cytoskeleton of cells treated with 1:2000 dilution of Clitoria 
extract CE(B) showed differences in both cancer and normal cells (Figure 5-8). Actin in 
epithelial cells forms a mesh of filaments at the plasma membrane. In treated MDA-
MB-231 cancer cells there was less dense actin at the cell membrane than in untreated 
controls (Figure 5-8). Mean actin density was reduced from 48,000 pixels per cell (N=2 
images, 180 cells) in control cells to 40,000 pixels per cell (N=2 images, 122 cells) in 
treated cells.To see more clearly changes in individual cancer cells, they were seeded 
at half the density (10,000 cells cm-2) and stained after a higher dose treatment 
(1:1000) (Figure 5-9). With the lower density and higher dose, actin appeared granular 
instead of in filaments or a mesh (Figure 5-9). Normal 2DD fibroblasts were seeded at 
a lower density than cancer epithelial cells (6,000 cells cm-2) due to their larger size 
and treated with Clitoria at 1:1000 dilution to see if they responded differently from 
cancer cells. Fibroblasts in culture form stress fibres, which unexpectedly appeared 
more prominent after treatment than in untreated controls (Figure 5-10). There was 
also evidence that cancer cell division was inhibited by treatment, consistent with the 
live cell imaging observations: Some cancer cells treated with the lower dose (1:2000) 
were undergoing mitosis, indicated by the prominent cortical actin or chromosomes at 
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the metaphase plate (Figure 5-8 B) whereas no mitotic cells were observed after the 
higher treatment dose (1:1000) (Figure 5-9).  
 
Figure 5-8: Actin in breast cancer epithelial cells after 18 hours treatment with Clitoria. MDA-MB-
231 cells seeded at 20,000 cells cm
-2
. A: untreated controls. B: treated with Clitoria extract CE(B) at 
1:2000 dilution for 18 hours. A, B: F-actin. Arrows: cells undergoing mitosis. Dotted arrows: dense 








Figure 5-9: Actin in Clitoria treated breast cancer epithelial cells. MDA-MB-231 cells seeded at 
10,000 cells cm
-2
. A, C: untreated controls. B, D: treated with Clitoria extract CE(B) at 1:1000 












Figure 5-10: Stress fibres in Clitoria treated normal fibroblasts assayed at passage 23. 2DD 
fibroblasts seeded at 6,000 cells cm
-2
. A: untreated controls. B: treated with Clitoria extract CE(B) 
at 1:1000 dilution for 24 hours. A, B: F-actin. Arrows: cells undergoing mitosis. Dotted arrows: 











Surprisingly, changes to microtubules were less pronounced than changes to actin 
filaments. When stained for tubulin, cancer cells seeded at 20,000 cells cm-2 showed 
little change after an 18-hour 1:2000 treatment with Clitoria extract (Figure 5-11). To 
see whether an effect would be apparent with a higher treatment, or with less dense 
seeding, a 1:1000 dilution of extract was used with cancer cells seeded at 10,000 cells 
cm-2 but no strong effect was seen (Figure 5-12). Normal fibroblasts were also treated 
with a 1:1000 Clitoria extract dilution and seeded less densely (6,000 cells cm-2) due to 
their larger size. Microtubules were somewhat more noticeable in the normal fibroblasts 





Figure 5-11: Microtubules in breast cancer epithelial cells after treatment with Clitoria. MDA-MB-231 
cells seeded at 20,000 cells cm
-2
. A: untreated controls. B: treated with Clitoria extract CE(B) at 
1:2000 dilution for 18 hours. A, B: anti-tubulin β. Arrows: cells undergoing mitosis. 400x 




Figure 5-12: Microtubules in breast cancer epithelial cells treated with Clitoria. MDA-MB-231 cells 
seeded at 12,000 cells cm
-2
. A: untreated controls. B: treated with Clitoria extract CE(B) at 1:1000 





















Figure 5-13: Microtubules in normal fibroblasts treated with Clitoria. 2DD fibroblasts assayed at 
passage 23 and seeded at 6,000 cells cm
-2
. A: untreated controls. B: treated with Clitoria extract 











The nucleolus is a structure within the nucleus where synthesis of ribosomal 
components and assembly of the ribosome take place (Quin et al., 2014) and which 
detects many forms of cellular stress, leading to the accumulation of p53 via the 
nucleolar stress pathway (Rubbi and Milner, 2003). Nucleoli form around actively 
transcribing 47S ribosomal RNA subunit precursors during early G1 and disassemble 
at prophase in mitosis (Quin et al., 2014). A mature nucleolus has three distinct 
regions: fibrillar centres, surrounded by dense fibrillar components, situated within 
granular components (Kill, 1996). Chemotherapy drugs that intercalate DNA such as 
cisplatin also damage rDNA and thereby inhibit RNA Polymerase I transcription and 
ribosome biogenesis (Burger et al., 2010). Other anticancer agents including 
topoisomerase inhibitors and everolimus also affect ribosome biogenesis, either 
directly or indirectly (Quin et al., 2014). 
Many MDA-MB-231 breast cancer cells in interphase developed transparent nucleoli 
after 4-6 hours of Clitoria treatment which remained visible until the end of live cell 
observation at 48 hours (Figure 5-14). This phenomenon was repeatedly seen in 
different experiments, both in live cell imaging and in cell viability assays. It was also 
seen in the same cell line after treatment with fractions F17 and F18. In one live cell 
observation with a 88 ng/µL treatment of fraction F17 of Clitoria extract CE(B), 93% of 
MDA-MB-231 cancer cells developed transparent nucleoli at between 2.5 and 20 hours 
of treatment (mean 11 hours, N=27). Transparent nucleoli were not seen in untreated 
cells, treated normal cells or treated MCF-7 cancer cells. However, in one cell viability 
assay where cells were observed at the end of the 72-hour incubation, nucleoli 






Figure 5-14: Transparent nucleoli in breast cancer epithelial cells treated with Clitoria. A, B: Phase 
contrast images of MDA-MB-231 breast cancer epithelial cells, untreated (A) or after 5 hours 
treatment with Clitoria extract CE(B) at 1:2000 dilution (B). Example transparent nucleoli arrowed. 
200x magnification. Scale bar: 10 µm. 
 
 
The transparent nucleoli appeared similar to those observed by Burger et al. (2010) 
after treatment with cisplatin, therefore it was thought that Clitoria’s mechanism of 
action might include targeting ribosome synthesis in the nucleoli. To find out more 
about how the nucleoli were affected by treatment, MDA-MB-231 breast cancer cells 
and normal fibroblasts were treated with 700 ng/µL of fraction F17 or 420 ng/µL of 
fraction F18 and stained for Ki-67. Ki-67 is associated with the nucleolus in interphase 
and with the chromosomes in mitosis, and during nucleolar stress is released into the 
nucleoplasm as a consequence of loss of nucleolar integrity (Soldani et al., 2006). As 
the concentrations of the two purified fractions isolated in HPLC were different, cancer 
cells were observed hourly and fixed when changes were seen in the treated cells. F17 
treated cells and controls were fixed after 2 hours when rounding, indicative of cell 
stress, was observed (Figure 5-15 B), and F18 treated cells and controls were fixed 
after 5 hours when some cancer cells developed transparent nucleoli. Phase contrast 
images of control cancer cells before fixing showed some cells apparently in mitosis 
(Figure 5-15 A), although after fixing and staining few control cells could be seen with 
Ki-67 associated with chromosomes, indicative of mitosis (one is visible in Figure 5-19  
A), suggesting some rounded cells in mitosis may have detached from the slide during 




in phase contrast images. This supported the hypothesis that the treatments cause 
cells to lose attachment when they are rounded, either in mitosis or through stress. 
Overall, Ki-67 staining in foci was less intense in the treated cancer cells than controls 
and there was cytoplasmic Ki-67 in some F17 treated cells, suggesting a loss of 
nucleolar integrity as a consequence of stress (Figure 5-18), not seen in Figure 5-16 or 
Figure 5-23, probably due to different fixing protocols. Ki-67 tends to form many smaller 
foci during G1 phase and fewer, larger foci during S and G2 phases (Kill, 1996). In 
addition, cells treated with the kinase inhibitor and transcription inhibitor 5, 6-dichloro-1-
β-D-ribofuranosylbenzimidazole (DRB) display many small Ki-67 foci (Kill, 1996). 
However, in cancer cells that stained positive for Ki-67, there was no apparent 
difference in the number and size of foci between control and treated cells (Figure 5-16 
to Figure 5-19), therefore no conclusion could be drawn concerning transcription 
inhibition. No connection could be made between the transparent nucleoli and the 
appearance of Ki-67 staining in cancer cells. 
 
 
Figure 5-15: Morphology of cancer cells treated with Clitoria fraction F18. Phase contrast images of 
MDA-MB-231 breast cancer epithelial cells, untreated (A) or after 5 hours treatment with Clitoria 
fraction F18 at 420 ng/µL (B) A: cells appear flat as in interphase (arrow) or rounded as in mitosis 
(arrowhead). B: cells appear rounded as if stressed (arrows) and some show transparent nucleoli 
(arrowheads). 200x magnification. Scale bar: 20 µm. 
 
 
Over time, a population of normal cells in culture gradually enters a state of irreversible 
growth arrest known as senescence, which is distinct from the reversible state of 




is a marker of cell senescence (Lawless et al, 2010). As expected with normal 
fibroblasts, a small number stained negative for Ki-67 indicating they were senescent 
(Figure 5-21). Similar to cancer cells, Ki-67 foci were less intensely stained and some 
cells treated with fractions F17 or F18 showed cytoplasmic Ki-67 (Figure 5-20, Figure 
5-22). There was no consistent difference in the Ki-67 foci between control and treated 
fibroblasts. Fewer cells remained on slides than expected, suggesting some had lost 
adherence during fixing, either through the effects of treatment or through rounding in 
mitosis. Ki-67 staining in these experiments showed that treated cells were stressed, 







Figure 5-16: Ki-67 and actin staining in breast cancer epithelial cells treated with fraction F17 of 
Clitoria. MDA-MB-231 cells seeded at 10,000 cells cm
-2
. A, C: untreated controls. B, D: treated with 
Clitoria extract CE(B) fraction F17 at 700 ng/µL for 2 hours. A, B: Ki-67. C, D: F-actin. Arrows: 
granular actin. Dotted arrows: actin prominent at plasma membrane. Arrowhead: cell staining 












Figure 5-17: Ki-67 and actin staining in breast cancer epithelial cells treated with fraction F18 of 
Clitoria. MDA-MB-231 cells seeded at 10,000 cells cm
-2
. A, C: untreated controls. B, D: treated with 
Clitoria extract CE(B) fraction F18 at 420 ng/µL for 5 hours. A, B: Ki-67. C, D: F-actin. 400x 











Figure 5-18: Ki-67 and tubulin staining in breast cancer epithelial cells treated with fraction F17 of 
Clitoria. MDA-MB-231 cells seeded at 10,000 cells cm
-2
. A, C: untreated controls. B, D: treated with 
Clitoria extract CE(B) fraction F17 at 700 ng/µL for 2 hours. A, B: Ki-67. C, D: β-tubulin. Arrows: 











Figure 5-19: Ki-67 and tubulin staining in breast cancer epithelial cells treated with fraction F18 of 
Clitoria. MDA-MB-231 cells seeded at 10,000 cells cm
-2
. A, C: untreated controls. B, D: treated with 
Clitoria extract CE(B) fraction F18 at 420 ng/µL for 2 hours. A, B: Ki-67. C, D: β-tubulin. Arrows: 















Figure 5-20: Ki-67 and actin staining in fibroblasts assayed at passage 19 and treated with fraction 
F17 of Clitoria. 2DD normal fibroblasts seeded at 6,000 cells cm
-2
. A, C: untreated controls. B, D: 
treated with extract CE(B) fraction F17 at 700 ng/µL for 2 hours. A, B: Ki-67. C, D: F-actin. 








Figure 5-21: Ki-67 and tubulin staining in fibroblasts treated with fraction F17 of Clitoria. 2DD 
normal fibroblasts assayed at passage 19 and seeded at 6,000 cells cm
-2
. A, C: untreated controls. 
B, DH: treated with Clitoria extract CE(B) fraction F17 at 700 ng/µL for 2 hours. A, B: Ki-67. C, D: β-

















Figure 5-22: Ki-67 and actin staining in fibroblasts treated with fraction F18 of Clitoria. 2DD normal 
fibroblasts assayed at passage 21 and seeded at 6,000 cells cm
-2
. A, C: untreated controls. B, D: 
treated with Clitoria extract CE(B) fraction F18 at 420 ng/µL for 5 hours. A, B: Ki-67. C, D: F-actin. 
Arrowheads: cytoplasmic Ki-67. Arrows: noticeable stress fibres in treated cells. 400x 














Figure 5-23: Ki-67 and tubulin staining in fibroblasts treated with fraction F18 of Clitoria. 2DD 
normal fibroblasts assayed at passage 21 and seeded at 6,000 cells cm
-2
. A, C: untreated controls. 
B, D: treated with Clitoria extract CE(B) fraction F18 at 420 ng/µL for 5 hours. A, B: Ki-67. C, D: β-








5.2.5 Cytoskeletal proteins after fraction treatment 
In the same experiment, to see short-term changes to the cytoskeleton that might be 
related to the transparent nucleoli, cells were stained for filamentous actin and tubulin. 
The effect of Clitoria fraction F17 on actin in cancer cells after 2 hours was reminiscent 
of the longer term effect of the crude extract. After treatment with fraction F17 actin was 
again less prominent at the plasma membrane and more granular in the cytoplasm in 
MDA-MB-231 breast cancer cells (Figure 5-16). Actin was also less noticeable than in 
controls after the 5-hour fraction F18 treatment (Figure 5-17). 
In normal fibroblasts, the more prominent stress fibres that had been seen after 
overnight treatment with the crude extract were not seen after 2 hours’ treatment with 
fraction F17 (Figure 5-19) but were seen after 5 hours’ treatment with fraction F18 
(Figure 5-21). Microtubules appeared more noticeable after treatment with F18 (Figure 
5-23). This confirmed that fractions F17 and F18 were responsible for some of the 
effects of the overnight crude Clitoria extract and suggested a difference in activity 
between the two fractions when a short-term (2-5 hours) treatment was used compared 
to a longer term (18-24 hours), or that the more prominent stress fibres and 
microtubules developed at between 2 and 5 hours. 
5.2.6 Cell death 
No observation of cell death following treatment with Indian Clitoria was made using 
live-cell imaging. To obtain more information about the nature of cytotoxicity induced by 
Clitoria treatment, which might help elucidate the mechanism of action, breast cancer 
cells were stained with reagents that identify early and late apoptosis. During early 
apoptosis the membrane phospholipid phosphatidylserine (PS) moves to the 
extracellular surface (Martin et al., 1995) and can be stained with Annexin V 
conjugated to a fluorescent marker, or Apopxin green. The red dye propidium iodide 
enters cells with compromised membrane integrity and binds to nucleic acid of cells in 
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late apoptosis. Some MCF-7 breast cancer epithelial cells treated with Clitoria extract 
CE(B) at 1:2000 dilution showed green annexin V-FITC coloration at the plasma 
membrane typical of early apoptosis, while untreated control cells did not (Figure 5-24). 
Treated cells appeared rounded as if stressed but no blebbing or visual marker of late 
apoptosis could be seen. No red propidium iodide staining was seen (data not shown), 
suggesting that membranes were not fully compromised. Cells given a 0.5 µM 
treatment of the apoptosis induction agent staurosporine (STS) for 16 hours as a 
positive control lifted from the slide, strongly suggesting cell death had occurred and 




Figure 5-24: Indications of early apoptosis in Clitoria treated MCF-7 breast cancer epithelial cells. 
Annexin V assay. A, B: untreated controls, 200x magnification. C, D: treated with Clitoria CE(B) 
extract at 1:2000 dilution for 24 hours, 400x magnification. A, C: phase contrast. B, D: Annexin V-
FITC, contrast improved and inverted. Annexin V binds phosphatidylserine on outer plasma 











Figure 5-25: Indications of early apoptosis in Clitoria treated MDA-MB-231 breast cancer epithelial 
cells. A, B: untreated controls. C, D: treated with CE(B) extract at 1:2000 dilution for 24 hours. E, F: 
treated with 1.5 µM staurosporine for 2 hours. A, C, E: CytoCalcein
TM
 Violet 450 staining cytoplasm. 
B, D, F: Apopxin green, contrast enhanced and inverted. Apopxin green stains phosphatidylserine 
on outer plasma membrane in early apoptosis. Examples of early apoptotic cells arrowed. 
Apoptotic and necrotic detection assay. 400x magnification. Scale bars: 10 µm. 
 
 
An apoptotic and necrotic detection assay with Apopxin green was trialled to obtain 
better staining of apoptotic cells. Some MD-MB-231 breast cancer epithelial cells 
treated with Clitoria extract CE(B) showed signs of early apoptosis with Apopxin green 






hours were rounded and smaller than controls, and some stained faintly positive for 
Apopxin green at the plasma membrane, suggesting they were in early apoptosis 
(Figure 5-25 E, F). No propidium iodide stain to indicate late apoptosis was seen in any 
cells in this assay (data not shown).  
Further assays would have been necessary to refine the protocols for the apoptosis 
assays for optimum staining, but this was not done due to limitations in the supply of 
extract. Nonetheless, the images did not exclude the possibility that cells treated with 
Clitoria at these dilutions were in early apoptosis.  
5.2.7 Summary 
In summary, the effects on cell division, speed of mitosis, appearance of actin and 
transparent nucleoli that were seen with crude Clitoria extract were also seen with one 
or more treatments of the bioactive fractions F17 or F18. The reduced motility and 
reduced membrane fluttering that had been seen with the crude extract were not seen 
after treatment with a fraction (Table 5-1).
168 
 
Table 5-1: Summary of effects of Clitoria crude extract and its fractions F17 and F18 on cancer and normal cells 
1
. 
 Crude Clitoria extract CE(B) (unless indicated, 
1:2000) 
Clitoria fraction F17 Clitoria fraction F18 
 Breast cancer epithelial cells  
Effect (unless indicated, 18-48H) MCF-7  MDA-MB-231 2DD normal 
fibroblasts 
MDA-MB-231  2DD normal 
fibroblasts 
MDA-MB-231  2DD normal 
fibroblasts 
Cell death (live-cell observation) - - - - - - - 
Cell death (apoptosis assays) + Indication of 
early apoptosis 
+ Indication of 
early apoptosis 
N.A. N.A. N.A. N.A. N.A. 


















Reduced cell division ++ No mitosis ++ + + 44 ng/µL 
++ 88 ng/µL
 
















- 140 ng/µL -
 
More abnormal cell division No mitosis
 
- - - 44 ng/µL - + 140 ng/µL
 
- 
+ 88 ng/µL                 
Reduced actin mesh        




N.A. N.A. N.A. N.A. 






Granular actin in cytoplasm        
18-24H N.A. + - N.A. N.A. N.A. N.A. 
2H or 5H N.A. N.A. N.A. + 700 ng/µL 
(2H) 
- - - 
Stress fibres more apparent        
18-24H N.A. - 
4 
++ 1:1000 N.A. N.A. N.A. N.A. 




++ 420 ng/µL (5H) 







Cytoplasmic Ki-67 N.A. N.A. N.A. + 700 ng/µL 
(2H) 
+ 700 ng/µL 
(2H) 
+ 420 ng/µL 
(5H) 
+ 420 ng/µL (5H) 
1 
++: Strong effect. +: Moderate effect. -: No effect seen. N.A.: Not assayed.  
2 
Ruffling is a characteristic of cancer cells in culture. 
3
 Actin tends not to form a mesh in fibroblasts in culture. 
4
 Epithelial cancer cells in culture tend not to form stress fibres. 
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5.3 Discussion  
Cell viability assay results had led to the hypothesis that Clitoria and its cytotoxic 
fractions F17 and F18 were targeting actively cycling cells, like current chemotherapy 
drugs, resulting in higher sensitivity in cancer cells which cycle faster than normal cells. 
Live-cell observation showed that cell division was affected by Clitoria treatment, 
therefore it was suspected that Clitoria might be acting as an inhibitor of microtubule 
function like the taxanes and vinca alkaloids which also derive from natural products. 
Cell movement was also affected, therefore the actin cytoskeleton was also considered 
a target. Unexpectedly, when the cytoskeletal proteins were viewed with fluorescence 
microscopy, microtubules were almost unaffected by treatment and the actin 
cytoskeleton was substantially disrupted. Clitoria’s cytotoxic mechanism seen with 
breast cancer cells appeared to be acting principally through the actin cytoskeleton. 
Fraction F17’s effects on the actin cytoskeleton over a short (2 hour) period were 
reminiscent of the effects of crude extract after an 18 or 24 hour period. Live-cell 
imaging and fluorescence microscopy provided detailed information for small samples 
of cells which showed that cancer cells were more sensitive than normal cells to effects 
of Clitoria and F17 during mitosis.  
The disruption in the actin cytoskeleton in cancer cells treated with Clitoria and F17 
consisted of a reduction of actin mesh at the cell cortex and a granular appearance in 
filamentous actin visible after 24 hours treatment with crude extract and to a lesser 
degree after 2 hours treatment with F17. This was similar to, but not as pronounced as, 
that seen by Kulms et al. (2002) when cervical cancer cells were treated with 100 µM of 
the actin destabiliser cytochalasin B for 1 hour. It was also similar to the effects of the 
actin stabiliser jasplakinolide seen by Senderowicz et al. (1995), where actin mesh was 
reduced at the cell cortex and actin aggregates appeared in prostate cancer cells after 
80 nM treatment for 1 hour. However, cell types vary in response as other authors 
report that jasplakinolide increased stress fibres in lung cancer cells and increased 
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actin mesh in breast cancer cells (Hayot et al., 2006). This apparent paradox of actin 
stabilisers and destabilisers having similar effects may be explained by jasplakinolide’s 
secondary mechanism of action, increasing the rate of actin nucleation and reduction of 
the concentration of actin monomers available for microfilament formation (Bubb et al., 
2000). As stabilisers and destabilisers of actin filaments can have similar effects and 
cell type specific effects, it is difficult to draw any conclusions from fluorescence 
microscopy results about whether Clitoria and F17 act through a stabilising or 
destabilising mechanism.  
The possibility of a disrupted actin cytoskeleton being responsible for the other effects 
seen with Clitoria, namely reduced and slower cell division, reduced cell motility and 
indications of cell death, was considered. Clitoria completely blocked cell division in 
breast cancer cells and reduced cell division in normal fibroblasts, and fraction F17 
reduced cell division in both cell lines in a dose dependent manner. Moreover, treated 
cells that entered mitosis spent longer in the rounded state before progressing to 
cytokinesis. During mitosis, actin filaments and microtubules associate to organise the 
spindle and position the metaphase plate, and in cervical cancer cells in culture, astral 
microtubules, connected to actin retraction fibres that tether the cell to the substrate, 
may provide pulling forces for correct spindle positioning (Théry et al., 2007). If 
microtubule-associated actin filaments or retraction fibres are disrupted, proper 
positioning of the spindle could be prevented or delayed, leading to the prolonged 
mitosis seen with Clitoria on normal fibroblasts and the considerably extended or 
incomplete mitosis seen with fraction F17 on cancer cells. In support of this, the actin 
destabilizing drug latrunculin can cause spindles to form asymmetrically in yeast 
(Theesfeld et al., 1999). A reduction in cell division was also seen in three prostate 
cancer cell lines treated with jasplakinolide for 48 hours, with 50% growth reduction at 
treatments of 41-170 nM (Senderowicz et al., 1995). 
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More F17 treated cancer cells (11%) appeared to undergo a prolonged and abnormal 
cytokinesis, compared to controls (6%), suggesting a defect in the formation of the 
contractile ring. Treated daughter cells were observed to pull against each other, while 
the plasma membranes on all sides showed gross blebbing. The contractile ring is 
formed of actomyosin fibres and can be incorrectly positioned if actin retraction fibres 
cannot align it correctly (Théry et al., 2007). Cytochalasin B treatment can prevent the 
formation of a contractile ring and cleavage furrow in liver cancer cells (Cimini et al., 
1998). Frequently, binucleated and multinucleated cells have been seen after treatment 
with cytochalasin B (Somers and Murphey, 1982; Zieve, 1884) or jasplakinolide 
(Senderowicz et al., 1995). Binucleation can occur in the absence of a functional 
contractile ring (Wu et al., 2010). No increase in binucleation was seen in treated cells 
in this study, but it cannot be ruled out that with a higher concentration of F17, or if the 
period of observation was longer, cells with abnormal cytokinesis might have failed to 
divide resulting in binucleation.  
Another mechanism whereby actin cytoskeleton disruption might cause blebbing during 
cytokinesis is suggested by evidence from Werner et al. (2013). Similar blebbing and 
shape deformation during cytokinesis were seen when levels of an actin capping 
protein, EPS8, were prevented from rising in late mitosis (Werner et al., 2013). EPS8, 
which promotes actin mesh construction, is degraded to allow rounding in 
prometaphase, and levels rise at cytokinesis to permit the cortex to reform at distal 
ends of daughter cells for separation (Werner et al., 2013). EPS8 is upregulated in 60% 
of human breast cancer samples and in the cell line MDA-MB-231, where it promotes 
cell proliferation and migration (Chen et al., 2015). Clitoria and F17 may be targeting an 
actin binding protein that, like EPS8, regulates the actin cytoskeleton in a temporal 
manner. A limitation of live-cell imaging is that the field of view includes a relatively 
small sample of cells. A larger sample would be required to see whether the abnormal 
cytokinesis events are a statistically significant result of treatment.  
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Results from cell viability assays and cell counting suggested strongly that Clitoria and 
its bioactive fractions caused cell death, yet cell death was not observed in live-cell 
imaging and only faint early signs of apoptosis were seen in assays designed to detect 
early and late apoptosis. Although non-lethal treatments were chosen for live-cell 
observation it is surprising that no increase in cell death was seen after treatment and 
calls into question the conclusions from Chapters 3 and 4. Cells may appear to be 
dying in the cell viability assays and not in the live-cell imaging due to the different 
presentations of data in the types of assay, or the small samples in live-cell imaging are 
unrepresentative. More live-cell observations with a range of concentrations of extract 
or fraction would be needed to confirm these results, and cell death should be 
confirmed by more than one type of assay.  
Targeting the actin cytoskeleton could initiate cell death. Binucleated cells are normally 
arrested at the G1 checkpoint and undergo p53-dependent apoptosis (Woods et al., 
1995), therefore if this had occurred in the cell viability assays it could account for 
some of the cell death in cells with functional p53, although not in MDA-MB-231 breast 
cancer cells which have mutant p53 (Morse et al., 2005). As treated cells spend more 
time in mitosis in a rounded state with less adhesion to the substrate they may be more 
vulnerable to detachment. Treated cells in mitosis may be particularly liable to 
detachment if Clitoria and F17 target actin retraction filaments that tether the cell to the 
substrate and could also be detached during agitation inherent in the assay process, 
and be lost in the supernatant. Detachment could initiate anoikis cell death in 
anchorage-dependent cells (Gilmore, 2005). In the fluorescence microscopy assays, 
dying cells may have lost adhesion and lifted off the glass slides during incubation in 
the same way as the staurosporine treated cells. With higher dose treatments in the 
cell viability assays cell death may have occurred through oncosis rather than 
apoptosis due to loss of ATP, failure of ion channels and loss of membrane integrity 
like with other chemotherapy drugs including doxorubicin (Weerasinghe and Buja, 
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2012). No one type of assay is sufficient for an assessment of cell death, and 
consequently most authors use more than one. For example, Hwang et al. (2013), 
used several, including an Annexin V-based assay and a caspase activation assay to 
confirm apoptosis in cervical cancer cells when treated for 24-48 hours with 8 µM of 
cytochalasin B. The activation of specific caspases could be detected with FLICA 
assays as performed by Cheng et al. (2010), to discover which apoptotic pathways 
were activated. Other forms of cell death assay would need to be run to resolve the 
question of whether and to what extent Clitoria and the fractions trigger cell death, but 
this was not done in this study due to limitations on the supply of extract.  
Other groups have seen cell death after treatment with an actin targeting drug but the 
precise mechanism by which actin destabilising drugs cause apoptosis is not clear. 
Hwang et al. (2013) saw evidence for an increase of reactive oxygen species, arrest in 
S phase, and activation of a mitochondrial apoptosis pathway, with activated caspase-9 
and caspase-3. This was in agreement with Kulms et al. (2002) where 50 µM 
cytochalasin B for 1 hour caused a moderate level of apoptosis in cervical cancer cells, 
cytochrome c release from mitochondria and caspase-3 cleavage. However, 
cytochalasin B also caused clustering of the CD95/Fas receptor, suggesting that there 
was crosstalk occurring between the extrinsic and intrinsic apoptosis pathways (Kulms 
et al., 2002).  
Disruption to the actin mesh stops lamellipodia formation, which inhibits cell migration, 
as seen in pancreatic cancer cells when branching was inhibited by silencing of 
ARP2/3 (Rauhala et al., 2013). Cell motility was reduced by 40-50% in both cell types 
by Clitoria and less membrane ruffling was seen in breast cancer cells, suggesting that 
actin cytoskeleton disruption was inhibiting the formation of lamellipodia (Borm et al., 
2005). Fraction F17 did not stop cell motility or ruffling, but as fluorescence microscopy 
experiments showed a reduced actin cytoskeleton after a 2-hour treatment of 700 
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ng/µL of F17, the 88 ng/µL treatment in live-cell imaging may have been too low to 
induce these effects. Actin targeting drugs can reduce cell motility: this was seen with 
cytochalasin D in melanoma cells (Stracke et al., 1993) and with the actin stabiliser 
curcumin in prostate cancer cells (Holy, 2004). It is also possible that another, 
unisolated fraction in Clitoria is responsible for reduction in motility and ruffling. 
Interestingly, normal fibroblasts treated with Clitoria for 24 hours or fraction F18 for 5 
hours, but not F17 for 2 hours, displayed more noticeable stress fibres than untreated 
controls, suggesting that F18 has a stabilising or growth-promoting effect on stress 
fibres whereas F17 does not, or that 2 hours is too short a treatment time to see this. 
Cancer cells, which tend not to form stress fibres (Wehrle-Haller and Imhof, 2003), 
have a disrupted actin cytoskeleton when treated with Clitoria or fraction F17, but not 
F18. This suggests either that the cell types respond differently to treatment, or that 
F17 and F18 have subtly different effects on the cytoskeleton and Clitoria, which 
includes both fractions, has the effects of both fractions. A cell type specific response 
was seen with increased stress fibres in lung cancer cells and increased actin mesh in 
breast cancer cells after 16 hours treatment with 10 nM jasplakinolide (Hayot et al., 
2006). In another example of a cell type specific response, a one hour treatment with 
60 µM curcumin also caused androgen-dependent prostate cancer cells to develop 
more prominent stress fibres but androgen-independent prostate cancer cells did not 
(Holy, 2004). More experiments will be needed to resolve whether the more noticeable 
stress fibres in fibroblasts in this study are a cell type specific or fraction specific 
response. 
To achieve the effects seen in this study on the actin cytoskeleton, Clitoria and its 
bioactive fractions may bind directly to actin filaments or to upstream targets: Actin 
binding proteins (ABPs), small Rho family GTPases or their effectors, or GEF or GAP 
regulators of Rho GTPases which control their spatial and temporal activation. The 
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actin cytoskeleton includes many ABPs with overlapping roles in filament formation. 
For instance, branched actin is nucleated by ARP2/3 and stress fibres rely on formins 
for the same purpose (Olson and Sahai, 2009), therefore a Clitoria target with different 
roles in branched and unbranched actin might explain the different effects on mesh and 
stress fibres. Alternatively, the extract may target an ABP that is upregulated in cancer 
cells such as the capping protein EPS8 that promotes mesh formation (Chen et al., 
2015), which could explain the distinction between cancer and normal cells’ responses.  
If Clitoria and its fractions target a Rho GTPase, the most likely target is RhoA, as it 
has a role in processes affected by Clitoria. In cell migration, active RhoA precedes 
active Rac in lamella formation (Machacek et al., 2009) and RhoA can induce tail 
retraction in cervical cancer cells (Kurokawa and Matsuda, 2005). Inhibition of RhoA 
reduces membrane ruffling in cancer cells (Kurokawa and Matsuda, 2005), and 
reduces adhesion (O’Connell et al., 1999). Experiments in Caenorhabditis elegans 
showed that silenced RhoA prevents cleavage furrow formation (Jantsch-Plunger et al., 
2000), and when the Rho target ROCK was inhibited in human glioma cells, formation 
of the cleavage furrow took three times longer than in control cells (Kosako et al., 
2000). Consequently, the abnormal cytokinesis seen in F17 treated cancer cells in this 
study might be due to low activation of RhoA or a RhoA target kinase, leading to 
incomplete cleavage furrow formation. However, RhoA inhibition would not explain the 
increased stress fibre development seen in Clitoria and F18 treated fibroblasts, as 
RhoA inhibition generally leads to less stress fibre development (Pellegrin and Mellor, 
2007). 
The bioactive agent in Clitoria could also exert its effects through inhibition or activation 
of GEFs or GAPs. For example, the GEF Ect2 can bind to either RhoA or Rac at 
different stages of mitosis, and both Ect2 and the GEF GEF-H1 control the positioning 
of the contractile ring (D’Avino, 2009; Heng and Koh, 2010). In mouse embryo cells, 
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the GEF P190RhoGEF induces RhoA to form stress fibres but does not promote cell 
membrane ruffling (van Horck et al., 2001) and activity of the GAP P190RhoGAP is 
decreased during cell rounding in cervical cancer cells (Maddox and Burridge, 2003). 
However, the functions of the RhoA regulators have not been fully elucidated, many 
have multiple GTPase targets, and effects may be cell type specific, therefore a full 
picture of their activities is not available. 
Transparent nucleoli were visible in phase contrast in MDA-MB-231 breast cancer cells 
after 2-5 hours of treatment with crude Clitoria extract, F17 or F18, and when observing 
cells in cell viability assays, suggesting that treatments target the nucleoli. Many cancer 
cells have dysregulated transcription and upregulated ribosome biogenesis, therefore 
this might be a target where cancer cells were more vulnerable than normal cells. 
Images of fibrosarcoma cells treated with the alkylating agent cisplatin which inhibits 
transcription of rRNA genes also showed transparent nucleoli (Burger et al., 2010). 
Actomyosin fibres are found in nucleoli where they may have a motor function in 
elongation of ribosomal RNA transcripts (Fomproix and Percipalle, 2004), suggesting a 
potential mechanism whereby actin disruption leads to reduced ribosome synthesis. Ki-
67 protein localises to the nucleoli in interphase (Kill, 1996). When F17-treated MDA-
MB-231 cells were stained with Ki-67, cytoplasmic Ki-67 increased, suggesting the 
nucleolus structure was compromised and nucleolar contents were being released from 
the nucleus into the cytoplasm. Environmental stresses and interruption of RNA 
polymerase I transcription can compromise nucleolar integrity and trigger a nucleolar 
stress response, by which nucleolar proteins in the nucleoplasm bind to mouse double 
minute 2 and  prevent its marking p53 for degradation (James et al., 2014). However, 
the appearance of transparent nucleoli could not be associated with any other change 
in Ki-67 staining or cell behaviour. As transparent nucleoli were not seen in any other 
cell line, and were no longer apparent at 72 hours, it was concluded that they may be a 
normal response of this cell line to stress. 
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In conclusion, Clitoria had distinct effects on cancer and normal cells which were more 
pronounced on cancer cells, and Fraction F17 was responsible for most of the effects 
seen with the crude extract. All the responses of cancer cells could be explained by 
disruption to the actin cytoskeleton, which was seen in fluorescence microscopy with 
Clitoria and F17. Although no cell death was seen, F17 appears to be targeting cells 
during cell division, similarly to other cytotoxic agents, which would have proportionally 
more effect on faster dividing cancer cells and may account for some of the difference 
in cell viability between cancer and normal cells. Cell motility was also reduced by 
Clitoria treatment and as inappropriate cell migration is a characteristic of metastatic 
cancer cells and there are no agents in clinical use that target metastasis, this could be 
a productive area for investigation. Fraction F18 appeared less potent than F17 and 
was not seen to disrupt the actin cytoskeleton in cancer cells at the concentrations 
tested. As a natural product extract, Clitoria is a complex mixture and it is not surprising 
that a fraction did not induce the same response as the whole extract, or that the two 
fractions had nonidentical effects. If more extract had been available, these 
experiments could have been repeated to elucidate whether apparent differences 
between the fractions were due to concentration, time of treatment or different 
mechanisms of action, and whether higher treatment doses led to cell death. 
5.4 Next steps 
Experiments to elucidate the cytotoxic mechanism were limited by supplies of Indian 
Clitoria extract, therefore root material was sourced from Jakarta, Indonesia and 
Marlow, UK and extracted at Brunel. In the next stage of the study, the extractions 
were compared with Indian Clitoria in HPLC and cell viability assays were run to 
compare their cytotoxicity with Indian Clitoria (see Chapter 6, Alternative sources of 
Clitoria). Work continued to identify the bioactive agents (see Chapter 7, Identification 
of bioactive agents in Clitoria). 
178 
 
Chapter 6 Alternative sources of Clitoria  
6.1 Introduction 
When plant material is investigated for potentially useful secondary metabolites it must 
be processed carefully to preserve the bioactive chemicals. Plant material is normally 
washed thoroughly in distilled water immediately on collection, dried in shade to avoid 
fungal growth and to minimise chemical reactions induced by UV radiation, and ground 
to increase its surface area prior to extraction (Seidel, 2012). If the type of compound to 
be extracted is known, an appropriate extraction method can be chosen and may be a 
conventional extraction method – maceration, infusion, decoction or continuous 
extraction in a Soxhlet – or one of the new non-conventional techniques such as 
microwave- or ultrasound-assisted extraction (Brusotti et al., 2013). Soxhlet extraction 
is popular as it requires little solvent and no expensive equipment, although the high 
temperatures required to boil the solvent make it unsuitable for thermolabile 
compounds (Bucar et al., 2013) such as carotenoids (Silva et al., 1998).  
The role of the extraction solvent is to diffuse into plant cells, dissolve the secondary 
metabolites and carry the compounds in solution (Seidel, 2012). Non-polar solvents 
such as hexane extract non-polar compounds, for example fatty acids, sterols, some 
terpenoids and alkaloids; medium polarity solvents such as chloroform are effective for 
extraction of some alkaloids and flavonoids, as performed by Yam et al. (2010), and 
polar solvents, for example methanol, are best for extracting polar compounds such as 
flavonoid glycosides (Seidel, 2012). If the target compound is unknown, a standard 
method for a series of extractions using progressively more polar solvents (hexane, 
dichloromethane, ethyl acetate, methanol) may be followed and each extraction can be 
analysed (Brusotti et al., 2013). After extraction the solvent is removed using rotary 
evaporation or nitrogen gas for weighing of yield and to provide a more stable dried 
product for chilled or freezer storage (Seidel, 2012). Water is less commonly used as a 
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solvent because solvents with lower boiling points reflux at lower temperatures and are 
more quickly evaporated (Brusotti et al., 2013). Traditional medicine practitioners 
typically use water as a solvent to prepare medicines as it is non-toxic and easily 
available. If the target compound is unknown and the extract is a traditional medicine 
then a solvent system close to that used in its preparation as a medicine is appropriate 
(Brusotti et al., 2013).  
The literature shows that simple, inexpensive solvents have been used for extractions 
of Clitoria plant material without knowledge of the target secondary metabolites. 
Kamilla et al. (2014) macerated both leaf and root in methanol to obtain extracts for an 
anti-nociceptive assay on rats, and Jacob and Latha (2013) used a methanolic extract 
of Clitoria seed with anticancer effect on a mouse model of Dalton’s lymphoma. An 
ethanolic extract of Clitoria leaf was cytotoxic on brine shrimp (Das and Chatterjee, 
2013). Water was used by Kelemu et al. (2004) to extract insectidal proteins from 
Clitoria seed. Neda et al. (2013) made extracts of Clitoria flowers in both methanol and 
water, finding that the aqueous extract was more cytotoxic on ovarian and breast 
cancer cell lines than the methanolic extract. Water, methanol and chloroform were 
also successful for extracting agents with antibacterial activity from Clitoria flowers, 
while extracts obtained with organic solvents hexane and petroleum ether had no 
antibacterial activity (Uma et al., 2009). With a known target, Kumar et al. (2008) 
succeeded in extracting and isolating the terpenoid taraxerol from Clitoria root with four 
48-hour macerations in ethanol.  
It has been estimated that in a plant genome 15-25% of genes code for enzymes that 
catalyse the synthesis of secondary metabolites (Pichersky and Gang, 2000). Many are 
specific to a species, genus or family because the capacity for producing a new 
secondary metabolite that offers evolutionary advantage is likely to be transmitted to 
subsequent generations and to become prevalent in the local population (Hamberger 
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and Bak, 2013). Although the genome of plants in the same species is largely similar, 
evolution is a continuous process in response to local conditions (Anderson et al., 
2011), leading to both local genetic variation and wide genetic variation between 
locations (Nosrati et al., 2012). In a survey of accessions of Clitoria ternatea from 24 
locations from South America, Australia, the Carribean and Asia, including India, plants 
were grown in identical conditions in Georgia, USA, yet considerable variation was 
seen between location origins in morphological characteristics such as branching, 
number of seeds produced and time to first flowering (Morris, 2009). Climate, soil, 
competition and defence against local predators are drivers for genetic diversity and 
speciation (Züst et al., 2012). Even when all populations of a species have the 
capability of synthesizing a chemical it may be in response to an environmental 
stimulus, which can lead to considerable variation in the quantity present between 
populations (Table 6-1).  
Table 6-1: Examples of causes of variation in plant secondary metabolite production.  
Plant species Type of variation Example  
Ocimum sanctum, tulsi Development of plant 
part 
Relative amount in oil of phenylpropene eugenol, which 




Diurnal  Scent production peaks between 23:30 and 3:30 hours
1 
Euclea divinorum, magic 
guarri 




Induced after injury Leaves produce lectin insecticide after attack by caterpillars
 3 
Pinus elliotii, slash pine 
 
Climate Monoterpene emission rates increased exponentially with an 




Geographic Proportion of zingiberenes, principal components in the 
essential oil, varied: 4-28% (Australia), 7-36% (India), 0.4-2% 
(Sri Lanka)
 1 
Glycine max, soybean Induced by microbial 
symbiont 
Amount of flavonoids genistein and coumestrol produced by 
root tip increased 4-fold in response to Nod factors from 
nitrogenating bacteria Bradyrhizobium japonicum
 4 
1
 Data from Figueiredo et al. (2008). 
2 
Data from Scogings et al. (2015). 
3
 Data from Vandenborre et al. (2009). 
4
 Data 
from Schmidt et al. (1994). 
 
 
For these reasons, when stocks of Indian Clitoria extract ran low, further supplies were 
requested from the original Indian source, but it proved impossible to obtain more 
extract within the timescale of this study. When it could not be supplied, Clitoria plants 
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were located in Jakarta, Indonesia and grown in Marlow, UK specifically for this study 
(Figure 6-1). Only two mature plants developed from 12 seeds planted in Marlow and 
they died off in October of the same year. It was not known whether plants from these 
habitats (Table 6-2) would synthesise the same secondary metabolites as Indian 
Clitoria or the same quantity of the bioactive agent. The objective of this part of the 
study was to find out whether alternative supplies could substitute for Indian Clitoria in 
providing a supply of the bioactive agent.  
 
Figure 6-1: Images of Clitoria collected in Guwahati (A), Jakarta (B), Marlow (C). 
 
 
Table 6-2: Environmental data for Clitoria growing locations. 
Location Guwahati, India Jakarta, Indonesia Marlow, UK 
 
Month of collection October March October 
Type of planting Garden, in soil Nursery, in soil Garden, in compost in 
pots 
Annual range of daily average 
temperature (°C) 
1 
23-33 31-33 8-23 
Annual rainfall (mm)
 1 
1750 755 780 
Height above sea level (m) 
2 
59 16 32 
Latitude 
2 
26° N 6° S 51° N 

























Data from World Weather Online (2015). 
2
 Data from Dateandtime.info (2015). 
3 
Data from WHO (2015). 
4





Measured in 2012. 
6 
Measured in 2010. 
7 
Data for Reading, UK. 
8 









6.2.1 Comparison of Clitoria extracts from Indonesia and UK in HPLC 
The number and type of experiments to elucidate the bioactive mechanism of Clitoria 
had been limited by the small quantity of Indian extract. Clitoria appeared to have 
A B C 
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interesting cytotoxic activity that might be related to cell division and further 
experiments were planned. As it proved impossible to obtain more extract from India, 
plant root was obtained from Jakarta, Indonesia and Marlow, UK and extracted at 
Brunel. Extracts CE(E), CE(F), CE(G), CE(H) and CE(J) were made from Indonesian 
root and extract CE(UK) from UK root. Extract CE(G) from Indonesian root followed the 
protocol described for Indian root extraction. Different extraction protocols were 
employed for the other Indonesian root extracts, to see if differences in respect to 
temperature or extraction vessel changed the final extraction product (see Chapter 2, 
Materials and methods, for full details). The extracted material was weighed before 
resuspension in ethanol (see Section 2.13.6).  
The extracts were compared on HPLC by running them with the method that had been 
developed for Indian Clitoria. The two major peaks were seen in chromatograms for 
Indonesian and UK root with similar retention times as in Indian Clitoria extract and 
there were other similar peaks. However, the Indonesian and UK extract 
chromatograms appeared less clean than the Indian chromatogram, with many peaks 




     
 
      
 





Figure 6-2: HPLC chromatograms from Clitoria extracts. Indonesian extracts CE(E), CE(F), CE(G), 
CE(H), CE(J) and UK extract CE(UK). Indian extract CE(B) included for comparison. 10 µL injection 
of each extract diluted 1:50 dilution in methanol (MeOH). Waters X-bridge column, 150 x 3.0 mm, 
flow rate 0.6 mL/min, column temperature 50°C. Gradient of MeOH:water with 0.05% trifluoroacetic 
acid: 25-70% MeOH over 14 min, 70-100% MeOH over 2 min, return to start conditions over 0.5 min, 
hold for 2.5 min. R.T.: retention time. Maxplot, 230-400 nm.  
Extract CE(F) 



























19 0 R.T. (min) 
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Table 6-3: Characteristics of UV spectra of major peaks in extractions from Indonesian and UK 
Clitoria root. Indian Clitoria root included for comparison. 10 µL injection of 1:50 dilution of each 






















UV maxima (nm) 
Indonesian: 
CE(E) 8.2 0.20 286.4 325.6 8.5 0.21 287.6 325.6 
CE(F) 8.2 0.10 286.4 325.6 8.5 0.11 287.6 325.6 
CE(G) 8.0 0.09 285.6 323.8 8.3 0.10 285.6 325.0 
CE(H) 7.9 0.13 284.4 323.8 8.2 0.14 285.6 325.0 
CE(J) 8.0 0.11 284.4 325.0 8.3 0.13 285.6 325.0 
UK: 
CE(UK) 7.9 0.11 284.4 325.0 8.2 0.14 285.6 325.0 
Indian: 
CE(B) 9.2 1.07 286.4 324.4 9.5 1.10 287.6 324.4 
1
 From chromatograms in Figure 6-2. 
2 
Retention Time (R.T.). 
 
 
To see if the Indonesian and UK extractions had cytotoxic effects on cells, cell viability 
bioassays were run on breast cancer and normal cells. Results showed that all extracts 
were, like the Indian extract, cytotoxic (Figure 6-3). A dose response was seen with 
most extracts but was more prominent on 2DD cells than on MDA-MB-231 cells. 
Further work would be necessary to confirm the dose response. This was different from 
cells’ responses to the Indian extract which had displayed a clear dose response on 
cancer cell lines. To see whether any of the Indonesian or UK extracts were selective, 
the percentage viability of the two cell lines was compared for each extract and 
treatment (Figure 6-3 C). Normal cells did not consistently survive better than cancer 








Figure 6-3: Cytotoxicity in Indonesian and UK Clitoria extracts. Cell viability in (A) 2DD normal fibroblasts and (B) MDA-MB-231 breast cancer epithelial cells 
after 48 hours’ treatment with Indonesian extracts CE(E), CE(F), CE(G), CE(H) or CE(J) or UK extract CE(UK). PrestoBlue assays. 2DD cells assayed at 
passages 16, 26 (CE(E)), 26 (CE(F)), 16 (CE(G)), 20, 26 (CE(H)), 20 (CE(UK)). Viability is expressed as % of control (=100%). C: Same data as A and B, paired to 
show survival in cancer and normal cells with same treatment. N: number of replicates. For N=6 or 8, means of 2 independent experiments. For N=10, mean 
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The estimated half maximal inhibitory concentration (IC50) was calculated for all 
Indonesian extracts and for the UK extract based on data from cell viability assays 
where MDA-MB-231 cells were treated for 48 hours (Table 6-4). Extract CE(H) was the 
most potent. 












CE(E) 192 188 
CE(F) 396 516 
CE(G) 262 500 
CE(H) 140 80.2 
CE(J) 230 390 
UK extract
 4 
CE(UK) 290 933 
1
 For MDA-MB-231 breast cancer epithelial cells over 48 hours treatment. 
2 
Using data from Figure 6-3.  
3
 From Chapter 2, Materials and methods, Table 2-2. 
4 
Extract preparations described in Chapter 2, Materials and methods, Table 2-1. 
 
 
Indonesian extract CE(H), the most potent of all extracts made at Brunel, was chosen 
for further analysis. To see if its toxicity would be increased with a longer treatment 
time, as had been the case with the Indian Clitoria, assays were run over 24, 48 and 72 
hours (Figure 6-4). Unexpectedly, with these data, survival at 48 hours appeared to be 
greater than survival at 24 hours, but the significance was based on a single data point 
with large variation and would need to be confirmed in further work. The results 
suggested that there was no time dependency. This was different from the response of 
cancer cells to Indian Clitoria, where extending the time of treatment from 48 to 72 






Figure 6-4: Survival at timepoints in cells treated with Indonesian Clitoria. Cell viability after 
treatment with Clitoria extract CE(H) in (A) 2DD normal fibroblasts after 24 hours (passage 21) or 48 
hours (passages 20, 26), (B) MDA-MB-231 breast cancer epithelial cells after 24, 48 or 72 hours. 
PrestoBlue assay. Viability is expressed as % of control (=100%). **: p<0.02, student’s t-test, 24 to 
48 and 48 to 72 hours. A, 24 hours and B, 24, 72 hours: Values represent means ± SD of 4 
replicates in one experiment. A, 48 hours and B, 48 hours, 1:6400 to 1:1600: 8 replicates in two 
independent experiments. B, 48 hours, 1:800 to 1:200, 10 replicates in 3 independent experiments. 
 
 
Extract CE(H) was investigated further to see whether its effects on cells resembled 
those of the Indian Clitoria extract. In live cell imaging with MDA-MB-231 cancer cells, 
86% of cells treated with extract CE(H) were seen to die abruptly by rupture of the 
plasma membrane and normal cells were more sensitive than cancer cells (Figure 6-5, 
Figure 6-6). The sample was small for normal cells (N=7) because many cells had died 
before observation began. Cell division was reduced but not completely prevented in 
the surviving cells. Cell motility appeared to be unaffected. These effects were different 
from live cell observation on the crude Indian Clitoria extract, but as the Indian live cell 
observation experiment had used a non-lethal treatment dose, it could not be excluded 
that the effects were different because extract CE(H) was more concentrated. Cell 
division with gross blebbing and delayed or incomplete mitosis seen when cancer cells 




Dilution of crude plant extract 
** 
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Figure 6-5: Cell death after treatment with Indonesian Clitoria extract. Images of MDA-MB-231 
breast cancer epithelial cells in live cell imaging. A, B: untreated controls. C, D: treated with Clitoria 
extract CE(H) at 1:4000 dilution. A, C: at start of observation. B, D: after 24 hours’ observation. 
Arrows: cells rounding for cell division. Arrowheads: cells that appear to have died. 200x 
magnification. Scale bar: 10 µm. Supplementary movies 15, 16, see Appendix D. 
 
 
The transparent nucleoli that had been present when the MDA-MB-231 breast cancer 
cells were treated with the Indian Clitoria extract or one of its fractions were not seen 
after treatment with the Indonesian extract CE(H) (data not shown). Taking these 
results together, the crude Indonesian extract CE(H) killed cells in a dose response 
fashion, similar to the crude Indian extract, and reduced cell division, but few other 







                   
                  
Figure 6-6: Cell death and reduced cell division after treatment with Indonesian Clitoria extract. 
Counts made from live cell observations. N=number of live cells in field of view at start of 
observation. A: 2DD normal fibroblasts observed at passage 20, B: MDA-MB-231 breast cancer 
epithelial cells after 24 hours’ treatment with Clitoria extract CE(H) at 1:4000 dilution. 




Table 6-5: Summary of effects of Indian and Indonesian Clitoria crude extracts on MDA-MB-231 
breast cancer cells 
1
. 
 Crude Clitoria extract 
Effect Indian CE(B)
 2
 Indonesian CE(H) 
Cell death (live cell observation) - ++
 




Time dependency (cell viability 
assays) 
++ - 
Reduced motility ++ - 
Reduced membrane ruffling ++ -
 







++: Strong effect. +: Moderate effect. -: No effect seen. 
2 






6.2.2 Fractionation of Indonesian Clitoria extract 
While none of the Indonesian or UK Clitoria crude extracts were selective, it was 
thought that components might be present in the Indonesian extracts that were 
selective. To investigate this, bioassay-led fractionation was performed with the same 
strategy that had been successful for isolating the bioactive fractions of the Indian 
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extract. Initially, only the analytical column was available, therefore fractionation was 
performed on a semi-preparative scale. Extract CE(H), the most potent Indonesian 
extract, was selected for semi-preparative fractionation on the analytical column. As 
bioactivity had been noted in subfractions 10.3-10.5 in Indian Clitoria, subfractions from 
Indonesian Clitoria were collected from the area of the chromatogram corresponding to 
fractions 10.1-10.6 and coarser fractions from the rest of the chromatogram, using the 
same HPLC subfractionation method as for Indian Clitoria. Fractions F5 and F6, which 
coincided with the major peaks, were pooled to increase concentration. The 
concentration of each single fraction was calculated to be approximately equivalent to a 
1:900 dilution of crude extract, based on column loading (See Appendix C). In a 
bioassay, results showed there was bioactivity in fractions, although not the same 
fractions as for Indian Clitoria. Pooled fractions F5 and F6 killed cancer cells selectively 
over normal cells (Figure 6-7 A), similar to results seen with Indian Clitoria extract. 
Fractions F9 and F10.1 appeared equally cytotoxic to both cell lines, whereas they had 
not been cytotoxic in the Indian Clitoria extract. On the other hand, fractions F10.3, 
F10.4, F10.5 did not kill cells, whereas there had been evidence that they were 
selectively cytotoxic in the Indian extract.  
A further assay was run on fractions from a different series of fractionations to test 
whether fractions F5-F6 were bioactive in a dose dependent fashion. To obtain enough 
material for a dilution series on cancer and normal cells with the highest concentration 
equivalent to that of fraction F5-F6 in the previous bioassay, 11 fractionation runs from 
the analytical column were pooled (see Appendix C). In a 48 hour assay cancer cells 
were again more sensitive to fractions F5-F6 than normal cells (Figure 6-8). As cancer 
cell survival was significantly different from control at only the highest concentration 
used, the dose dependency was not confirmed, but it was confirmed that bioactive 
agents which were preferentially cytotoxic on cancer cells compared to normal cells 
were present in the major peaks in the Indonesian extract CE(H), as had been seen 
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with the corresponding peaks in Indian Clitoria extract. 
 
 
         
 
 
Figure 6-7: Bioassay of Clitoria extract CE(H) fractions. A: Cell viability in MDA-MB-231 breast 
cancer epithelial cells and 2DD normal fibroblasts after 72 hours’ treatment with fractions of 
Clitoria extract CE(H). PrestoBlue assay. 2DD cells assayed at passage 18. Viability is expressed as 
% of control (=100%). Values represent means ± SD of 2 replicates. B: Chromatogram and 
schematic of fractions. Waters X-bridge column, 150 x 3.0 mm, flow rate 0.6 mL/min, column 
temperature 50°C, injection volume 30 µL. Gradient of methanol:water with 0.05% trifluoroacetic 
acid: 25-100% methanol over 24 min, return to start conditions over 4 min. Maxplot, 230-400 nm. 
 
 
Survival in serial dilutions (Figure 6-8) was higher than expected compared to the 
single treatment assay (Figure 6-7) but may have been higher due to the shorter 
treatment time of 48 hours. The crude Indonesian extract CE(H) had not shown a large 
difference in survival between 48 hours and 72 hours (Figure 6-4) and this suggested 
that the cytotoxic agent in the major peaks (fraction F5-F6) was time dependent, an 
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Figure 6-8: Bioactivity in Indonesian Clitoria fractions F5-F6. Cell viability in 2DD normal fibroblasts 
and MDA-MB-231 breast cancer epithelial cells after 48 hours’ treatment with fractions F5-F6 of 
extract CE(H). 2DD cells assayed at passage 20. PrestoBlue assay. Dilutions are of stock solution 
of fraction F5-F6 in ethanol (see Appendix C). Viability is expressed as % of control (=100%). *: 
p<0.04, 2DD to MDA-MB-231 (student’s t-test). Values represent means ± SD of 2 replicates. 
 
 
The fractions from semi-preparative fractionation on the analytical column had been 
coarse. When a preparative column became available, a larger quantity of extract could 
be fractionated and smaller areas of the chromatogram might be isolated, as had been 
done with Indian Clitoria. The method for semi-preparative fractionation on the 
analytical column was scaled up for preparative fractionation following the method used 
for Indian Clitoria. The run time was extended from 28 to 61 minutes, the gradient was 
made shallower to maintain the same profile over a longer run time, the flow rate was 
increased from 0.6 mL/min to 4.7 mL/min and the injection volume was increased from 
20 µL to 90 µL. Fractions were collected at 1-minute intervals, each containing 4.7 mL 
of eluent. The major peaks which had been collected in fractions F5 and F6 from 
fractionation on the analytical column were collected in fractions F17 and F18 in 
preparative fractionation. First, all fractions from preparative fractionation were tested 
on cancer cells only, with the aim of selecting those that were most bioactive for testing 
on both cancer and normal cells together. As with Indian Clitoria, approximate peak 
area presented a means of estimating the amount of material in each fraction when 
moving from an analytical to a preparative column (see Appendix C). From these 
calculations, it was concluded that when the material from one preparative fraction was 
resuspended in 20 µL ethanol, 1 µL would be sufficient to treat one well and would 
Fraction F5-F6 dilution 
 












theoretically have around 25% of the bioactive effect seen in the bioassay in Figure 6-7 
A after semi-preparative fractionation. This was considered appropriate as 0% cells 
had survived in fractions F9 and F10.1 in the assay with single treatment doses over 72 
hours after semi-preparative fractionation, and in the same assay around 20% of 
cancer cells had survived the fraction F5-F6 treatment. 
As expected, bioactivity was seen in some fractions from preparative fractionation 
(Figure 6-9 A). Bioactive fractions F17, F34, F36 and F38 colocated with peaks 
representing UV absorbent compounds whereas F43 and F53 did not colocate with 











Figure 6-9: Bioassay of Indonesian Clitoria extract fractions. A: Cell viability in MDA-MB-231 breast cancer epithelial cells after 72 hours’ treatment with 
fractions of extract CE(H). PrestoBlue assay. Viability is expressed as % of control (=100%). Values represent means ± SD of 2 replicates. B: Chromatogram 
from fractionation. Fractions were collected at 1 minute intervals. Fractions F21-F22 were pooled. Fractions F29-F30 were pooled. 90 µL injection of extract 
CE(H) diluted 1:10. Waters X-bridge column, 250 x 10.0 mm, flow rate 4.67 mL/min, column temperature 50°C. Gradient of MeOH:water with 0.05% 
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Bioactivity in fraction F17 was indeed present at about 25% of the activity seen in semi-
preparative fractionation at the equivalent fraction, F5-F6, but fraction F18 was not 
bioactive at this treatment dose (Figure 6-10). The estimate of material based on 
approximate peak area was not as reliable a guide to the bioactivity as it was for the 
Indian extract. The major peaks in the Indonesian extract were less pure than those in 
the Indian extract, as confirmed by Liquid Chromatography-Mass Spectrometry (LC-
MS) (see Chapter 7, Identification of bioactive agents in Clitoria root extract), which 
would have affected the relationship between peak height and activity. The bioactive 
material in F18 may have been too dilute to see an effect and if the fractions tested had 
been more concentrated, an effect similar to the Indian fraction F17 and F18 response 
might have been seen. Additionally, there was poor resolution in the chromatogram 
and a large amount of material eluted at the solvent front, showing it was likely that with 
a 90 µL injection the column was overloaded. The poor resolution may have caused 
bioactive material to be collected in adjacent fractions where it was too dilute for its full 
effect to be seen.  
Not all bioactive fractions from preparative fractionation colocated with bioactive 
fractions from semi-preparative fractionation (Figure 6-10). Fractions F43 and F53 had 
not been bioactive in semi-preparative fractionation. As fraction F53 fell on the border 
between adjacent semi-preparative fractions, the material was likely divided between 
the fractions collected and was too dilute for bioactivity to be visible in assays after 
semi-preparative fractionation. Fraction F43 had not been strongly bioactive and may 
have been too dilute in semi-preparative fractionation. Fractions F1-F4 from semi-




      
 
 
Figure 6-10: Bioactive fractions in Indonesian Clitoria. Chromatogram from preparative 
fractionation showing bioactive fractions with around 80% cell viability or less on cancer cells after 
preparative fractionation (blue boxes; data from Figure 6-9) and with 20% cell viability or less on 
cancer cells after semi-preparative fractionation on analytical column (red boxes; data from Figure 
6-7) aligned by peak. Gradient of MeOH:water with 0.05% trifluoroacetic acid: 25-100% MeOH over 
57 min, return to start conditions over 4 min. Maxplot, 230-400 nm. 
 
 
To see if there might be a selective response in one or more of the fractions from 
preparative fractionation, a dilution series bioassay was conducted on both cancer and 
normal cells with four strongly bioactive (≤80% viability) fractions from preparative 
fractionation (Figure 6-9): F16-F18, F34, F36, F38. To obtain the material, two smaller 
injections of 50 µL were fractionated to ensure that the column would not be 
overloaded, and fractions from the two runs were combined. Using peak area to 
calculate fraction dilution and treatment had been only moderately successful, 
therefore fraction treatments were again based on estimates of column loading 
compared to the previous bioassay with fractions from preparative fractionation (see 
Appendix C). Fractions F16-F18 were pooled so that the most concentrated treatment 
would theoretically be three times the concentration of the treatment in the previous 
assay (Figure 6-9). Well resolved chromatograms were obtained with the 50 µL 
injections (Figure 6-11). In this assay, fractions F34 and F36 were strongly bioactive, 
but cancer cells were not more sensitive to these fractions than normal cells, and there 
was no significant difference in the cell types’ response (Figure 6-11). No cytotoxic 
effect significantly different from controls was seen with the pooled fractions F16-F18, 
therefore no difference in survival between the two cell lines could be seen although 
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low response to fractions F16-F18 was unexpected, but may have been lower due to a 
shorter treatment time (48 hours) than for the assay with single treatments over 72 
hours, and further suggested that the response to these fractions was time dependent. 
Fraction F38 was not bioactive at the concentration tested (data not shown) which was 
surprising, but the peak eluted later than in previous HPLC runs and may not all have 
been collected in fraction F38. 
6.2.3 Comparison of fractions from Indian and Indonesian extracts 
Fraction F17 was the only fraction that was bioactive in both Indian and Indonesian 
extracts (Figure 6-12). This confirmed that at least one of the major peaks was 
bioactive in both extracts. It could not be excluded that if a higher concentration of 
fraction F18 from Indonesian Clitoria had been assayed, it would also have been 










                                       
 
 
Figure 6-11: Bioassay with serial dilutions of Indonesian Clitoria. A: Example chromatogram from 
preparative fractionation of extract CE(H) showing fractions collected. 50 µL injection volume of 
extract CE(H) diluted 1:10. Waters X-bridge column, 250 x 10.0 mm, flow rate 4.67 mL/min, column 
temperature 50°C. Gradient of MeOH:water with 0.05% trifluoroacetic acid: 25-100% MeOH over 57 
min, return to start conditions over 4 min. Maxplot, 230-400 nm. B, C, D: Cell viability in 2DD normal 
fibroblasts and MDA-MB-231 breast cancer epithelial cells after 48 hours’ treatment with fractions 
F16-F18 (B), F34 (C) or F36 (D) of extract CE(H). 2DD cells assayed at passage 20. PrestoBlue 
assay. Dilutions are of stock solution of fraction in ethanol (see Appendix C). Viability is expressed 
as % of control (=100%). Values at 1:100 for F34, 1:100 and 1:200 for F36 are different from control 
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Figure 6-12: Comparison of bioactive fractions in (A) Indian and (B) Indonesian Clitoria extracts. 
Chromatograms from preparative fractionation showing bioactive fractions with (A) around 60% 
viability or less and (B) around 80% viability or less on cancer cells after preparative fractionation 
(blue boxes). Data from Chapter 4 (A) and Figure 6-10 (B). Gradient of MeOH:water with 0.05% 




However, the amount of material in bioactive fraction F17 appeared lower, compared to 
the other components in the extract, in the Indonesian extract CE(H) than in the Indian 
extract CE(B), based on the relative heights of that peak in HPLC (Figure 6-2), and in 
the Indonesian extracts there was no correlation between the height of the 1st major 
peak and the concentration (R2=0.45; p=0.06) (Figure 6-13). It was likely that the 
bioactive effects of the crude Indian extract might be more dependent on the contents 
of the major peaks, while in the Indonesian crude extract other bioactive components, 
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Figure 6-13: Height of major peak in Clitoria root extracts related to extract concentration. Height of 
1
st
 major peak corresponding to Clitoria bioactive fraction F17 in Indonesian (blue) CE(E), CE(F), 
CE(G), CE(H), CE(J), UK (red) CE(UK) and Indian (green) CE(B) extracts, compared to concentration 
of crude extract. Data from Table 6-4, Figure 6-2. 
 
  
6.2.4 Indonesian extraction conditions 
When extractions according to the Indian protocol had shown no selectivity on cells, 
subsequent extractions were performed at different temperatures. A lower temperature 
might retain substances that were degraded at 64°C and a higher temperature might 
extract the bioactive substance more efficiently. In order to compare extractions, the 
Indonesian crude extracts’ potency was calculated as estimated half maximal 
concentration (IC50) for cancer cells over a 48 hour treatment time (see Materials and 
methods). When extraction temperature was compared with IC50, a linear relationship 
was seen whereby a lower extraction temperature correlated with a lower IC50 and 
higher potency (Figure 6-14 A). A lower extraction temperature also correlated with a 
lower extraction yield (Figure 6-14 B). It appeared that lower temperature extractions 
caused less material to be extracted, and components that were extracted at low 
temperature were strongly bioactive and not selective. There was no statistical 
correlation between the extraction temperature and the height of the 1st major bioactive 
peak in HPLC for Indonesian extracts (R2 = 0.143; p=0.26). Indian and UK extracts 






























      
       
Figure 6-14: Indonesian Clitoria extract potency and yield related to extraction temperature. 
Maximum temperature applied during extraction process for Indonesian extracts CE(E), CE(F), 
CE(G, CE(H) and CE(J) related to (A) half maximal inhibitory concentration (IC50), linear regression 
coefficient (R
2






Indonesian and UK root material was investigated for potential as alternative supplies 
of the bioactive agents in Clitoria. To be a viable alternative supply, an extract would 
need to contain adequate concentrations of the material seen in Indian Clitoria extract 
in the two major peaks. Crude extracts from both locations were cytotoxic although with 
the concentrations chosen, there was evidence for dose dependency in only three 
Indonesian extractions, CE(H), CE(E) and CE(F). Unlike the Indian crude extract, 
neither Indonesian nor UK crude extracts were selective, despite a range of 
temperatures being trialled with Indonesian root extraction. There was selectivity in 
Indonesian CE(H) in fractions F5-F6 from semi-preparative fractionation on the 
analytical column, similar to the Indian extract, but it was lost when moving to smaller 
fractions F16-F18 from the preparative column (Figure 6-15). This was probably due to 
overdilution of the fraction, as from estimates of material in the fraction based on peak 



















































F16-F18, and the F17 and F18 peaks in the Indian extract were seen to be more pure 
in later LC-MS. Nonetheless, the response of Indonesian fraction F16-F18 tended 
towards selectivity and the Indonesian and UK peaks had similar retention times and 
UV spectra in HPLC-photodiode array detection to the Indian peaks at F17 and F18, 
indicating that they are probably the same or very similar compounds, but either the 
compounds occur more abundantly in Indian Clitoria or lower amounts of these 
compounds were extracted. UK Clitoria had similar major peaks, suggesting that it also 
contains these compounds. A further UV-absorbent strongly bioactive agent (fraction 
F34) was found that was not present in detectable quantities in the Indian extract. The 
bioactive agents with very low UV absorbance in the Indian extract (fractions F46, F48) 
were not present in the Indonesian extract. 
The preparative column was expected to permit injections of 100 µL, the maximum 
HPLC loop size. Surprisingly, a 90 µL injection of extract CE(H) diluted 1:10 overloaded 
the preparative column, and injection volume had to be reduced to maintain resolution. 
50 µL was found to give good resolution, and other injection volumes were not trialled 
due to lack of time. Based on this data, four preparative fractionations of 50 µL of 
Indonesian extract CE(H) might provide 12 µL of resuspended combined fraction F16-
F18, sufficient for one cell viability assay, but isolating enough material for 
investigations into the bioactive mechanism of individual fractions would require many 
more fractionation runs. The two Marlow Clitoria plants provided only 7 g of dried root 
and UK extract was the least potent, therefore it probably would not offer an alternative 
supply.  
Extract CE(G) was extracted following the Indian protocol but when it was seen not to 
be selective, extractions were tried at other temperatures. For temperatures below the 
boiling point of methanol (64°C) the Soxhlet was redundant, therefore extractions 
CE(H) and CE(UK) were performed by maceration. From analysis of extraction 
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temperatures it was seen that the most potent Indonesian extract, CE(H), was 
extracted at the lowest temperature (25°C) and had the lowest yield, and from its 
chromatogram it was clear that the F17/F18 peaks were lower in comparison to the 
other peaks. This suggests that the F17/F18 compounds require a temperature higher 
 
Figure 6-15: Schematic of bioassay led fractionation of Indonesian Clitoria extract CE(H). Mapping 
of 15 fractions from semi-preparative fractionation on the analytical column to 61 fractions in 
preparative fractionation. Shaded boxes: Bioactive fractions. N.S.: not significant.  
 
 
than 25°C for efficient extraction, and that at 25°C non-selective compound F34, not 
present in the Indian Clitoria, dominates the bioactive effect. F34 may be volatile or 
destroyed at higher temperatures. Indonesian extracts CE(F) and CE(G) were 
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extracted at the highest temperatures, had high yields and might provide more 
abundant sources of the F17/F18 compounds than CE(H), but it is unknown how many 
fractionations would be needed to collect material for assays. 
Bioactive compounds that are extracted successfully in methanol by Soxhlet at 64°C 
include tannins, some alkaloids (Seidel, 2012), saponins (Jones and Kinghorn, 2012) 
and phenols (Tomsone et al., 2012), therefore Clitoria bioactive agents could belong to 
any of these classes. Shamsa et al. (2008) found high phenol levels in Soxhlet 
methanol extractions of 12 Iranian medicinal plants. A higher temperature increases 
the efficiency of extraction by making cell walls more permeable and decreasing the 
viscosity of the solvent (Santos-Buelga et al., 2012). Xu et al. (2005) compared the 
effect of different conditions on ethanol extraction of Rubus L. genus (red raspberry) 
and found that highest levels of flavonoids were obtained at 80°C and lower levels were 
extracted at 95°C, probably due to oxidation above 80°C (Cai et al., 2010).  
All extractions in this study were performed for 18 hours as in the Indian protocol. 
However, a shorter extraction may be sufficient, as in a small scale comparison of 
extraction durations with Indonesian CE(H) in methanol at 25°C with stirring, it was 
found that the height of the F17/F18 peaks reached a maximum at 2 hours’ extraction 
and remained at that level at durations up to 16 hours (Fisher and Garrard, personal 
communication). Xu et al. (2005) also found that flavonoid content from Rubus L. 
peaked at 2 hours of ethanol Soxhlet extraction and declined at 3 hours. 
The Indian and Indonesian extractions had similar chromatograms yet different 
biological results. The main differences were in the height of the major peaks relative to 
the minor peaks, therefore the minor peaks may be more important for bioactivity in the 
Indonesian extract. Alternatively the different bioactivity may lie in minor compounds 
with strong potency or compounds with low UV detection, and synergistic effects may 
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differ. Cultivation conditions for Indian and Indonesian Clitoria are unknown and outside 
the control of this study, but could have affected secondary metabolite content 
(Pavarini et al., 2012). Pendbhaje et al. (2011) states that Clitoria requires average 
daily temperatures of 15°C and grows in the Southern hemisphere at latitudes up to 
24°S, conditions met by tropical locations Assam, although in the Northern hemisphere, 
and Jakarta, but not by temperate UK (Table 6-2). UK Clitoria died off in October, 
unlike Indian Clitoria which is perennial. The age of a plant affects the chemicals 
produced: for instance, triterpene and flavonoid production in legume root is higher 
during root development and nodule formation (Delis et al., 2011). The time of harvest 
may also have impacted secondary metabolite production. Triterpene content in Salvia 
officinalis (sage) in Saxony was almost 2-fold greater in a September cut than in a June 
cut (Bart, 2011). It is likely that the three growing regions have different pathogens and 
microbial symbionts to which the plants respond by synthesising different chemicals or 
different quantities of the same chemicals (Pichersky and Gang, 2000). Environmental 
pollution may contribute to more defensive secondary metabolite production in Indian 
or Indonesian extracts than in UK Clitoria (Iriti and Faoro, 2009).  
Correct plant material treatment at collection is vital to retain the bioactive compounds 
(Seidel, 2012). The Indonesian root was washed and air-dried in shade before shipping 
to the UK but this study had no control over its precise collection and cleaning 
procedures. It cannot be ruled out that some bioactivity in Indonesian Clitoria is due to 
enzymatic activity before washing or to the presence of a microbial contaminant. 
In conclusion, it was likely that the selective bioactive agents seen in major peaks in 
Indian Clitoria extractions were also present in Indonesian and UK Clitoria but in 
smaller quantities, suggesting that they are common to this plant species and not due 
to a contaminant or a local genetic variation. The different quantities obtained in 
extracts could be due to environmental conditions or handling after collection. The 
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extraction process could be refined with shorter extraction times or different solvents, 
but without a significant improvement in yield of the bioactive agents Indonesian 
Clitoria cannot be considered as a substitute source for further experiments. Clitoria 
does not grow well in the UK, therefore it is unlikely to produce enough root to provide 
an alternative source. 
6.4 Next steps 
With Indian stocks of Clitoria extract running low and Indonesian Clitoria containing 
small quantities of the active agent seen with Indian Clitoria, work turned to 
identification of the bioactive agent in Clitoria major peaks (see Chapter 7). It was 
hoped that the chemical could be purchased or synthesised, obviating the need for 





Chapter 7 Results: Identification of bioactive agents in Clitoria root 
extract 
7.1 Introduction 
The most commonly used techniques for structural elucidation of natural product 
compounds are mass spectrometry (MS) and nuclear magnetic resonance (NMR) 
(Pinheiro and Justino, 2012). MS equipment typically consists of an ion source, a mass 
analyser and a detector, coupled to a data analysis system (Gross, 2004). In an 
electrospray ionisation (ESI) ion source a sample in a liquid solvent is ionised by 
pumping it though a highly charged capillary to form aerosolised droplets which, 
desolvating, shed ions that enter the mass analyser (Banerjee and Mazumdar, 2012). If 
the molecular ion has sufficient energy it may fragment into fragment ions (Johnstone 
and Rose, 1996). The mass analyser separates the molecular and fragment ions 
according to mass-to-charge ratio (m/z) (Banerjee and Mazumdar, 2012) which is then 
converted to a voltage signal and recorded accurately by the detector to provide a 
mass spectrum, a set of relative abundances of the ions produced (Johnstone and 
Rose, 1996). In positive mode ESI, the sample passes through a positive charge which 
creates protonated ions, while in negative mode the current is negative and the ions 
are deprotonated (Banerjee and Mazumdar, 2012). In tandem mass spectrometry 
(MSn) selected fragments are fragmented, providing further structural information (de 
Hoffman, 1996). The molecular weight and structure can be determined through 
deductions made from the mass spectrum and fragmentation pathways (de Hoffman, 
1996). 
Structural elucidation by NMR uses the resonance frequency of either 1H or 13C nuclei 
in a magnetic field to determine properties of the structure of an organic molecule. In 
NMR a sample is placed in a static magnetic field, which orients all the nuclear spins in 
one direction, then a radiofrequency wave is applied perpendicular to the magnetic field 
causing a change in the direction of spin (Havsteen, 2002). When the energy of the 
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magnetic field matches the separation between lower and higher energy levels, the 
nuclear spin is reversed and the energy absorbed, the resonance signal, is recorded as 
a line on a spectrum (Günther, 1995). As resonance depends on neighbouring nuclei in 
the environment, structural information can be obtained (Havsteen, 2002). NMR has 
the advantage that the data obtained can identify a molecule structure unequivocally, 
but its main disadvantage in natural product analysis is that although some authors 
claim 100 µg of material is sufficient, NMR typically requires at least 500 µg of pure 
compound whereas the more sensitive MS can detect 1-10 µg of compound (Bucar et 
al., 2013). For this reason MS is often used for natural products where sufficient 
quantities for NMR cannot be isolated (Vukics and Guttman, 2010). 
Infrared spectroscopy subjects a molecule to electromagnetic radiation in the infrared 
region in order to excite it to a higher vibrational state, when it absorbs radiation at 
certain wavelengths depending on the vibrational interactions of its atoms (Lin-Vien et 
al., 1991), and detects the wavelengths absorbed to form an infrared spectrum. Fourier 
transform infrared spectroscopy (FTIR), which involves a mathematical data conversion 
using the Fourier transform process, improves sensitivity and is suitable for very small 
samples (George and McIntyre, 1987). An FTIR spectrum can provide structural 
information about functional groups but interpretation of an FTIR spectrum for a 
complex molecule is often difficult. MS and FTIR can confirm the identity of a molecule 
by comparison with a library spectrum, but NMR is required to confirm the structure of 
an unknown molecule. Molecules with a chromophore have characteristic but not 
unique ultraviolet (UV) spectra and, before the introduction of MS and NMR, UV 
spectra were used to identify UV absorbent compounds, but they provide limited 
information and are no longer used alone (Pinheiro and Justino, 2012).  
Hyphenated techniques where a separation technique such as HPLC or gas 
chromatography (GC) is coupled to a spectroscopic technique such as NMR or MS 
209 
 
became popular in the 1980s (Kite et al., 2003). GC-MS is effective for natural products 
that are volatile and heat stable at high temperatures (up to 400°C) such as some 
alkaloids and saponins, but LC-MS is more extensively used for a wide range of natural 
product compounds (Patel et al., 2010), and is normally preferred over LC-NMR for 
spectroscopic analysis of complex mixtures for reasons of cost and sensitivity (Kite et 
al., 2003). Further hyphenation is possible with a combination such as LC-photodiode 
array (DAD)-MS which includes UV spectrophotometry at the time of the LC 
separation, so that the different sensitivities of UV and MS ensure substances are seen 
(Gross, 2004). Due to advances in the technology of the interface between LC and MS 
such as ESI where ionization takes place at atmospheric pressure, the cost of LC-MS 
systems has reduced and made them more accessible to laboratories (Wolfender, 
2009).  
Plants contain many classes of secondary metabolites with potentially bioactive 
properties, which can be grouped broadly into alkaloids, phenols, and terpenes and 
terpenoids (Azmir et al., 2013). A literature review of the three plants that are the 
subject of this study showed that they have been found to contain a number of 
compounds that may be bioactive (see Introduction for those with cytotoxic properties 
and Appendix A for other secondary metabolites found in the plants). Phytochemical 
analyses of the same plant parts in methanol extractions showed the presence of 
certain classes of secondary metabolites (Table 7-1). 
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Table 7-1: Secondary metabolite classes found in methanol extractions of the Indian plant parts 
used  in this study. 







Proteins + + N. A. 
Carbohydrates + + + 
Resins + N. A. N. A. 
Tannins N. A. + N. A. 
Saponins + N. A. + 
Flavonoids N. A. + - 
Alkaloids N. A. + + 
Sterols + N. A. N. A. 
Phenols + + + 
Glycosides N. A. + + 
+: present. -: not found. N. A.: not assayed. 
1 
Deka and Kalita (2011).
 2 
Deka and Kalita (2013). 
3 
Jagtap and Satpute (2014).  
 
 
Clitoria fractions F17 and F18, the major peaks from HPLC, had been isolated in 
preparative fractionation and shown to be selectively bioactive (Figure 7-1). Facilities 
for spectroscopic analysis at Brunel were limited to FTIR, therefore structural 
elucidation of the F17 and F18 compounds was performed in collaboration with 
Aberystwyth University and the University of Bath where there were LC-MSn facilities 
and expertise in the identification of compounds in complex natural product extracts. 
Selective bioactivity had also been seen in fraction F10 from semi-preparative 
fractionation, which was investigated with FTIR at Brunel before the collaboration was 





Figure 7-1: Strategy for isolation of natural products, showing the approach taken in this study 
with Indian Clitoria extract. This chapter covers the step in the bold outlined box. Adapted and 




7.2.1 Evidence for flavonoids 
The major peaks from HPLC for Clitoria coincided with bioactive fractions F17 and F18 
from bioassay-led fractionation. Both peaks in Clitoria extract CE(B) had UV spectra 
with λmax1 in the range 300-550 nm and λmax2 close to the range 240-285 nm which are 
the characteristic ranges of the flavonoid B- and A-rings respectively (Figure 7-2) 





Figure 7-2: UV spectra of Clitoria bioactive fractions. A: Part of chromatogram of Clitoria CE(B) 
showing major peaks. R.T.: retention time. B: UV spectra of major peaks in fraction F17 (red) and 
F18 (blue). C: structure of flavone, characteristic of the flavone class of flavonoids. Structure taken 
from Chemspider (2015). 
 
 
7.2.2 Comparison of Indian Clitoria extracts 
Two extractions of Indian Clitoria were available for investigation in this study. Extract 
CE was 2-fold more concentrated than CE(B) (see Chapter 2, Materials and Methods, 
for full details). Natural product extracts can vary in composition between extractions, 
therefore the two extractions were compared with HPLC-DAD before structural 
elucidation was performed. The chromatograms resembled each other closely, with two 
major well-resolved peaks present in both extracts although there was a ~1 min 
difference in retention time (Figure 7-3, Table 7-2).  
To assess whether the major peaks in the two extracts contained the same 
compounds, the UV spectra of the two major peaks in both extracts were compared. 
The absorbance maxima in each peak were sufficiently close (<2 nm difference) to 
represent very similar compounds in the two extractions (Table 7-2). Structural 
elucidation proceeded with CE(B) because of its greater availability.  
 
9.5 min 



















         
        
Figure 7-3: HPLC Chromatograms from Indian Clitoria extracts. A: extract CE, loading 36 µg. B: 
extract CE(B), loading 18 µg. Waters X-bridge column, 150 x 3.0 mm, flow rate 0.6 mL/min, column 
temperature 50°C, 10 µL injection of each extract diluted 1:50 in methanol (MeOH). Gradient of 
MeOH:water with 0.05% trifluoroacetic acid: 25-70% MeOH over 14 min, 70-100% MeOH over 2 min, 
return to start conditions over 0.5 min, hold for 2.5 min. Maxplot, 230-400 nm. 
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CE 36 7.9 1.70 324.4 287.6 8.2 1.72 324.4 287.6 




7.2.3 Structural elucidation of compounds in Clitoria major peaks 
To analyse the bioactive fractions from Clitoria extract, a sample was investigated with 
LC-MS in collaboration with Aberystwyth University. The major peaks could be 
identified in the LC chromatogram and MS total ion count from similar peak shape and 
UV spectra to those obtained at Brunel (Table 7-3, Figure 7-4). 


















Retention time (min) 
2 18 6 12 4 14 0 16 10 8 
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Table 7-3: Retention times and UV maxima of major peaks in Clitoria extract CE(B) when separated 

























 λmax1 λmax2 
Brunel 
4 
19 9.2 0.48 286.4 324.4 9.5 0.50 287.6 324.4 
Aberystwyth 60 24.05 0.40 287.0 324.0 24.44 0.41 286.0 324.0 
1
 Fractions from preparative fractionation of Clitoria CE(B). 
2 
Retention time (R. T.). 
3
 Retention factor (Rf) (see Chapter 2, Materials and methods). 
4 





Figure 7-4: LC-MS chromatogram (A) and total ion count (B) of Indian Clitoria extract CE(B) 
showing the peaks corresponding to bioactive fractions F17 and F18. 
 
 
The F17 peak from Indian Clitoria which corresponded to the peak at 24.05 min in LC-
MS was analysed in negative ion mode (Figure 7-5 A, B). It was determined that the 
compound had a molecular weight (MW) of 312 as evident by the pseudomolecular ion 
at m/z 311 ([M-H]-). The ion at m/z 623 ([2M-H]-) was a dimer of the molecular ion with 
MW=624. The MW of the F17 compound was confirmed in positive ion mode where 
there was a pseudomolecular ion at m/z 313 ([M+]) and a dimer was present at m/z 625 
([2M+H] +). An ion at 335 ([M+]) represented a sodium adduct M+Na (+22).  
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Figure 7-5: Mass spectrometry traces of bioactive peaks in Indian Clitoria from LC-MS. A, B: F17 
peak. C, D: F18 peak. A, C: negative ion mode. B, D: positive ion mode. 
 
 
The F18 peak which corresponded to the peak at 24.44 min in LC-MS was analysed in 
negative ion mode (Figure 7-5 C, D). It was determined that the F18 compound had a 
MW of 342 from the pseudomolecular ion at m/z 341 ([M-H]-). A dimer was present at 
m/z 683 ([2M-H]-). The MW of the F18 compound was confirmed in positive ion mode 
where there was a pseudomolecular ion at m/z 343 ([M+]) and a dimer was present at 
m/z 685 ([2M+H] +). Ions at 365 ([M+]) and 706 ([M+]) represented sodium adducts 
M+Na (+22) and 2M+Na (+22) respectively. 
Fragmentation analysis of the two compounds was carried out with MSn in negative 
mode giving major fragments 205 and 106 ([M-H]-) for the F17 peak and 205 and 136 
([M-H]-) for the F18 peak. Based on this data, the compounds in the F17 and F18 
peaks were determined to be Compounds A and B respectively with fragmentation at 
the C3-9 bond (Figure 7-6). A Reaxys database search indicated that Compounds A and 
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B are novel (Threadgill, personal communication). Although Figure 7-6 shows the most 
likely structures of compounds A and B, isomers with methoxy groups at position 6 or 8 
on the ring instead of 5 and 7 cannot be ruled out for either compound. It is also 
possible that the A-ring carries two hydroxy groups and two methyl groups instead of 
two methoxy groups. The same molecular ions and fragments were found in 
Indonesian Clitoria extract CE(H) major peaks (Parveen, personal communication) 
from which it was concluded that Compounds A and B are probably also present in 
Indonesian Clitoria. 




Figure 7-6: Structures of Compound A (A) and Compound B (B) determined through structural 
elucidation with fragmentation at C3-9 bond and sizes of major fragments. A shows carbon 
numbering (following Ye et al., 2005). MW: molecular weight. 
 
 
7.2.4 Non-polar bioactive compounds 
In semi-preparative fractionation of Clitoria extract CE(B) with the analytical column, 
bioactivity had been seen in a compound that was less polar than the major peaks 
(fractions F10.3, F10.4, F10.5 in Figure 4-8). The compound was strongly selective and 
not highly UV absorbent, and had not been present in Indonesian Clitoria (44-53 min 
on Figure 6-9). The fractions collected from the analytical column contained very small 
amounts of material which were likely to be too small for detection with LC-MS, 
therefore an alternative identification technique was employed that required smaller 
amounts of material. An attempt was made to identify the bioactive compound from 
dried Clitoria subfractions F10.3 and F10.4 with Fourier transform infrared 
spectroscopy (FTIR). F10.3 did not give a trace in FTIR, likely because the amount of 
7 
A  Compound A  C18H16O5 
        MW=312 
 
B  Compound B   C19H18O6 
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205 107 205 137 
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material was too small for detection. Unfortunately, no match for the FTIR spectrum for 
fraction F10.4 (Figure 7-7) was found on the natural products database linked to the  
          
 




Figure 7-7: Fourier transform infrared spectroscopy (FTIR) spectrum for Clitoria fraction F10.4. A: 
bioactive subfraction F10.4 on HPLC chromatogram (data from Figure 4-8). Gradient of MeOH:water 
with 0.05% trifluoroacetic acid: 25-100% MeOH over 24 min, return to start conditions over 4 min. 
Maxplot, 230-400 nm. B: FTIR range 4000-650 cm
-1
. C: expansion of B to show region 4000-850 cm
-1
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FTIR. From analysis of the spectra (Table 7-4) it was possible to exclude the possibility 
of the compound having an aromatic or nitro group; amides, esters and alcohols were 
unlikely to be present; and peaks characteristic of carboxylic acids were present (Stuart 
et al., 1996). It was hoped that later fractionation on the preparative column would 
provide more material and that the material could be identified in LC-MS.  
Table 7-4: Fourier transform infrared spectroscopy (FTIR) spectrum bands from bioactive fraction 











3500-2500 medium O-H stretch Typical of carboxylic acid (normally 3500-2500 
cm
-1
). May also indicate water or methanol 
remaining in fraction. 
2928 medium CH2 asymmetrical stretch May also indicate CH3 in lipid. 
2860 medium CH2 symmetrical stretch  
2350-2800 low  Typical of atmospheric CO2. 









1437 medium C-O-H in plane bending  Typical of carboxylic acid (normally 1400 cm
-1
). 
Or CH3 asymmetrical bend Typical of lipid. 




1277 low Not assigned  
1141 high Not assigned  
801 very high Not assigned Potential CCl4 contaminant
 4
 (normally 794 cm
-1
) 





 Derived from Stuart et al. (1996). 
2 




 Russell (2015). 
4 
Commonly used as a FTIR solvent (Criddle, 1990). 
 
 
7.2.5 Biochanin A candidate compound 
In initial results from LC-MS/MS, a signal for m/z 283 ([M-H]-) was identified in negative 
mode in the F18 peak. At that point in the study, before structural elucidation, it was not 
known whether 283 ([M-H]-) represented a fragment ion or a molecular ion. This initial 
data was used to search for potential candidate compounds that were flavonoids, 
because it appeared likely from UV spectra that the compounds in the major peaks 
were flavonoids. A search on the Kegg Ligand database revealed that flavonoids 
biochanin A, geraldone and glycitein had MW=284. All were known to be present in 
plants of the Fabaceae family which includes Clitoria and to be bioactive (Ahmed et al., 
2014; Wang et al., 2008; Pan et al., 2001). Geraldone was not easily available, and 
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biochanin A and glycitein were easily available but the cost of glycitein was prohibitive. 
Biochanin A was obtained and evaluated as a candidate compound in HPLC and 
bioassays. Supplies of extract CE(B) were limited, therefore biochanin A was tested 
directly against Indonesian extract CE(H) in the same experiment. The peak for 
biochanin A did not colocate with Clitoria major peaks (Figure 7-8), and its UV 
spectrum was not similar to those of the major peaks (Figure 7-9 A, Table 7-2), 
therefore it was not present in those peaks in detectable quantities. In HPLC biochanin 
A eluted later than the major peaks in Clitoria and was a more non-polar compound, 
therefore it was then considered as a potential candidate for a bioactive compound in 
the bioactive fraction F10. In a 23-minute HPLC method, retention time of biochanin A 
was ~16 min (Rf=0.70) but there was no peak above baseline at retention time=16 min  
         
 
 
        
 
 
Figure 7-8: Comparison of biochanin A and Indonesian Clitoria with HPLC. A: HPLC maxplot 
chromatogram for biochanin A. 1 µL injection of a 154 mM solution of biochanin A in dimethyl 
sulfoxide diluted 1:100 in methanol. B: HPLC maxplot for Clitoria extract CE(H) run with same 
method as biochanin A. Gradient of MeOH:water with 0.05% trifluoroacetic acid: 25-100% MeOH 
over 19.5 min, return to start conditions over 3.5 min. Waters X-bridge column, 150 x 3.0 mm, flow 
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Figure 7-9: UV spectrum and structure of biochanin A.  A: UV spectrum of biochanin A peak at 16 




in extract CE(H) (Figure 7-8). It was concluded that biochanin A was not present in 
extract CE(H) in quantities detectable in HPLC.  
 









 (min) λmax1 (nm) λmax2 (nm)
2 
1 18.1 272.1 308.9 
2 19.1 274.5  
3 19.3 274.5  
4 20.1 279.3  
5 20.3 234.3  
        
1 
Retention time (R. T.). 
        
2 
Left blank where peak has one absorbance maximum. 
 
Figure 7-10: UV spectra of peaks in region of Rf=0.70 in Clitoria extract CE(B). A: Same figure as 
Figure 4-8 C. Chromatogram with scale expanded in 18-28 min region. Maxplot, 230-400 nm. Waters 
X-bridge column, 150 x 3.0 mm, flow rate 0.6 mL/min, column temperature 50°C, injection volume 
10 µL. Gradient of methanol (MeOH) and water with 0.05% trifluoroacetic acid: 25-100% methanol 
over 24 min, return to start conditions over 4 min. See Appendix B for details of extract 
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There were peaks above baseline in the region of Rf=0.70 in Indian Clitoria from 
previous experiments (Figure 7-10 A) but none had a similar UV spectrum to biochanin 
A (λmax1=259.4 nm) (Figure 7-10 B).  
Biochanin A is a flavonoid present in Fabaceae and might have bioactivity similar to 
that seen with Clitoria bioactive fractions F17 and F18. To investigate this, biochanin A 
was tested in a cell proliferation assay on normal and cancer cells. There was a clear 
dose response in all four cell lines, but, interestingly, unlike the response to fractions 
F17 and F18, there were differential effects on the cancer cells (Figure 7-11), with 
MCF-7 ER positive breast cancer epithelial cells surviving better than MDA-MB-231 ER 
negative breast cancer cells. There was no significant difference in response between 
the normal cell lines and the MCF-7 cells. It appeared that there was a difference in 
response related to ER status. These results were interesting but were not pursued as 




Figure 7-11: Cytotoxicity of biochanin A. Cell viability in MCF-10A normal breast epithelial cells, 
2DD normal fibroblasts, MDA-MB-231 breast cancer epithelial cells and MCF-7 breast cancer 
epithelial cells after 72 hours’ treatment with biochanin A. PrestoBlue assay. Viability is expressed 
as% of control (=100%). **: p<0.02, MDA-MB-231 to 2DD, student’s t-test. Values represent means ± 



















Flavonoids are a class of polyphenols with a C6-C3-C6 skeleton mostly derived from 
benzo-λ-pyrone (Figure 7-12 I) (Havsteen, 2002). Flavones are characterised by the 
C=C double bond on the C-ring and carboxy group at C-4, and isoflavones have the B-
ring at position 3 on the C-ring (Figure 7-12 D-G) (Fotsis et al., 1997). LC-MSn proved 
effective for structural elucidation of the bioactive compounds in Clitoria fractions F17 
and F18, novel Compounds A and B, which are isoflavones and classed as 
homoisoflavones, also called 3-benzyl-4-chromones (Tait et al., 2006) due to the 
additional CH2 group between their B- and C-rings (Figure 7-12 A, B). Identification of 
Compounds A and B in both Indian and Indonesian Clitoria suggests that they are 
generally synthesised by this species. Just 20 homoisoflavones were known up to now 
and Compounds A and B are uncommon homoisoflavones: the naturally occurring 
homoisoflavones listed in a 2014 comprehensive review have hydroxy-substitution at 
C-5 in the A-ring (Lin et al., 2014), where novel Compounds A and B have a methoxy 
group. Only one other homoisoflavone in this group has been found in Fabaceae 
(Figure 7-12 C), the other 19 occurring in Asparagaceae (Lin et al., 2014). 
Compounds A and B are structurally similar, differing only in the methoxy group in 
compound 2 on the B-ring, which accounts for their similar peak elution times and UV 
spectra, and are strongly UV-absorbent due to their high level of conjugation. 
Flavonoids are normally present in plants as glycosides (Vukics and Guttman, 2010) 
but Compounds A and B are aglycones. It is possible that glycosides of the compounds 
are also present and eluting earlier in HPLC due to their higher polarity or that they 
were originally present and were hydrolysed during drying of the root, extraction or 
HPLC (Havsteen, 2002; Santos-Buelga et al., 2012; Seidel, 2012). Koblovská et al. 
(2008) found both aglycone and glycoside isoflavones in citrus plants after LC-MS. The 
fragmentation at the homoisoflavonoid C3-9 bond is consistent with Ye et al. (2005) who 







                                        
 
                                       
 
                    
                                                  
 
 
Figure 7-12: Structures of novel Compounds A (A) and B (B), 5,4′-dihydroxy-7-methyl 3-benzyl 
chromone (C), isoflavones biochanin A (D), genistein (E), daidzein (F) and glycitein (G), 8-methyl-
DBP (H), flavonoid precursor benzo-A-pyrone (I) and β-estradiol (estrogen) (J). Structures of 
isoflavones, benzo-A-pyrone and β-estradiol taken from Chemspider (2015). Structure of 5,4′-
dihydroxy-7-methyl 3-benzyl chromone taken from Kumar et al. (2006). Structure of 8-methyl-DBP 
taken from Rafi and Vastano (2007). 
 
 
homoisoflavonoids in Ophiopogon japonicus root. The position and nature of the 
groups on the A-ring remain to be confirmed (Parveen, personal communication) and 
as supplies of extract are not sufficient for isolating enough pure sample for NMR, 
synthetic supplies of Compounds A and B will be necessary for firm identification.  
Weak cytotoxicity on liver and laryngeal cancer cells is seen with one other 
homoisoflavone (Duan et al., 2009) of the 20 listed by Lin et al. (2014). A bioactive 
homoisoflavanone from Polygonatum odoratum (Vietnamese coriander) similar to one 






















1-benzopyran-4-one8-methyl-DBP (8-methyl-DBP) (Figure 7-12 H) (Rafi and Vastano, 
2007). These authors found that in breast cancer cells 8-methyl-DBP inhibited growth 
in a clonogenic assay, induced G2/M cell cycle arrest and phosphorylation of anti-
apoptotic Bcl-2 and increased p53 expression (Rafi and Vastano, 2007). Another 
homoisoflavanone inhibited activity of the proliferative MAPK pathway and the pro-
survival transcription factor NF-κB and protected neurons from inflammation (Zeng et 
al., 2015). The cytotoxic activity of Compounds A and B is therefore consistent with 
similar compounds.  
Homoisoflavonoids also have antimutagenic activity against chemical mutagens 
(Miadoková et al., 2002; Wall et al., 1989), insulin-sensitizing activity in glucose uptake 
(Choi et al., 2004) and some have antiviral activity (Tait et al., 2006). Roy et al. (2013) 
found that homoisoflavonoids could inhibit microbial efflux pumps and sensitise them 8 
fold to growth inhibition by the DNA intercalating agent ethidium bromide. Compounds 
A and B may likewise have other interesting bioactive properties. 
Flavonoid roles in plants include flower colours, regulation of plant growth, antibacterial 
agents, toxic metal-chelating agents, attracting symbiotic bacteria for nitrogen fixation 
and protection against UV damage and free radicals (Di Carlo et al., 1999; Havsteen, 
2002; Jones et al., 2007). Present in fruits, nuts, vegetables and grains, flavonoids 
constitute 1% of the human diet where they may have anti-oxidant and cancer-
protective effects, regulate capillary permeability and act as anti-inflammatories (Di 
Carlo et al., 1999). Isoflavones have better bioavailability than other classes of 
flavonoids and longer half-lives (~9 hours) in the body (Cassidy et al., 2006; Hollman, 
2004). Some isoflavone glycosides such as quercetin glucosides are absorbed in the 
small intestine via specific transporters but other glycosides can only be cleaved in the 
colon by gut enzymes or bacterial enzymes with some degradation of the aglycone, 
resulting in lower bioavailability (Hollman, 2004).  
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Low toxicity makes flavonoids interesting as potential medicines. Flavonoids do not 
accumulate in the liver and only demonstrate toxicity in very large quantities such as 1 
mg/kg of daidzein which caused breeding female rats to have smaller mammary glands 
but nonetheless had no effect on offspring (Galati and O’Brien, 2004). Polyphenon E, a 
mixture of green tea catechins which are flavan-3-ol type flavonoids, has shown 
cytotoxic activity in vitro on a range of different cancers and some clinical trials for 
treatment or prevention of cancer have shown positive results (Bettuzzi et al., 2006). 
Ipriflavone, an isoflavone and semi-synthetic derivative of daidzein, is prescribed for 
post-menopausal women to prevent and treat osteoporosis (Delarmelina et al., 2014) 
and many other flavonoids are being studied or are in clinical trials. 
Biochanin A (Figure 7-12 D), an isoflavone known to be present in other plants of the 
Fabaceae family (Wang et al., 2008), was considered as a candidate compound but its 
peak in HPLC did not coincide with Clitoria bioactive fractions and its UV spectrum was 
not similar to that of F17 or F18 bioactive compounds. However, biochanin A had a 
dose related cytotoxic effect on cells and a differential response on cell lines as ER 
negative breast cancer cells were 3-4 fold more sensitive to biochanin A than either 
normal cells or ER positive breast cancer cells. Biochanin A was seen by Verma and 
Goldin (1998) to have a biphasic effect on ER positive breast cancer cells, enhancing 
proliferation at low treatment doses (<10 µM) and inhibiting proliferation at 100 µM, and 
is known to bind ER (Jefferson et al., 2002). It is possible that biochanin A inhibits cell 
viability more in cancer cells than in normal cells, but that MCF-7 cells respond to 
estrogenic growth signals which override the growth inhibition. However, this effect 
would need to be confirmed in further work. 
Glycine max (soy), a Fabaceae family member, contains the isoflavones genistein, 
daidzein and glycitein (Figure 7-12 E, F, G). They seem to have cancer-protective 
effects, thought to be one of the reasons that populations in Japan and China with a 
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high level of soy in their diet have a lower incidence of breast cancer than people in the 
USA (Sarkar and Li, 2003). Genistein has anti-proliferative effects on non small cell 
lung cancer and breast cancer cells (Sarkar and Li, 2003). In breast cancer cells it 
binds to ERα and may act as an antagonist competitively with estrogen, or bind to and 
antagonise estrogen-metabolizing enzymes (Bouker and Hilakivi-Clarke, 2000) or bind 
to anti-proliferative ERβ preferentially over ERα (Rietjens et al., 2012). However, 
genistein also has a biphasic effect as at low concentrations (<1 µM) it is an ER agonist 
and a growth factor in breast cancer cells (Zava and Duwe, 1997). The isoflavones 
have some structural similarity with estrogen (Figure 7-12 I) despite being largely 
planar molecules whereas estrogen has five tetrahedral carbons. Tsai et al. (2015) 
isolated two homoisoflavanones from the Asparagaceae plant Lilirope muscarii, calling 
them homoisoflavones in their publication. Interestingly, these homoisoflavanones 
appear to be agonists of ERβ but not ERα (Tsai et al., 2015), which suggests the 
possibility that Compounds A and B may also have estrogenic activity or specific ERβ 
binding capability.  
Analysis of the less polar Clitoria bioactive fraction F10.4 by FTIR was inconclusive 
with no match on the available natural products database (15,000 entities), and 
purchasing access to a larger database of FTIR spectra was beyond the scope of this 
project. However, the sample was probably not sufficiently pure, as three small peaks 
were apparent in the HPLC fraction, or it may be another novel compound. The small 
peaks indicated low UV absorbency, and elution at around 100% methanol suggested 
a low polarity compound. Known components of the root extract include the pentacyclic 
triterpenoid taraxerol (C30H50O) (Kumar et al., 2008), a cytotoxic agent on mouse skin 
cancer (Takasaki et al., 1999). Taraxerol’s structure suggests relatively low polarity and 
weak UV absorbency but it is unlikely to be responsible for the bioactivity in fraction 




In conclusion, two novel bioactive compounds were found in methanolic Clitoria root 
extract by LC-MSn and identified as homoisoflavones, members of a relatively rare 
group of flavonoids. Other homoisoflavones are seen in the literature to be bioactive, 




Chapter 8 Discussion 
8.1 Introduction 
Target-based drug development, where large libraries of compounds are screened for 
activity against a molecular target, has led to the introduction of successful targeted 
therapies for breast cancer which are largely responsible for the UK 5-year survival rate 
rising from 61% in 1980-81 to 87% in 2010-11(CRUK, 2014b). However, they are not 
effective on all types of breast cancer, and all cancer therapies have significant side-
effects, therefore there is a need for more treatment options. Other strategies for drug 
discovery can also be productive. In a bioassay-led approach, an assay with biological 
relevance is used to isolate compounds with useful bioactivity from a natural product 
extract, without initial knowledge of the drug target. Natural products offer a diversity of 
bioactive compounds, and plants used in traditional medicine have provided many 
drugs in use today. In this study, a bioassay-led approach with an Indian medicinal 
extract has been successful in isolating two potentially useful anti-cancer compounds. 
Current chemotherapy drugs take advantage of the faster cycling of cancer cells over 
normal cells by targeting cell division. The taxanes and vinca alkaloids target the 
tubulin cytoskeleton by disrupting microtubules during their reorganisation to form the 
mitotic spindle in cell division. Actin is also present in all cells and is reorganised during 
cell division where it has a critical role. Both microtubules and actin filaments have 
many functions, therefore off-target effects are inevitable, yet microtubule-targeting 
drugs have become popular chemotherapy drugs and actin-targeting drugs have not 
(Trendowski, 2014). 
The principal reason for the absence of actin targeting drugs in current chemotherapy 
appears to be lack of selectivity. Consequently, researchers have attempted to find 
molecular targets that are differentially expressed in cancer. The tropomyosin targeting 
small molecule TR100 (Figure 8-1 C) and the natural toxin cytochalasin B (Figure 8-1 
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B) illustrate the difficulty. TM5NM1/2 is a tropomyosin that was chosen as a target 
when it was found to be expressed at lower levels in normal fibroblasts than 
transformed fibroblasts and to be consistently expressed in a panel of neuroblastoma 
and melanoma cell lines, whereas other tropomyosins vary in expression level between 
cell types (Stehn et al., 2013). TR100 was chosen for study from a chemical library 
after showing activity against TM5NM1/2 (Stehn et al., 2013). TR100 treated 
neuroblastoma cells demonstrated loss of cytoplasmic F-actin, aggregated actin, 
reduced growth and reduced motility and there was low toxicity towards normal 
neurons and muscle cells (Stehn et al., 2013). However, IC50 values for neuroblastoma 
and melanoma cell lines treated with TR100 for 48 hours ranged from 1.2-4.5 µM and 
1.85-4.7 µM respectively, little different from the IC50 of 4.1 µM obtained for normal 
melanocytes, showing no clear evidence of selectivity (Stehn et al., 2013). The natural 
toxin cytochalasins are well studied for their actin destabilising activity and over 3000 
articles had been published on in vitro activity of cytochalasin B by 1990 (Bousquet et 
al., 1990) but the compounds are difficult to obtain because they must be isolated from 
fungal sources (Trendowski et al., 2014). Cytochalasin B has a cytostatic effect on 
melanoma cells (Bousquet et al., 1990) and inhibits cytokinesis leading to binucleation 
in normal cells and multinucleation in cancer cells, as seen in mouse mammary 
epithelial and cancer cells (Steiner et al., 1978). It can delay the appearance of lung 
cancer in mice injected with lung cancer cells, but had no effect on tumour growth 
(Bousquet et al., 1990). Without a strong cytotoxic effect or selectivity on cancer cells, 
few groups are now studying the cytochalasins as potential cancer therapies. 
Flavonoids are a class of compounds that are consumed and metabolised by humans 
on a daily basis, therefore it is attractive to think that they would have low toxicity if 
administered as drugs. Average dietary intake of flavonoids is estimated at 1g/day from 
fruit, vegetables, grains and seeds, and they are thought to prevent against many 
pathologies, including cancer, allergy and inflammation (Chahar et al., 2011). Human 
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small intestines and gut bacteria have synthesised enzymes to cleave aglycones from 
sugars, and both aglycones and flavonoid glycosides can be absorbed through the gut 
epithelium (Erlund, 2004). Flavonoids are metabolised in the colon, liver and kidney 
(Hollman, 2004). There are reports in the literature of individual flavonoids having 
potential toxicity and some in vivo studies demonstrate toxicity, but there is little 
evidence of harm to humans. Quercetin, a flavonol found in onion and tea, is the most 
abundant dietary flavonoid with average intake 5-40 mg/day but a review of dietary 
quercetin concluded that only very high consumers of fresh produce, who may reach 
200-500 mg/day, would be at risk of toxicity (Sone et al., 1999; Russo et al., 2012). 
Epidemiological evidence that high fruit and vegetable consumption either makes no 
difference to overall mortality or extends life expectancy by 1 year over moderate 
consumption (Hung et al., 2004; Leenders et al., 2013) seems to argue against 
substantial flavonoid toxicity. Therefore flavonoids as a class offer an attractive source 
of lead compounds for anticancer drugs through the drug discovery process. 
8.2 Major findings 
In this study, Clitoria root extract was found to be 2-3 fold more cytotoxic on two breast 
cancer cell lines than on two normal cell lines and cytotoxic in a dose- and time-
dependent manner. This is the first report of selectivity in a Clitoria root extract. A 
flower extract of Clitoria showed a dose- and time-dependent cytotoxicity on breast, 
ovarian and laryngeal cancer cells and not on normal fibroblasts, according to results 
from one experiment (Neda et al., 2013), but these authors did not investigate the 
bioactive mechanism. Neda et al. (2013) saw evidence in GC-MS of compounds 
present in the flower extract, but none was confirmed as the bioactive agent. Other 
authors describe non-selective cytotoxicity with Clitoria extracts of leaf and aerial parts 
on Dalton's lymphoma ascites cells (Ramaswamy et al., 2011; Jacob and Latha, 2013); 
with flower extract on laryngeal carcinoma cells (Sarumathy et al., 2011); with extract of 









            
 
 




                     
 
                                      
 
Figure 8-1: Structures of molecules discussed in the text. A: novel homoisoflavones Compounds A 
and B. B: actin targeting drugs. C: indole TR100. D: flavonoids. MW: molecular weight. Structures 
of Compounds A and B taken from Parveen (personal communication). Structure of TR100 taken 
from Stehn et al. (2013). All other structures taken from Chemspider (2015). 
 
 
brine shrimp (Rahman et al., 2006), although Rahman et al. (2006) include no control 
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addition, none of these groups have investigated the mechanism or the bioactive 
agent.  
In this study, Clitoria root extract and its bioactive fractions were also shown to reduce 
cell motility, which has not previously been reported with Clitoria extract, and to 
mediate these activities by disrupting the actin cytoskeleton. The active agents, seen 
from bioassay-led fractionation with HPLC to be responsible for the majority of Clitoria 
root extract effects on cells, were identified in LC-MS as two novel homoisoflavones 
(Figure 7-12 A). The compounds appear to be present in Clitoria grown in three widely 
separated locations, strongly suggesting that the enzymes responsible for their 
synthesis are expressed by the species and not by a local Indian variant, and that the 
compounds are not an environmental contaminant. According to a review by Lin et al. 
(2014) they are unique among homoisoflavones reported in the literature so far in 
having a carboxyl group in position 5 on the A-ring. Other authors describe the 
cytotoxic nature of cyclic peptides, a protein, triterpenoids and a sterol found in Clitoria 
root but none show evidence of selectivity towards cancer cells (see Chapter 1 
Introduction, Table 1-9). 
8.3 Cytotoxic mechanism 
Evidence of disruption to the actin cytoskeleton is presented in Chapter 5, Mechanism 
of action. Due to lack of time and limited quantities of compound the mode of action 
could not be pursued further, therefore Compounds A and B were compared with 
similar compounds in the literature. No studies were found that discussed 
homoisoflavones’ effects on actin, but a recent paper provided a way of explaining the 
action of Compounds A and B on actin, if they act similarly to quercetin. Quercetin 
(Figure 8-1D) binds directly to actin and is able to inhibit actin polymerisation (Böhl et 
al., 2005; Böhl et al., 2007). Similar to effects seen with Clitoria, in breast cancer cells 
quercetin inhibits cell migration and shows a weak fragmentation of actin at the cell 
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membrane, and normal breast epithelial cells are unaffected (Staedler et al., 2011). 
These authors used the same two breast cancer epithelial cell lines and normal breast 
epithelial cell line as the current study (Staedler et al., 2011). Quercetin also causes 
binucleation in breast cancer cells, not seen in the current study but associated with 
contractile ring defects (Staedler et al., 2011; Wu et al., 2010). Quercetin has 
undergone a small Phase I clinical trial where patients with a range of different cancers 
were given a weekly intravenous dose of quercetin up to 2.5 g without significant 
toxicity and one ovarian cancer patient showed improvement in serum biomarker levels 
(Ferry et al., 1996). Quercetin is currently being studied as an antiangiogenic agent 
(Ravishankar et al., 2015) and seems to enhance the effects of conventional 
chemotherapy drugs (Miles et al., 2014). 
To understand how quercetin could bind to actin, a review of the literature describing 
structural elements of actin polymerisation was conducted. The actin monomer has a 
barbed or plus end where polymerisation is more favourable and a pointed or minus 
end (Figure 8-2 A). For polymerisation of monomer G-actin in solution to form 
filamentous (F-) actin, the DNase-binding loop (D-loop), so called because actin has 
another function in binding and sequestering DNase, in the pointed end of one 
monomer adopts an open conformation (illustrated in Figure 8-2 C) for interacting with 
the barbed end cleft between subdomains (SDs) 1-3 in the next monomer (Oda et al., 
2009).  
A modelling study of possible quercetin binding sites on actin shows that it is most 
likely to bind to the tetramethylrhodamine (TMR) binding site on actin (Böhl et al., 2007; 
Otterbein et al., 2001), therefore quercetin may have a similar mode of action to TMR. 
TMR (Figure 7-12 B) is an actin destabiliser that accelerates both actin polymerisation 
and nucleotide exchange, resulting in strand breakage (Pelikan Conchaudron et al., 
2006). The structure of TMR bound to actin at the TMR-binding site, a pocket in the 
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region of the C-terminus at the front of the SD 1-3 cleft on SD 1 (Figure 8-2 A), has 
been determined by x-ray crystallography (Kudryashov and Reisler, 2003). Binding of 
TMR has two effects on actin filament structure. Firstly, it causes a conformational 
change in the D-loop to a more ordered helix shape that is thought to bind with lower 
affinity in the SD 1-3 cleft, therefore it is suggested to weaken intrastrand bonding 
(Kudryashov and Reisler, 2003). In addition, allosteric changes open the ATP-binding 
cleft making it more accessible to solvent and accelerating nucleotide exchange 
(Pelikan Conchaudron et al., 2006). As ADP-F-actin is less stable than ATP-F-actin,  
 
Figure 8-2: Binding sites on actin. A: Actin monomers with SDs (subdomains) in blue, green, 
yellow, pink, showing major binding sites (image taken from Allingham et al. (2006) and annotated). 
B: Actin (blue) bound to cytochalasin D (orange) (image taken from Nair et al. (2008) and 
annotated). C: Actin (blue) bound to profilin (grey) with D-loop in open conformation (image taken 
from Dominguez and Holmes (2011) and annotated). ATP is shown in stick form in all images.  
 
 
this encourages depolymerisation from the pointed end (Oda et al., 2009). The TMR-
binding site is a pocket lined with hydrophobic residues that has a good induced fit with 
quercetin’s three hydrophobic ring systems, leaving its hydrophilic hydroxyl groups 
exposed in solvent (Otterbein et al., 2001; Böhl et al., 2007). In a comparison with 
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genistein (Figure 8-1D), which does not significantly depolymerise actin, quercetin’s 
higher activity appeared to be related to the position of its B-ring (Böhl et al., 2007). 
Although quercetin has kinase inhibition activity on phosphoinositide 3-kinase by 
competing with ATP, binding in the actin ATP-binding cleft and competing with ATP 
could be ruled out because ATP was in excess in the conditions tested (Russo et al., 
2012; Böhl et al., 2007). Compounds A and B have notable structural similarities with 
quercetin that suggest they too would bind actin in the TMR pocket. They are similar in 
size, have three ring systems and have oxygens at similar positions. They do not share 
quercetin’s hydroxyl group on C3 which defines it as a flavonol, but because Böhl et al. 
(2007) saw no correlation between the number of hydroxyl groups on flavonoids and 
binding affinity to actin they consider the hydroxyl groups not relevant to binding. The 
additional carbon in Compounds A and B between the B and C rings confers rotational 
flexibility which may assist binding and place the B-ring in a similar position to 
quercetin’s B-ring. In support of this, the flavanone taxifolin (Figure 7-12) has rotational 
flexibility and bound with similar affinity to actin as quercetin which is planar (Böhl et al., 
2007). This additional carbon gives the C ring more freedom of movement than in 
genistein, another isoflavonoid.  
Compounds A and B were next compared to natural product toxins that stabilise or 
destabilise actin. The natural product filament stabilisers have a large peptide ring that 
binds to two or three neighbouring actin subunits in a filament, three in the case of 
jasplakinolide (Figure 8-1B), and appear also to have an allosteric effect in subunits at 
a distance from the binding site (Allingham et al., 2006). Having no large peptide ring, 
Compounds A and B would be unlikely to mimic the effect of actin stabilisers.  
Natural product actin destabilisers bind either in the ATP-binding cleft or in the SD 1-3 
cleft in the barbed end (Figure 8-2 A) (Allingham et al., 2006). Latrunculin A (Figure 8-1 
B) binds in the ATP-binding cleft and sequesters actin monomers by preventing 
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nucleotide exchange (Yarmola et al., 2000). However, latrunculin binding relies on a 
biologically rare and very specific ring structure that is not shared by Compounds A and 
B (Allingham et al., 2006). Cytochalasin D (Figure 8-1 B) is an example of an actin 
destabiliser that binds the barbed end of G-actin and F-actin in the SD 1-3 cleft (Figure 
8-2 B), which has two effects. Its bulky form inhibits the next actin monomer’s D-loop 
binding in the cleft and it allosterically alters the shape of the D-loop in the same 
monomer to a more ordered shape, therefore may weaken binding to the adjacent 
monomer (Nair et al., 2008).  
 
 
Figure 8-3: Model of flavonoid activity with actin filaments in breast cancer cells. A: without 
flavonoid, filaments are stable. B: with flavonoid, drug accelerates nucleotide exchange from ATP 
to ADP in the strand, D-loop binding may be weakened, ADP-actin depolymerises faster than ATP-
actin. F: Flavonoid, i.e. Clitoria extract, Compound A, Compound B or quercetin. G-actin: globular 
(unpolymerised) actin. F-actin: filamentous actin. ADP: adenosine diphosphate. ATP: adenosine 
triphosphate. Illustration based on the exchange diffusion model for profilin discussed in Yarmola 
and Bubb (2009). 
 
 
Compounds A and B appear too small to span or fill the SD 1-3 cleft like cytochalasin D 
but they could bind in the cleft and sterically hinder the D-loop binding. However, due to 
structural similarity, Compounds A and B are more likely to bind in the TMR-binding 
loop similarly to quercetin. If this is correct, Compounds A and B would weaken 
intrastrand binding by altering the shape of the D-loop and its fit in the SD 1-3 cleft, and 
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accelerate ATP exchange to ADP, making the filament less stable as illustrated in 
Figure 8-3. 
In the cell, the actin cytoskeleton interacts with a large number of actin binding proteins 
(ABPs). One ABP that binds near the TMR binding site and has importance in cancer is 
profilin (Figure 8-2 C), and it was considered how Compounds A and B might compete 
with and either agonise or antagonise profilin binding to actin. Profilin has four isoforms 
of which profilin-1 is expressed in almost all eukaryotic cells at >50 μM (Witke, 2004). 
Several authors present evidence of profilin-1 as a tumour suppressor that is 
downregulated in breast cancer. Ding et al. (2014) concluded from 193 human breast 
tumours that profilin-1 was downregulated by around 20% compared to normal tissue, 
with lowest expression found in the more advanced cancers. However, Rizwani et al. 
(2014) found 1.6 ± 0.3-fold higher profilin-1 in breast cancer tissues than in surrounding 
cells, therefore its low level of expression in breast cancer is not universal.  
Profilin-1 appears to reduce cell proliferation and migratory activity, consistent with a 
tumour suppressor role. Profilin-1 upregulation led to reduced proliferation and G1 cell 
cycle arrest and reduced speed of cell migration in breast cancer cells (Zou et al., 
2010; Lorente et al., 2014). When profilin-1 is downregulated in breast cancer cells, 
motility increases, invasion in matrigel increases and xenografts in mice become 
hyperinvasive (Bae et al., 2009; Ding et al., 2014). Profilin-1 also has other anticancer 
effects as it is able to reduce cell motility by binding phosphatidylinositol 4,5-
bisphosphate, preventing its hydrolysis by phospholipase C and its signalling via the 
mammalian target of rapamycin (mTOR) pathway which promotes survival, proliferation 
and motility, and it can increase the activity of phosphatase and tensin homolog, a 
suppressor of the mTOR pathway in cancer, in breast cancer cells (Bae et al., 2010; 
Das et al., 2009). 
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The overall effect of profilin-1 as a tumour suppressor on the actin cytoskeleton seems 
to be to destabilise filaments and inhibit their growth (Yarmola and Bubb, 2009). Profilin 
can fit in the SD 1-3 cleft at the same time as the D-loop of the adjacent monomer 
therefore it does not block polymerisation (Figure 8-2 C) (Schutt et al., 1993), and it 
interacts with the region of the TMR-binding site (Schutt et al., 1993). Similar to TMR, 
profilin-1 can open the ATP-binding cleft and change the shape of the D-loop (Porta 
and Borgstahl, 2012) (Dominguez, 2004). In addition, as the profilin-G-actin monomer 
is more stable than the profilin-F-actin filament, profilin effectively sequesters actin in 
the cytoplasm (Yarmola and Bubb, 2009). In normal cells actin is present in a 50:50 
ratio of G:F-actin, but ~100-fold more G-actin is bound to profilin and unavailable for 
polymerisation (Dominguez and Holmes, 2011).  
The effect of Compounds A and B interacting with profilin-1 was considered with 
reference to its expression level in the cell lines used in this study. Profilin-1 expression 
levels were found for the MDA-MB-231 breast cancer cell line and the MCF-10A 
normal breast epithelial cell line used in this study and were relatively low and high 
respectively (Janke et al., 2000; Zou et al., 2007). In breast cancer cells with low 
profilin-1 Clitoria may mimic and partially replace profilin-1 depolymerisation activity. In 
cancer cells, fragmented filaments at the cell cortex would hinder cell migration and cell 
ruffling as seen with Clitoria. In support of this hypothesis, images of MDA-MB-231 
breast cancer cells with overexpressed profilin-1 have increased circumferential stress 
fibres and also appear to show aggregated actin (Zou et al., 2009) similar to the 
granular actin seen after treatment with Clitoria and its fraction F17. During cell 
division, disruption to retraction filaments could cause cells to lose adhesion and a 
weaker actin-rich contractile ring could delay cytokinesis as seen with Clitoria and 
contribute to the blebbing at cytokinesis seen with some cancer cells treated with 
Clitoria fraction F17. 
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No data could be found for levels of profilin-1 expression in normal fibroblasts but it 
was hypothesised that these normal cells contained abundant profilin-1. When profilin-
1 is abundant, Compounds A and B may compete with it for actin binding but would 
have to be present in large concentrations, and to bind actin with similar affinity, to 
have any significant effect. However, if the majority of profilin-1 sequesters G-actin 
monomers, Compounds A and B may promote depolymerisation of F-actin not bound 
to profilin-1, reducing the growth or stability of actin filaments at the leading edge of 
cells and reducing cell motility. β-actin and γ-actin are present in the cytoskeleton of all 
cells (Perrin and Ervasti, 2010). β-actin is found in stress fibres and the contractile ring 
and γ-actin in branched filaments, lamellae and the cortex of dividing cells, and in 
stationary cells γ-actin relocates from the peripheral branched actin to stress fibres 
(Dugina et al., 2009). The more noticeable stress fibres in normal fibroblasts treated 
with Clitoria and fraction F18 may be due to γ-actin moving from the lamella to the 
stress fibres as a result of becoming stationary. Therefore this model offers a potential 
explanation for the differential response of cancer and normal cells to Clitoria and 
Compounds A and B. 
The possibility of Compounds A and B inhibiting small GTPase RhoA either directly or 
indirectly was considered. RhoA is frequently upregulated in breast cancer and 
associated with cell proliferation and metastasis (Bellizzi et al., 2008). The reduced cell 
motility, reduced ruffling and delayed mitosis seen in this study could be associated 
with lower RhoA activity. Few examples of flavonoid interaction with small Rho 
GTPases or their effector GEFs and GAPs could be located in the literature, but there 
are examples of lower RhoA activity after treatment with quercetin and the flavonoids 
isoquercetin and flavone. When mice with implanted breast cancers were fed 
quercetin, expression of RhoA, Rac1 and Cdc42 genes was reduced 1.5-2 fold and the 
tumours were reduced in size (Martinez-Montemayor et al., 2010). In nerve cells, 
inhibition of neurite formation caused by RhoA was reversed by treatment with 
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isoquercetin which reduced RhoA activity (Palazzolo et al., 2012), and Baek et al. 
(2009) saw that flavone inhibited RhoA activation and reduced vascular contraction in 
rat aortic rings. In contrast, in a study looking at proteins in oral cancer cells whose 
expression was altered as a result of quercetin treatment, neither Rho nor Rac protein 
expression was found to be changed (Lai et al., 2013). With this evidence, and as 
Clitoria affects processes that involve RhoA, lower RhoA activation cannot be ruled out. 
The differential response of fibroblasts to cancer cells and the apparent fragmentation 
of actin filaments in cancer cells might be explained by different GEFs and GAPs acting 
on RhoA in the different cell types. 
8.4 Limitations 
The aims of the project (see Chapter 1, Introduction) were all met. A major limitation of 
the study was the small supply of extracts which limited both the type and number of 
assays possible with Clitoria. Cheilocostus extract was also cytotoxic and one fraction 
appeared to have differential toxicity towards cancer cells but due to the limited supply 
of extract this work could not be pursued. However, the low supply prompted a search 
for other sources of Clitoria extract leading to the interesting finding that the bioactive 
homoisoflavones were present in plants from at least two and probably three locations.  
It could not be confirmed that treated cells were dying in the cell viability assays, 
although this appeared to be the case from visual examination. If more extract had 
been available, assays would have been designed to resolve whether cells had died 
due to treatment, had lost adhesion through treatment and died due to lack of 
attachment and anoikis, or had detached without dying. It also proved challenging to 
transfer doses between different types of assay, as a treatment of crude Clitoria that 
appeared to kill 40% of cells in a cell viability assay did not kill cells in live cell imaging. 
However, the assays provide very different types of information and this illustrates the 
need for different types of assay to build a complete picture.  
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It was not possible to identify the selective non-polar bioactive agents in FTIR, and LC-
MS work in the limited timescale of the study focussed on the two major bioactive 
peaks. With more extract, structural elucidation of these compounds could be pursued.  
8.5 Further work 
Compounds A and B are relatively simple to synthesise from freely available 
precursors and this work is under way in collaboration with Aberystwyth University and 
University of Bath. Once adequate supplies of the compounds are available, assays 
will be repeated with the same cell lines to confirm that these compounds are 
responsible for the effects seen in this study. To see whether the effects are specific to 
breast cancer or are common to other cancers, the compounds will be tested on other 
cancer cell lines. Other normal cell lines will also be assayed to see whether the 
selectivity extends to more cell types. 
With synthesised compounds, more investigations into the nature of cell death and the 
mechanism of action can be performed. It can be confirmed at what treatment dose the 
compounds are cytotoxic or cytostatic, and whether the relationship between doubling 
time and sensitivity holds and extends to other cell lines. Suitable techniques for 
confirming whether cells die through apoptosis or oncosis include flow cytometry with 
Annexin V and assays for markers of apoptosis such as mitochondrial membrane 
permeability, caspase activation and DNA laddering. To investigate the compounds’ 
effect on actin further, direct binding to actin can be assayed with a tryptophan 
fluorescence quenching assay as performed by Böhl et al. (2005), and the G-actin:F-
actin ratio in treated cells can be assayed to see whether and by how much the 
compounds depolymerise actin filaments using techniques in Stehn et al. (2013) or in 
Lu et al. (2005).  
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It is not immediately clear how actin depolymerisation might lead to cell death in cancer 
cells. From live cell imaging it appears that cancer cells treated with F17 undergo a 
prolonged mitosis, frequently not completing it by the end of the assay, suggesting that 
the spindle or the contractile ring are not functioning correctly. Actin filaments have a 
role in spindle positioning which can be disrupted with latrunculin B (Gachet et al., 
2001) and the contractile ring is formed of actomyosin filaments which fail to form 
correctly with cytochalasin B treatment (Zieve, 1884), therefore these functions can be 
investigated. The microtubules and contractile ring can be visualised with fluorescence 
microscopy. To see if cells enter mitotic arrest, they can be synchronised in prophase 
and assayed for cell cycle stage after a period of time with flow cytometry. Alternatively, 
actin retraction fibres could be disrupted, allowing detachment from the substrate and 
anoikis cell death. Retraction fibres can be visualised through the proteins in the focal 
adhesion complex that attaches them to the substrate. 
Cell motility is seen in live cell imaging to be reduced by treatment with Clitoria extract 
and fraction F17. This effect could be quantified with cell migration assays. RhoA is 
involved in cell motility, actin stress fibres and the formation of the contractile ring and 
any changes in RhoA activity in treated cells could be investigated. 
 
8.6 Conclusion 
Fractions from the major peaks in Clitoria are 2-3 fold more cytotoxic on breast cancer 
cells than normal cells and appear to target the complex actin cytoskeleton similarly to 
another flavonoid, quercetin. It is likely that the bioactive compounds in these fractions 
are novel homoisoflavones Compounds A and B. If Compounds A and B replace the 
function of a tumour suppressor cytoskeletal protein that is downregulated in cancer, 
they offer selectivity not seen with other cytoskeleton targeting drugs, that may be 
effective on a range of cancers and in many patient groups. Alternatively, if the 
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compounds target cells during mitosis, which cancer cells undergo more frequently, 
they have potential as chemotherapeutic agents similar to microtubule inhibitors. As 
flavonoids they are likely to be well tolerated by patients. Because sufficient quantities 
of the compounds can be synthesised in the laboratory, obtaining plant material from 
natural resources and running low yield extractions will be unnecessary. Anti-
proliferative and cytotoxic effects are directly relevant against cancer growth and 
angiogenesis, and anti-migratory effects may combat metastasis for which there are 
currently no effective drugs. Efficacy on both ER positive and ER negative breast 
cancer cell lines suggests that they may offer a further option for the 25% of breast 
cancer patients who are ER negative and have few other treatment options.  
With their cytotoxicity and metastasis inhibition activities that appear to target more 
actively dividing cells, novel Compounds A and B may offer a low cost option for a 
large group of cancer patients. The UK National Institute of Health and Care 
Excellence (NICE) has ruled out NHS use of olaparib (£4,200 per month) and Kadcyla 
(£90,000 per course of treatment) after a cost-effectiveness assessment (FT, 2015). 
Pharmaceutical companies justify high drug prices by quoting high research and 
development costs for drugs where the target patient groups are often a small subset 
of cancer patients (Kantarjian et al., 2013). A debate has arisen between those who 
maintain that drug companies should be rewarded for innovation, risk and expense and 
others who say that they cannot continue to charge high prices for drugs that show 
small improvements in life expectancy or time to regression, or minimal advantages 
compared to near rivals (Ward, 2015). In contrast, chemotherapy drugs are less 
targeted and can be given to more patients. Unlike many current drugs which target a 
small subset of cancers, have a small target market and are consequently very 
expensive, novel Compounds A and B may be very cost effective. In conclusion, the 
two novel homoisoflavones isolated from Clitoria in this study appear to be potential 
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Appendix A: Compounds in Indian plants 
Table A1: Compounds in Clitoria ternatea reported in the literature. 
Class Component Part of plant 
1 
alcohol hexacosanol R 
2 
alkaloid caffeine F 
3 
amino acid glycine R 
4 
leucine  R 
4 












α-aminobutyric acid R 
4 
γ-methyleneglutamic acid R 
4 
γ-aminobutyric acid R 
4 
aspartic acid R 
4 








































15 ternatins F 
7
 










kaempferol 3-O-neohesperiodoside L 
5
 
kaempferol 3-(2”-rhamnosyl-6”-malonyl)glucoside F 
7
 


















malvidin 3-glucoside F 
5
 
myricetin 3-(2G-rhamnosylrutinoside) F 
7
 
petunidin 3-O-beta-D-glucopyranoside F 
5
 
quercetin 3-(2G-rhamnosylrutinoside) F 
7
 
quercetin 3-(2”-rhamnosyl-6”-malonyl)glucoside F 
7
 





quercetin 3-rutinoside F 
7
 











nucleoside adenosine S 
6
 
protein or peptide nucleoprotein similar to insulin S 
6
 
a lectin S 
6
 
p-hydroxycinnamic acid polypeptide S 
6
 
butelase 1 NS 
10 




cyclic cliotides R 
13 
pyridine pyridine-2-d,6-methyl F 
3 
simple aromatic 3-(4-hydroxyphenyl)-2-propenoic acid (E)-form S 
5
 


























terpene hirsutene F 
3 
1  
S: seed. L: leaf. R: root. F: flower. NS: part of plant not specified. 
2
 Barik et al. (2007). 
3
 Compounds identified with >50% probability by Neda et al. (2013). 
4
 Mukherjee et al. (2008).         
5
 Bisby (1994). 
6
 Kumar Gupta et al. (2010). 
7
 Kazuma et al. (003). 
8
 Sandhar et al. (2011). 
9 
Swain et al. (2012).            
10
 Nguyen et al. (2014). 
11 
Osborn et al. (1995). 
12 
Kelemu et al. (2004). 
13 
Nguyen et al. (2011).
 14 
Chauhan (2012).         
15





Table A2: Compounds in Mucuna pruriens reported in the literature. 
Class Component Part of plant 
1 
acid gallic acid NS 
2 
palmitoleic acid S 
3
 
stearic acid S 
3
 
oleic acid S 
3
 
linoleic acid S 
3
 
arachidic acid S 
3
 
behenic acid S 
3
 







































5-methoxy-N,N-dimethyl-tryptamine (5-MeO-DMT)  S 
10
 
5-methoxytryptamine (5-MT) S 
10
 

















































































benzoquinone coenzyme Q-10 S 
17 
cyanide hydrogen cyanide S 
18
 
heterocycle β-carboline NS 
14
 








































S: seed. L: leaf. R: root. F: flower. St: stem. NS: part of plant not specified. 
2 
Nidiry et al. (2011). 
3 
Siddhuraju et al. (1996). 
4
 Misra and Wagner (2006). 
5 
Ekanem et al. (2004).
 6 
Pras et al. (1988).    
7 
Misra and Wagner (2004) 
8 
Luthra and Singh (2010). 
9
 Pras et al. (1993). 
10 
Misra and Wagner (2007). 
11





Infante et al. (1990). 
14 
Chandrashekharaiah et al. (2011). 
15 
Brain (1976).                     
16 
Daxenbichler et al. (1971).
  17 
Manyam et al. (2004). 
18 
Morris and Janick (1999). 
19 
Donati et al. (2005).
 20
 Murthy and 
Mishra (2009).   
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Table A3: Compounds in Cheilocostus speciosus reported in the literature. 





































































































































































prosapogenin A of dioscin R
8 


































































S: seed. L: leaf. R: rhizome or root.  
2
 Bhuyan and Zaman (2008). 
3 
Eliza et al. (2009a). 
4
 Gupta et al. (1986). 
5 
Duraipandiyan et al. (2012).
  6
 Srivastava et al. 
(2011). 
7
 Srivastava et al. (2011). 
8 
Joy et al. (1998). 
9 
Chang et al. (2011). 
10
 Saraf (2010). 
11
 Bhattacharya and Nagaich 
(2010). 
12
 Dasgupta and Pandey (1970). 
13
 Inoue and Ebizuka (1996).
 14 





Appendix B: Calculation of treatment dose for fractions after fractionation 
of Indian Clitoria and Cheilocostus 
The treatment doses after semi-preparative fractionation of Indian Clitoria and 
Cheilocostus extract were calculated from estimates of the amount of material placed 
on the column (column loading) in HPLC fractionation runs (Table B1). 
Table B1: Calculation of approximate dose of Clitoria and Cheilocostus in bioassays based on 
distribution of material across fractions after semi-preparative fractionation. 
Extract Clitoria extract CE(B) Cheilocostus  















Fractions in bioassay F1-F10 F1F9, F10.1-F10.6 F1 -F7 
Figure presenting results Figure 4-7 Figure 4-8 Figure 4-15 
Concentration of crude extract ( µg µL
-1
) 90 90 90 
Dilution of crude extract 1:10 1:10 1:10 
Concentration of diluted sample (µg µL
-1
) 9 9 9 
No of fractionation runs 6 3  3 
Total of injection volumes from 
fractionation runs (µL) 
120 60  30 
Loading (ug) [=injection volume x 
concentration] 
1080 540 270 
Number of fractions 10 15 7 
Approx material per fraction if evenly 
distributed (µg) [=loading /number of 
fractions] 
108 36 38.6 
Ethanol resuspension volume (µL) 20 10 10 
When fraction resuspended in ethanol, 





5.4 3.6 3.86 
Amount of stock solution added to 100 
µL medium (µL) [A] 
1.5 1.5 1.5 
Approximate concentration of each 
fraction treatment (ng μL
-1
) 
81 54 58 
Equivalent dilution of crude extract 1:1111 1:1667 1:1560 
1 
Semi-preparative fractionation on analytical column. 
 
 
As bioactivity was present in the UV absorbent peaks at F5-F6, it was thought that 
peak area in HPLC might provide a more accurate measure of the material in the 
fraction. Approximate peak area of the 1st major peak (F5 in semi-preparative 
fractionation on analytical column; F17 in preparative fractionation) was calculated from 
the total absorbances for all injections combined at λmax (323 nm) multiplied by the 
fraction eluent volume. The concentration for fraction F17 in preparative fractionation 
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was calculated to be ~70% of the concentrations of the semi-preparative fraction F5-F6 
(Table B2). In the subsequent dilution series bioassay after preparative fractionation, 
peak area was again used to estimate treatment dose (Table B2). 
 
Table B2: Calculation of approximate dose of Clitoria extract CE(B) in preparative fractionation 
using peak area, by comparison with semi-preparative fractionation.  









Dilution series after 
preparative fractionation 
Fractions in bioassay F1-F10 F1-F61 F17, F18, F31, F46 
Figure presenting results Figure 4-7 Figure 4-10 Figure 4-13, Figure 4-14 
Concentration of crude 
extract (µg/µL) 
90 90 90 
Dilution of crude extract 1:10 1:10 1:10 
Concentration of diluted 
sample (µg/µL) 
9 9 9 
Number of fractionation 
runs  
6 1 4 
Total absorbance (323 







22.0 1.1 8.29 
Volume of eluent in one 
fraction (mL) [2] 
1.02 4.67 4.67 
Approx peak area (AU mL) 
[ [1] x [2] ]  [material] 
22.4 5.15 38.8 
Resuspension volume in 
ethanol for stock solution 
(μL) 
20 4.5 15.5 
Approx material per uL 
stock solution (AU mL/μL)
 
1.12 1.14 2.50 
Dose of stock solution in 
each well (μL) 
1.5 1.0 1.0 
Material in well of 100 μL 
(AU mL) 
1.68 1.14 2.50 
1





Appendix C: Calculation of treatment dose for fractions after fractionation 
of Indonesian Clitoria 
The treatment dose after semi-preparative fractionation of Indonesian Clitoria extract 
was calculated from estimates of the amount of material placed on the column (column 
loading) in HPLC fractionation runs (Table C1). 
 
Table C1: Calculation of approximate dose of Clitoria extract CE(H) in dilution series bioassay after 
semi-preparative fractionation on analytical column.  
Assay Single treatment per fraction 
after semi-preparative 
fractionation on analytical 
column 
Dilution series after semi-
preparative fractionation on 
analytical column 
Fractions in bioassay F1-F4 (pooled), F5-F6 (pooled), 
F7, F8, F9, F10.1, F10.2, F10.3, 
F10.4, F10.5, F10.6 
F5-F6 (pooled) 
Figure presenting results Figure 6-7 Figure 6-8 
Concentration of crude extract (µg/µL) 140 140 
Dilution of crude extract 1:10 1:10 
Concentration of diluted sample (µg/µL) 14 14 
No of fractionation runs 3 11 
Total of injection volumes from 
fractionation runs (µL) 
90 190 
Loading (ug) [=injection volume x 
concentration] 
1260 2660 
Number of fractions 15 15 
Approx material per fraction if evenly 
distributed (µg) [=loading /number of 
fractions] 
84 177 
Ethanol resuspension volume (µL) 8 10 
When fraction resuspended in ethanol, 




Amount of stock solution added to 100 
µL medium (µL) 
1.5 1.0 
Approximate concentration of each 
fraction treatment (ng/µL) 
158 177 
Equivalent dilution of crude extract 1:889 1:790 
1 
Semi-preparative fractionation on analytical column. 
 
As bioactivity was present in the UV absorbent peaks at F5-F6, it was thought that 
peak area in HPLC might provide a more accurate measure of the material in the 
fraction as it had for Indian Clitoria. Approximate peak area of the 1st major peak (F5 in 
semi-preparative fractionation on analytical column; F17 in preparative fractionation) 
was calculated from the total absorbances for all injections combined at λmax (323 nm) 
multiplied by the fraction eluent volume. The concentration for fraction F17 in 
preparative fractionation was calculated to be ~25% of the concentrations of the semi-
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preparative fraction F5-F6 (Table C2). 
Table C2: Calculation of approximate dose of Clitoria extract CE(H) in single treatment bioassay 
after preparative fractionation. 
Assay Single treatment per fraction 
after semi-preparative 
fractionation on analytical 
column 
Single treatment per fraction 
after preparative fractionation  
Fractions in bioassay F1-F4 (pooled), F5-F6 (pooled), 
F7, F8, F9, F10.1, F10.2, F10.3, 
F10.4, F10.5, F10.6 
F1-F61 
Figure presenting results Figure 6-7 Figure 6-9 
Number of fractionation runs combined 3
 
1 









Volume of eluent in one fraction (mL) 
[2] 
1.02 4.67 
Approx. peak area (AU mL) [ [1] x [2] ]  
[material] 
2.14 1.87 
Resuspension volume in ethanol for 
stock solution (μL) 
8 20 




Amount of stock solution added to 100 
µL medium (µL) 
1.5 1.0 




Semi-preparative fractionation on analytical column. 
 
For the dilution series bioassay after preparative fractionation, the treatment was 
calculated from column loading in fractionation compared to the single treatment assay 




Table C3: Calculation of approximate dose of Clitoria extract CE(H) in bioassay with dilution series 
after preparative fractionation using estimates from the single treatment bioassay after preparative 
fractionation.  
Assay Single treatment per fraction 
after semi-preparative 
fractionation on analytical 
column 
Dilution series after preparative 
fractionation 
Fractions in bioassay F1-F61 F16-F18 combined F34, F36, F38 
Figure presenting results Figure 6-8 Figure 6-11 
Concentration of crude extract 
(µg/µL) 
140 140 140 
Dilution of crude extract 1:10 1:10 1:10 
Concentration of diluted sample 
(µg/µL) 
14 14 14 
No of fractionation runs 1 2 2 
Total of injection volumes from 
fractionation runs (µL) 
90 100 100 
Loading (ug) [=injection volume 
x concentration] 
1260 1400 1400 
Number of fractions 61 61 61 
Approx material per fraction if 
evenly distributed (µg) [=loading 
/number of fractions] 
20.66 23.0 
 




Ethanol resuspension volume 
(µL) 
20 20 10 
When fraction resuspended in 




1.03 3.45 2.30 
Amount of stock solution added 
to 100 µL medium (µL) 
1.0 1.0 1.0 
Approximate concentration of 
each fraction treatment (ng/μL) 
1.03 3.45 2.30 
Equivalent dilution of crude 
extract 





Appendix D: Supplementary information 
The following supplementary movies are made available with this thesis. 
Supplementary movies 1, 2 for Figure 5-2. 
Movie 1: MCF-7 control cells viewed for 48 hours. 
Movie 2: MCF-7 cells treated with Clitoria extract CE at 1:2000 dilution for 48 
hours. 
Supplementary movies 3-6 for Figure 5-3, Figure 5-7. 
Movie 3: MDA-MB-231 control cells viewed for 48 hours. 
Movie 4: MDA-MB-231 cells treated with Clitoria extract CE at 1:2000 dilution for 
48 hours. 
Movie 5: 2DD control cells viewed for 48 hours. 
Movie 6: 2DD cells treated with Clitoria extract CE at 1:2000 dilution for 48 hours. 
Supplementary movies 7-14 for Figure 5-4, Figure 5-5, Figure 5-6. 
Movie 7: MDA-MB-231 control cells viewed for 48 hours. 
Movie 8: MDA-MB-231 cells treated with Clitoria fraction F17 at 88 ng/μL for 48 
hours. 
Movie 9: MDA-MB-231 cells treated with Clitoria fraction F17 at 44 ng/μL for 48 
hours. 
Movie 10: MDA-MB-231 cells treated with Clitoria fraction F18 at 140 ng/μL for 48 
hours. 
Movie 11: 2DD control cells viewed for 48 hours. 
Movie 12: 2DD cells treated with Clitoria fraction F17 at 88 ng/μL for 48 hours. 
Movie 13: 2DD cells treated with Clitoria fraction F17 at 44 ng/μL for 48 hours. 
Movie 14: 2DD cells treated with Clitoria fraction F18 at 140 ng/μL for 48 hours. 
Supplementary movies 15-18 for Figure 6-5, Figure 6-6. 
Movie 15: MDA-MB-231 control cells viewed for 24 hours. 
Movie 16: MDA-MB-231 cells treated with Clitoria extract CE(H) at 1:4000 dilution 
for 24 hours. 
Movie 17: 2DD control cells viewed for 24 hours. 
Movie 18: 2DD cells treated with Clitoria extract CE(H) at 1:4000 dilution for 24 
hours. 
